Anti-peanut allergen antibodies and uses thereof

Antibodies targeting peanut allergens like Ara h 2 inhibit peanut allergy symptoms by at least 20%, addressing the severe and accidental reaction risks associated with peanut allergies.

WO2026235706A1PCT designated stage Publication Date: 2026-11-12WESEMANN DUANE R +4
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2025/028644
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Filing Date
2025-05-09
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Peanut allergy is common and often leads to severe symptoms due to a pathologic hyperimmune response, with limited effective therapies and a high risk of accidental reactions, particularly in children who cannot recognize the allergen.

Method used

Development of antibodies and antigen binding fragments that specifically target peanut allergens, such as Ara h 2, to inhibit or reduce allergic responses, including anaphylaxis, by binding to peanut antigens and reducing FcεRI receptor activity.

Benefits of technology

The antibodies effectively inhibit peanut allergy symptoms by at least 20%, reducing FcεRI receptor activity and allergic immune responses, providing a safer and more effective treatment option for peanut allergies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2025028644_12112026_PF_FP_ABST
    Figure US2025028644_12112026_PF_FP_ABST
Patent Text Reader

Abstract

Provided herein are antibodies or antigen binding fragments thereof that bind to a peanut allergen and their use in the treatment of peanut allergy.
Need to check novelty before this filing date? Find Prior Art

Description

Attorney Docket No. 043214-000108WOPTANTI-PEANUT ALLERGEN ANTIBODIES AND USES THEREOFTECHNICAL FIELD

[0001] The disclosure relates generally antibodies and antigen binding fragments of that bind to a peanut allergen, therapeutic compositions comprising the antibodies and methods of using those antibodies.GOVERNMENT SUPPORT

[0002] This invention was made with government support under Grant No. All 58811-04 awarded by the National Institutes of Health. The government has certain rights in the invention.SEQUENCE LISTING

[0003] The instant application contains a Sequence Listing which has been submitted electronically in XML file format and is hereby incorporated by reference in its entirety. Said XML copy, created on May 7, 2025 is named 043214-000108WOPT_SL.xml and is 28,915 bytes in size.BACKGROUND

[0004] Peanut allergy is common, affecting 1-2% of children in Europe and the USA. Unlike other common childhood food allergies, resolution is uncommon. Peanut allergy is driven by a pathologic hyperimmune response where exposure to peanut can lead to mild to severe symptoms such as nausea, vomiting, rashes, impaired breathing, drop in blood pressure, and even death. Normally, individuals with a healthy immune system are able to maintain nonresponsiveness to antigens encountered in common food substances like peanut; however, in peanut allergic subjects, the loss of immune tolerance to peanut antigens drives the pathologic hyperimmune response.

[0005] Despite the current best management, families of peanut allergic children have poor knowledge of how to avoid and also treat food allergy emergencies. Accidental reactions are common. Annual incidence rates are on the rise over the past decade, and accidental reaction incidence rates have been reported as 3%, 14%, and 50% in large studies. Nearly one third of nut-allergic children cannot recognise the nut to which they are allergic. This lack of recognition puts them at an increased risk of unintentional ingestion. Therefore, there is a14937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTsignificant medical need to develop safe and efficacious therapies for food allergy suitable for allergic patients. The disclosure addresses this need.SUMMARY

[0006] As described herein, the inventors have produced antibodies that bind to a peanut antigen and can reduce responses to peanut allergies, i.e., anaphylactic responses.

[0007] Accordingly, provided herein in one aspect is an antibody or antigen binding fragment thereof. In some embodiments of this aspect and all other aspects provided herein, the antibody or antigen binding fragment thereof comprises a heavy chain variable region (VH) comprising: (i) a complementarity determining region 1 (HCDR1) sequence having an amino acid sequence of GFSFGSSW (SEQ ID NO: 2); (ii) a complementarity determining region 2 (HCDR2) sequence having an amino acid sequence of VNGDGSSV (SEQ ID NO: 3); and / or (iii) a complementarity determining region 3 (HCDR3) sequence having an amino acid sequence of VKGKSRRSQYDQ (SEQ ID NO: 4). In some embodiments of this aspect and all other aspects provided herein, the antibody or antigen binding fragment thereof comprises a light chain variable region (VL) comprising: (i) a complementarity determining region 1 (LCDR1) sequence having an amino acid sequence of QDVDKY (SEQ ID NO: 15); (ii) a complementarity determining region 2 (LCDR2) sequence having an amino acid sequence of DVS (SEQ ID NO: 16); and / or (iii) a complementarity determining region 3 (LCDR3) sequence having an amino acid sequence of QQYDNLPIT (SEQ ID NO: 17).

[0008] In some embodiments of this and all other aspects provided herein, the antibody or antigen binding fragment comprises a heavy chain variable region amino acid sequence having at least 80% identity to the amino acid sequence EVQLVESGGGLVQPGGSLRLSCVASGFSFGSSWMHWVRQDPAKGLVWVARVNGD GSSVSYRDSMEGRFTISRDNAKNTLFLQMNSLRPEDTALYYCVKGKSRRSQYDQWG QGTLVTVSS (SEQ ID NO: 9), and optionally provided that at least one (e.g., 1, 2 or all 3) of SEQ ID NOs: 2-4 (HCDR1-HCDR3) hasl00% identity to SEQ ID NO: 9.

[0009] Stated in another way, the antibody or antigen binding fragment comprises a heavy chain variable region amino acid sequence having at least 80% identity to SEQ ID NO: 9, and wherein the sequence of the antibody or antigen binding fragment having at least 80% identity to SEQ ID NO: 9, and wherein: the heavy chain comprises a HCDR1 sequence having 100% identity to SEQ ID NO: 2; and / or the heavy chain comprises a HCDR2 sequence having 100% identity to SEQ ID NO: 3; and / or the heavy chain comprises a HCDR3 sequence having 100% identity to SEQ ID NO: 4.24937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPT

[0010] In some embodiments of this aspect and all other aspects provided herein, the antibody or antigen binding fragment, comprises a heavy chain amino acid sequence having at least 85% identity to EVQLVESGGGLVQPGGSLRLSCVASGFSFGSSWMHWVRQDPAKGLVWVARVNGD GSSVSYRDSMEGRFTISRDNAKNTLFLQMNSLRPEDTALYYCVKGKSRRSQYDQWG QGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTS GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTICNVNHKPSNTKVDKKVEPKSCDKT HTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD GVEVHNAI< TI< PREEQYNSTYRVVSVLTVLHQDWLNGI< EYI< CI< VSNI< ALPAPIEI< TI SKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO: 1)

[0011] For example, the antibody or antigen binding fragment, comprises a heavy chain amino acid sequence having at least 85% identity to SEQ ID NO: 1, and wherein: the heavy chain comprises a HCDR1 sequence having 100% identity to SEQ ID NO: 2; and / or the heavy chain comprises a HCDR2 sequence having 100% identity to SEQ ID NO: 3; and / or the heavy chain comprises a HCDR3 sequence having 100% identity to SEQ ID NO: 4.

[0012] In some embodiments of this and all other aspects provided herein, the antibody or antigen binding fragment comprises a light chain variable region amino acid sequence having at least 80% identity to the amino acid sequence DIQMTQSPSSLSASVGDRVTITCQASQDVDKYLNWYQQKPGKAPKLLIYDVSNLETG VPLRFSGGGSGTDFTFTISGLQAEDFATYYCQQYDNLPITFGQGTRLEIK (SEQ ID NO: 19), and optionally provided that at least one (e.g., 1, 2 or all 3) of SEQ ID NOs: 15-17 (LCDR1-LCDR3) have 100% identity to SEQ ID NO: 19.

[0013] Stated in another way, the antibody or antigen binding fragment comprises a light chain variable region amino acid sequence having at least 80% identity to SEQ ID NO: 19, and wherein the sequence of the antibody or antigen binding fragment having at least 80% identity to SEQ ID NO: 19, and wherein: the light chain comprises a LCDR1 sequence having 100% identity to SEQ ID NO: 15; and / or the light chain comprises a LCDR2 sequence having 100% identity to SEQ ID NO: 16; and / or the light chain comprises a LCDR3 sequence having 100% identity to SEQ ID NO: 17.

[0014] In some embodiments of this aspect and all other aspects provided herein, the antibody or antigen binding fragment, comprises a light chain amino acid sequence having at least 85% identity to 34937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTDIQMTQSPSSLSASVGDRVTITCQASQDVDKYLNWYQQKPGKAPKLLIYDVSNLETG VPLRFSGGGSGTDFTFTISGLQAEDFATYYCQQYDNLPITFGQGTRLEIKRTVAAPSV FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDST YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 14). For example, the antibody or antigen binding fragment, comprises a light chain amino acid sequence having at least 85% identity to SEQ ID NO: 14, and wherein: the light chain comprises a LCDR1 sequence having 100% identity to SEQ ID NO: 15; and / or the light chain comprises a LCDR2 sequence having 100% identity to SEQ ID NO: 16; and / or the light chain comprises a LCDR3 sequence having 100% identity to SEQ ID NO: 17.

[0015] In some embodiments of this aspect and all other aspects provided herein, the antibody or antigen binding fragment is a single domain antibody (such as a heavy chain variable domain of a heavy chain antibody (VHH), such as a NANOBODY® molecule), an scFv, a monoclonal antibody, a humanized antibody, a human antibody, a recombinant antibody, a chimeric antibody, or a Fab fragment.

[0016] In some embodiments of this aspect and all other aspects provided herein, the heavy chain variable region of the antibody or antigen binding fragment comprises a Framework region 1 (FW Hl) sequence differing by no more than four amino acids from EVQLVESGGGLVQPGGSLRLSCVAS (SEQ ID NO: 10). In some embodiments of this aspect and all other aspects provided herein, the antibody or antigen binding fragment comprises a Framework region 2 (FW H2) sequence differing by no more than four amino acids from MHWVRQDPAKGLVWVAR (SEQ ID NO: 11). In some embodiments of this aspect and all other aspects provided herein, the antibody or antigen binding fragment comprises a Framework region 3 (FW H3) sequence differing by no more than four amino acids from SYRDSMEGRFTISRDNAKNTLFLQMNSLRPEDTALYYC (SEQ ID NO: 12).In some embodiments of this aspect and all other aspects provided herein, the antibody or antigen binding fragment comprises a Framework region 4 (FW H4) sequence differing by no more than four amino acids from WGQGTLVTVSS (SEQ ID NO: 13).

[0017] In another embodiment of this aspect and all other aspects provided herein, the light chain variable region of the antibody or antigen binding fragment comprises a Framework region 1 (FW LI) sequence differing by no more than four amino acids from DIQMTQSPSSLSASVGDRVTITCQAS (SEQ ID NO: 20). In some embodiments of this aspect and all other aspects provided herein, the antibody or antigen binding fragment comprises a Framework region 2 (FW L2) sequence differing by no more than four amino acids from LNWYQQKPGKAPKLLIY (SEQ ID NO: 21). In some embodiments of this aspect and 44937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTall other aspects provided herein, the antibody or antigen binding fragment comprises a Framework region 3 (FW L3) sequence differing by no more than four amino acids from NLETGVPLRFSGGGSGTDFTFTISGLQAEDFATYYC (SEQ ID NO: 22). In some embodiments of this aspect and all other aspects provided herein, the antibody or antigen binding fragment comprises a Framework region 4 (FW L4) sequence differing by no more than four amino acids from FGQGTRLEIK (SEQ ID NO: 23).

[0018] In some embodiments of this aspect and all other aspects provided herein, the antibody or antigen binding fragment comprises a heavy chain constant region 1 (CHI) comprising an amino acid having at least 85% identity to ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL QSSGLYSLSSVVTVPSSSLGTQTICNVNHKPSNTKVDKKV (SEQ ID NO: 5).

[0019] In some embodiments of this aspect and all other aspects provided herein, the antibody or antigen binding fragment comprises a heavy chain constant region 2 (CH2) comprising an amino acid sequence having at least 85% identity to the amnio acid sequence APEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN AKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK(SEQ ID NO: 7)

[0020] In some embodiments of this aspect and all other aspects provided herein, the antibody or antigen binding fragment comprises a heavy chain constant region 3 (CH3) comprising an amino acid sequence having at least 85% identity to the amnio acid sequence GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 8)

[0021] In some embodiments of this aspect and all other aspects provided herein, the antibody or antigen binding fragment comprises a heavy chain constant region 3 (CH3) comprising an amino acid sequence having at least 85% identity to the amnio acid sequence GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 24)

[0022] In some embodiments of this aspect and all other aspects provided herein, the antibody or antigen binding fragment comprises a heavy chain hinge region (CH1 CH2 hinge) comprising an amino acid sequence having at least 85% identity to EPKSCDKTHTCPPCP (SEQ ID NO: 6)54937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPT

[0023] In another embodiment of this aspect and all other aspects provided herein, the antibody or antigen binding fragment comprises a light chain constant region (CL) comprising an amino acid sequence having at least 85% identity to RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVT EQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 18)

[0024] In one embodiment of this aspect and all other aspects provided herein, the antibody or antigen binding fragment comprises an IgGl backbone. In some embodiments, the antibody or antigen binding fragment comprises a human IgGl backbone. In some embodiments of this aspect and all other aspects provided herein, the antibody or antigen binding fragment does not comprise at least one constant region of IgE.

[0025] In some embodiments of this aspect and all other aspects provided herein, the antibody or antigen binding fragment further comprises a detectable label.

[0026] In some embodiments of this aspect and all other aspects provided herein, the antibody or antigen binding fragment binds to a peanut antigen. In some embodiments, the antibody or antigen binding fragment binds to a S2 albumin family member. In some embodiments, the antibody or antigen binding fragment binds to Ara h 2. In some embodiments, the antibody or antigen binding fragment binds to helix 3 of Ara h 2.

[0027] In another embodiment of this aspect and all other aspects provided herein, the antibody or antigen binding fragment fragment inhibits or reduces FcsRI receptor activity and / or one or more symptoms of a peanut allergy by at least 20% as compared to FcsRI receptor activity and / or one or more symptoms of a peanut allergy in the absence of the antibody or antigen binding fragment.

[0028] In another embodiment of this aspect and all other aspects provided herein, the antibody or antigen binding fragment fragment inhibits or reduces an allergen mediated immune response by at least 20% as compared to an allergen mediated immune response in the absence of the antibody or antigen binding fragment.

[0029] In another embodiment of this aspect and all other aspects provided herein, the antibody or antigen binding fragment fragment inhibits or reduces an anaphylactic response by at least 20% as compared to an anaphylactic response in the absence of the antibody or antigen binding fragment.

[0030] In another embodiment of this aspect and all other aspects provided herein, the antibody or antigen binding fragment fragment inhibits or reduces effector cell activation, e.g., effector64937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTcell activation by a S2 albumin family member such as Ara h 2, as compared effector cell activation in the absence of the antibody or antigen binding fragment.

[0031] Another aspect provided herein relates to a composition comprising an antibody or antigen binding fragment as described herein. In some embodiments, the composition comprises a pharmaceutically acceptable excipient or carrier.

[0032] In another aspect, provided herein is a cell conmprising an antibody or antigen binding fragment described herein.

[0033] In yet another aspect, provided hereien is a polynucleotide comprising a nucleotide sequence encoding an antibody or antigen binding fragment described herein. In some embodiments, the polynucleotide is comprised in a vector.

[0034] In another aspect, provided herein is a composition comprising a polynucleotide comprising a nucleotide sequence encoding an antibody or antigen binding fragment described herein. In some embodiments, the composition comprises a pharmaceutically acceptable carrier or excipient.

[0035] In still another aspect, provided herein is a cell comprising a polynucleotide comprising a nucleotide sequence encoding an antibody or antigen binding fragment described herein.

[0036] In yet still another, provided herein is a kit comprising an antibody or antigen binding fragment described herein, or a polypeptide comprising a nucleotide sequence encoding an antibody or antigen binding fragment described herein, or a composition or cell described herein. In some embodiments, the kit comprises instructions for use thereof.

[0037] Another aspect provided herein relates to a method for treating a peanut allergy comprising administering an antibody or antigen binding fragment, a polynucleotide, a composition, or a cell as described herein.

[0038] In some embodiments of this aspect and all other aspects provided herein, the method inhibits or reduces one or more symptoms of a peanut allergy. In some embodiments, the one or more symptoms of a peanut allergy include but are not limited to skin reactions, hives, skin redness, skin swelling, itching, tightening of the throat, difficulty breathing, shortness of breath, digestive problems such as diarrhea, stomach cramps, nausea, or vomiting, drop in blood pressure and anaphylaxis.

[0039] In some embodiments of this aspect and all other aspects provided herein, the method reduces FcsRI receptor activation.

[0040] In some embodiments of this aspect and all other aspects provided herein, the method reduces the duration or severity of the allergic immune response to peanut proteins. In some embodiments, the allergic immune response is a Th2 cell response, B cell activation, basophil 74937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTactivation, eosinophil activation, mast cell activation, and / or IgE induction. In some embodiments, the Th2 cell response, B cell activation, basophil activation, eosinophil activation, mast cell activation, and / or IgE induction is assayed from one or more biological samples obtained from the subject.

[0041] In some embodiments of this aspect and all other aspects provided herein, the subject is diagnosed with or in need of treatment for a peanut allergy.

[0042] Another aspect provided herein relates to a method for reducing or blocking anaphylaxis or at least one response associated with a peanut allergy, the method comprising administering an antibody or antigen binding fragment, a polynucleotide, a composition, or a cell as described herein.

[0043] In some embodiments of this aspect and all other aspects provided herein, the subject is diagnosed with or in need of treatment for a peanut allergy. In some embodiments, the subject is a mammal. In some embodiments, the subject is a human.

[0044] In some embodiments of this aspect and all other aspects provided herein, the method further comprises a step of diagnosing the subject with the peanut allergy.

[0045] Another aspect provided herein relates to any composition as described herein for use in the treatment of a peanut allergy, or at least one symptom thereof in a subject.BRIEF DESCRIPTION OF THE DRAWINGS

[0046] FIGs. 1A-1I show scRNA-seq reveals intrinsic human bone marrow plasma cell heterogeneity. (A) Study overview. (B) UMAP projection of sorted BMPCs, colored by cluster assignment (n = 65,048 cells). Clustering was performed after exclusion of immunoglobulin genes. (C) Quality control of clustered cells (number of RNA molecules and total genes detected, and percentage of mitochondrial and immunoglobulin genes). (D). Expression of plasma cell- and B cell-associated genes among clusters. (E-F) IgH isotypic composition of clustered cells. (G) IgH somatic hypermutation among clusters. (H) Frequency of binned surface CD 19 protein expression of BMPC clusters. (I) Clonal relationships between clusters. Polar axis represents a number of cells with V(D)J arrangement available in each cluster.

[0047] FIGs.2A-2L show transcriptional features of human bone marrow plasma cell subsets.(A) Heatmap of the top differentially expressed genes between clusters. (B) Bubble plot depicting expression of select genes associated with biological functions relevant to plasma cell biology. Bubble color represents expression compared to the mean. Bubble size represents the fraction of cells expressing the gene. (C-D) Gene set enrichment analysis (GSEA) of GO gene sets in cluster 6. In C, bubble color represents false discovery rate (FDR) and bubble size 84937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTrepresents the number of genes found in the dataset that belong to the gene set. NES: Normalized Enrichment Score, q = False Discovery Rate. (E-K) Expression of genes associated with amino acid and folate metabolism (E), ER stress (F), migration and adhesion (G), TNF superfamily receptors (I), NF-KB signaling (J), MHC antigen presentation (K). (L) Enrichment plot for GSEA performed on Cluster 8.

[0048] FIGs.3A-3J show Surface CD 19 expression suggests differential bone marrow plasma cell origins in humans. (A) IgH somatic hypermutation (SHM) among BMPCs categorized by surface CD19 protein expression (30% lowest, 40% medium, 30% highest). Kruskal-Wallis test was used to assess statistical differences. (B) Frequency of BMPCs with different IgH SHM levels (30% lowest, 40% medium, 30% highest) among surface CD19 protein expression categories. (C) Normalized surface CD 19 protein expression levels among IgH SHM categories. Kruskal -Wallis test was used to assess statistical differences. (D) Frequency of IgM, IgGl, and IgAl BMPCs among surface CD 19 protein expression categories. Lines connecting dots represent an individual donor. Friedman test was used to assess statistical differences. (E) Schematic depicting the proposed relationship between clonal structure and BMPC source. (F) IgH SHM among different clonal structures. Kruskal-Wallis test was used to assess statistical differences. (G) Frequency of heterogenic clones among surface CD19 protein expression bins. Kruskal-Wallis test was used to assess statistical differences. (H) IgH isotypic composition among clone structures. (I) Surface CD 19 expression bins among the 20 most mutated and 20 least mutated heterogenic clonal families. Vertical black lines represent expected proportions based on CD 19 bin definition. Clonal families were defined as predominantly CD19lowif more than 30% of the family is CD19lowand less than 30% of the family is CD19hlgh, and vice versa.(J) Frequency of CD 19hlghBMPCs among the 100 most mutated and 100 least mutated heterogenic clonal families. Mann-Whitney U test was used to assess statistical differences.

[0049] FIGs. 4A-4H show IgE bone marrow plasma cells show signs of high metabolic demand and ER stress. (A) UMAP projection of cells, colored by IgH isotype (left) and highlighting IgE BMPCs (right). (B-C) Contributions of food allergic or non-allergic donors (B) and cluster identities (C) to BMPCs of different IgH isotypes. (D) Volcano plots for comparisons between BMPCs of a given isotype versus all other BMPCs. Isotypes with multiple subclasses were aggregated into a single isotype class. (E) Enrichment plot for IgE cells. (F-G) Gene expression separated by isotype class. Bubble color represents expression compared to the mean. Bubble size represents the fraction of cells that express the gene. (H) Percentage of immunoglobulin genes expressed by BMPCs of different isotypes.94937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPT

[0050] FIGs. 5A-5F show IgE human bone marrow plasma cells harbor allergen-specific antibody sequences. (A) ELISA testing for binding of P69P4 in a human IgGl backbone (red) to peanut extract, Ara h 2, and Ara h 6. An anti-SARS-CoV-2 Spike IgG antibody was used as an isotype control (blue). (B) Affinity curves to biotinylated natural Ara h 2 by BLI for P69P4.(C) Molecular modeling of Ara h 2 (PDB: 8G4P). Epitopes 1, 2, and 3 determined in LaHood et al. are highlighted in teal, red, and dark blue, respectively. (D) Epitope binning sensograms for P69P4 using primary antibodies, 23P34 (Epitope 1.1), 13T5 (Epitope 2), and 22S1 (Epitope 3) from LaHood et al. Inhibition of response increase indicates overlapping epitopic regions targeted. (E-F) Temperature curves and quantification of anaphylactic responses of peanut-sensitized BALB / c mice after antibody injection and intravenous peanut challenge. PBS mice were not sensitized to peanut or administered mAbs prior to i.v. peanut challenge. An anti-SARS-CoV-2 Spike IgG antibody was used as an isotype control. Kruskal-Wallis test was used to assess statistical differences.

[0051] FIG. 6 shows FACS sorting of magnetically enriched CD138+human bone marrow plasma cells. Dump channel contains anti-CD3 and anti-CD14 antibodies.

[0052] FIGs.7A-7G show quality control of clustered cells. (A) UMAP projection of BMPCs, colored by donor’s allergy status. (B) Proportions of cells in each cluster by donor’s allergy status. Black dashed line represents expected proportion based on input number of cells per allergy status (n = 34,991 for allergic, n = 38,569 for non-allergic). (C) UMAP projection of BMPCs, colored by donor. (D) Proportions of cells in each cluster by donor. (E) Ridge plots for IgH gene expression on BMPCs of different IgH isotypes. (F) Heavy chain somatic hypermutation (IgH SHM) percentage of BMPCs of different IgH isotypes. (G) Percentage of ribosomal genes in the transcriptome of each cluster.

[0053] FIGs. 8A-8E show clonal relationship of cells. (A) Proportion of cells in each cluster by IgL isotype. (B) Clonal relationships between BMPCs of different isotypes. Lines connect cells that have the same IgH V and J segments, and over 82% identity in CDRH3 (Hamming distance determined by Shazam = 0.18). Line end width is proportional to the number of cells in the clonal family. (C-D) Top 20 most expanded clonal families. Composition of each family is colored by cluster identity (C) and IgH isotype (D). Remaining aggregated BMPCs are included for reference (“Others”). (E) UMAP projection of clustered BMPCs. Largest clone families (6754 & 16054) and predominantly mono-isotypic clone families (16657 & 2710) showed in (C) and (D) are highlighted in red.

[0054] FIG. 9 shows Pathway analysis for clusters of BMPCs. Differential expression gene testing was performed on BMPCs pseudobulked by donor and cluster identity. For each set of 104937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTgenes, gene set enrichment analysis was performed. Volcano plots and the top 20 GSEA results by false discovery rate (FDR) are shown for each cluster.

[0055] FIGs. 10A-10C show Surface CD 19 expression and SHM burden are correlated.(A) Normalized surface CD19 expression on CD19 expression categories among BMPCs.(B) Correlation between normalized surface CD19 expression and IgH SHM (n = 23,289). Spearman correlation was performed. 99.5% of the distribution in the X axis and 99.5% of the distribution in the Y axis are shown. (C) IgH SHM of BMPCs of different isotypes, subdivided by surface CD19 expression categories. Sample sizes for CD19 high / mid / low are: IgAl = 3,137 / 3,497 / 1,892; IgA2 = 165 / 218 / 141; IgE = 4 / 8 / 10; IgGl = 2,137 / 3,411 / 3,401; IgG2 = 926 / 1,188 / 760; IgG3 = 160 / 295 / 230; IgG4 = 103 / 128 / 73; IgM = 252 / 485 / 457; IgD = 42 / 41 / 30).

[0056] FIGs. 11A-11C show Features indicative of BMPC origin are retained at the donor level. (A) IgH SHM per surface CD19 expression bins per donor. Kruskal-Wallis test was used to assess statistical significance. (B) Frequency of IgH SHM bins per cluster per donor.(C) Surface CD 19 expression per IgH SHM bins per donor. Kruskal -Wallis test was used to assess statistical significance.

[0057] FIGs. 12A-12D show Surface CD 19 expression and SHM levels are retained at the donor level. (A) Surface CD19 expression on BMPCs per cluster per donor. (B) Frequency of surface CD 19 expression bins per cluster per donor. (C) Somatic hypermutation (SHM) in IgH chain per cluster per donor. (D) Frequency of IgH SHM bins per surface CD 19 expression bins per donor.

[0058] FIGs. 13A-13D show Features of clonal structure related to BMPC origins. (A) IgH somatic hypermutation (SHM) per surface CD 19 bin in clonal families with different clonal structures. Kruskal-Wallis test was used to assess statistical significance. (B) Frequency of surface CD 19 bins among IgA2, IgD, IgE, and IgG2 / 3 / 4 BMPCs. Lines connecting dots represent an individual donor. Friedman test was used to assess statistical significance. Only statistically significant differences are shown. (C) IgH SHM in the 20 least mutated and the 20 most mutated heterogenic clones (related to Fig.31). (D) Frequency of cluster identities among clonal families with different clonal structures.

[0059] FIGs. 14A-14F show Performance of GEX-based isotype calling when benchmarked against VDJ-based isotype calling. (A) Number of cells assigned IgH isotype class based on gene expression (GEX) library, compared to “true” isotype class calling based on VDJ library (n = 49,667). (B) Percentage of cells of a given IgH isotype class (as determined by GEX library) that are inferred to pertain to each IgH isotype class based on VDJ library (n = 49,667).114937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPT(C) Performance metrics of GEX-based isotype calling when benchmarked against VDJ library callings at the IgH class level. FPR = False positive rate. FNR = False negative rate.(D) Number of cells assigned IgH isotype subclass based on GEX library, compared to “true” isotype subclass calling based on VDJ library (n = 49,667). (E) Percentage of cells of a given IgH isotype subclass (as determined by GEX library) that are inferred to pertain to each IgH isotype subclass based on VDJ library (n = 49,667). (F) Performance metrics of GEX-based isotype calling when benchmarked against VDJ library callings at the IgH subclass level. FPR = False positive rate. FNR = False negative rate.

[0060] FIGs. 15A-15E show Plasma cell heavy chain isotype proportions in bone marrow.(A) Total IgE concentrations in plasma of donors. (B) Frequency of BMPCs of different IgH isotypes among donors. (C) Frequency of BMPCs of different IgH isotypes among clusters.(D) Age is not a covariate that explains differences in BMPC isotype proportions among allergic and non-allergic individuals. Spearman correlation was performed. (E) Sex is not a covariate that explains differences in BMPC isotype proportions among allergic and non-allergic individuals. Paired Friedman test was performed to identify differences.

[0061] FIGs. 16A-16B show IgE BMPC DEGs and clonal families. (A) Volcano plots of differentially expressed genes among IgE cells and different isotype classes. (B) UMAP projection of clustered BMPCs, highlighting clones that include at least 1 IgE BMPC.

[0062] FIGs 17A-17F show J chain expression among BMPCs. (A) Expression of JCHAIN among clonotypes of different structures. (B) Expression of JCHAIN among BMPCs of different IgH subclasses. (C) Expression of JCHAIN among BMPCs belonging to different surface CD 19 expression categories. (D) Expression of JCHAIN among BMPCs belonging to different IgH SHM categories. (E) JCHAIN expression among BMPCs of different isotypes, subdivided by surface CD 19 expression categories. Sample sizes for CD 19 high / mid / low are: IgAl = 3,137 / 3,497 / 1,892; IgA2 = 165 / 218 / 141; IgE = 4 / 8 / 10; IgGl = 2,137 / 3,411 / 3,401; IgG2 = 926 / 1,188 / 760; IgG3 = 160 / 295 / 230; IgG4 = 103 / 128 / 73; IgM = 252 / 485 / 457; IgD = 42 / 41 / 30). (F) JCHAIN expression among BMPCs of different isotypes, subdivided by IgH SHM categories. Sample sizes for IgH SHM high / mid / low are: nlgAl = 3,246 / 3,341 / 1,939; nIgA2 = 107 / 204 / 213; IgE = 2 / 11 / 9; IgGl = 2,222 / 3,725 / 3,002; IgG2 = 804 / 1,213 / 857; IgG3 = 314 / 109 / 96; IgG4 = 99 / 109 / 96; IgM = 74 / 396 / 724; IgD = 72 / 30 / 11).DETAILED DESCRIPTION124937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPT

[0063] Provided herein are methods and compositions comprising antibodies or antigen binding fragments that bind to a peanut allergen (e.g., Ara h2) and preferably inhibit or reduce symptoms of peanut allergy. Such antibodies or antigen binding fragments can be used in the treatment of a peanut allergy.Antibodies

[0064] Provided herein are exemplary antibodies and antigen binding fragments that bind to peanut allergens. In some embodiments, such antibodies or antigen binding fragments can inhibit or reduce symptoms of peanut allergy or reduce the duration or severity of the allergic immune response to peanut proteins.

[0065] The antibody or antigen binding fragment described herein can be in form of a full antibody or a fragment thereof, e.g., a Fab, F(ab')2, Fv, or a single chain Fv fragment (scFv). For example, the antibody or antigen binding fragment can be selected from the group consisting of Fv, Fab, Fab', F(ab)2, F(ab')2, single-chain antibody, single-chain antibody (scFV), sc(Fv)2, monovalent antibody lacking hinge region, whole antibody, disulfide-stabilized Fv (dsFv), diabody dAb, a bivalent or bispecific antibody, a single domain antibody, a monoclonal antibody, a humanized antibody, a human antibody, a recombinant antibody, or a chimeric antibody.

[0066] In some embodiments of any one of the aspects, the antibody or antigen binding fragment thereof comprises a heavy chain variable region (VH) comprising a complementarity determining region 1 (CDR HI) amino acid sequence of GFSFGSSW (SEQ ID NO: 2).

[0067] In some embodiments of any one of the aspects, the antibody or antigen binding fragment thereof comprises a heavy chain variable region comprising a complementarity determining region 2 (CDR_H2) amino acid sequence of VNGDGSSV (SEQ ID NO: 3).

[0068] In some embodiments of any one of the aspects, the antibody or antigen binding fragment thereof comprises a heavy chain variable region comprising a complementarity determining region 3 (CDR H3) amino acid sequence of VKGKSRRSQYDQ (SEQ ID NO: 4).

[0069] In some embodiments of any one of the aspects, the antibody or antigen binding fragment thereof comprises a light chain variable region (VL) comprising a complementarity determining region 1 (CDR_L1) amino acid sequence of QDVDKY (SEQ ID NO: 15).

[0070] In some embodiments of any one of the aspects, the antibody or antigen binding fragment thereof comprises a light chain variable region comprising a complementarity determining region 2 (CDR L2) amino acid sequence of DVS (SEQ ID NO: 16).134937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPT

[0071] In some embodiments of any one of the aspects, the antibody or antigen binding fragment thereof comprises a light chain variable region comprising a complementarity determining region 3 (CDR_L3) amino acid sequence of QQYDNLPIT (SEQ ID NO: 17).

[0072] In addition to the CDRs, the heavy chain variable region can also comprise one or more framework (FR) sequences. Accordingly, in some embodiments of any one of the aspects, the heavy chain variable region further comprises a framework region 1 (FR1, also referred to as FW HI herein) sequence that differs by no more than four, preferably no more than three, more preferably no more than two, most preferably no more than one amino acid from EVQLVESGGGLVQPGGSLRLSCVAS (SEQ ID NO: 10).

[0073] In some embodiments of any one of the aspects, the heavy chain variable region further comprises a FR2 (also referred to as FW H2 herein) sequence that differs by no more than four, preferably no more than three, more preferably no more than two, most preferably no more than one amino acid from MHWVRQDPAKGLVWVAR (SEQ ID NO: 11).

[0074] In some embodiments of any one of the aspects, the heavy chain variable region further comprises a FR3 (also referred to as FW_H3 herein) sequence that differs by no more than four, preferably no more than three, more preferably no more than two, most preferably no more than one amino acid from SYRDSMEGRFTISRDNAKNTLFLQMNSLRPEDTALYYC (SEQ ID NO: 12).

[0075] In some embodiments of any one of the aspects, the heavy chain variable region further comprises a FR4 (also referred to as FW_H4 herein) sequence that differs by no more than four, preferably no more than three, more preferably no more than two, most preferably no more than one amino acid from WGQGTLVTVSS (SEQ ID NO: 13).

[0076] In some embodiments of any one of the aspects, the antibody or antigen binding fragment thereof comprises a heavy chain variable region comprising an amino acid sequence having at least 80% (e.g., at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity to the amino acid sequence EVQLVESGGGLVQPGGSLRLSCVASGFSFGSSWMHWVRQDPAKGLVWVARVNGD GSSVSYRDSMEGRFTISRDNAKNTLFLQMNSLRPEDTALYYCVKGKSRRSQYDQWG QGTLVTVSS (SEQ ID NO: 9), optionally, at least one (e.g., 1, 2 or all 3) of SEQ ID NOs: 2-4 have 100% identity to the sequence of the heavy chain variable region. In some embodiments of any one of the aspects, the antibody or antigen binding fragment thereof comprises a heavy chain variable region comprising an amino acid sequence having at least 144937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPT85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity to SEQ ID NO: 9, optionally, at least one (e..g., 1, 2 or all 3) of SEQ ID NOs: 2-4 have 100% identity to SEQ ID NO: 9. In some embodiments of any one of the aspects, the antibody or antigen binding fragment thereof comprises a heavy chain variable region comprising an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity to SEQ ID NO: 9, optionally at least one (e.g., 1, 2 or all 3) of SEQ ID NOs: 2-4 have 100% identity to SEQ ID NO: 9. In some embodiments of any one of the aspects, the antibody or antigen binding fragment thereof comprises a heavy chain variable region comprising an amino acid sequence having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity to SEQ ID NO: 9, optionally at least one (e.g., 1, 2 or all 3) of SEQ ID NOs: 2-4 have 100% identity to SEQ ID NO: 9.

[0077] In some embodiments of any one of the aspects, the antibody or antigen binding fragment thereof comprises a heavy chain variable region comprising an amino acid sequence having at least 80% (e.g., at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity to SEQ ID NO: 9, and optionally wherein the heavy chain comprises a HCDR1 sequence having 100% identity to SEQ ID NO: 2; and / or the heavy chain comprises a HCDR2 sequence having 100% identity to SEQ ID NO: 3; and / or the heavy chain comprises a HCDR3 sequence having 100% identity to SEQ ID NO: 4.

[0078] In some embodiments of any one of the aspects, the antibody or antigen binding fragment thereof comprises a heavy chain variable region comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity to SEQ ID NO: 9, and optionally wherein the heavy chain comprises a HCDR1 sequence having 100% identity to SEQ ID NO: 2; and / or the heavy chain comprises a HCDR2 sequence having 100% identity to SEQ ID NO: 3; and / or the heavy chain comprises a HCDR3 sequence having 100% identity to SEQ ID NO: 4.

[0079] In some embodiments of any one of the aspects, the antibody or antigen binding fragment thereof comprises a heavy chain variable region comprising an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity to SEQ ID NO: 9, and optionally 154937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTwherein the heavy chain comprises a HCDR1 sequence having 100% identity to SEQ ID NO: 2; and / or the heavy chain comprises a HCDR2 sequence having 100% identity to SEQ ID NO: 3; and / or the heavy chain comprises a HCDR3 sequence having 100% identity to SEQ ID NO: 4. In some embodiments of any one of the aspects, the antibody or antigen binding fragment thereof comprises a heavy chain variable region comprising an amino acid sequence having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity to SEQ ID NO: 9, and optionally wherein the heavy chain comprises a HCDR1 sequence having 100% identity to SEQ ID NO: 2; and / or the heavy chain comprises aHCDR2 sequence having 100% identity to SEQ ID NO: 3; and / or the heavy chain comprises aHCDR3 sequence having 100% identity to SEQ ID NO: 4 In some embodiments of any one of the aspects, the antibody or antigen binding fragment thereof comprises a heavy chain variable region comprising an amino acid sequence having 100% identity to SEQ ID NO: 9.

[0080] In some embodiments of any one of the aspects, the antibody or antigen binding fragment thereof comprises a heavy chain variable region comprising an amino acid sequence having 100% identity to SEQ ID NO: 9.

[0081] The antibody or antigen binding fragment thereof described herein can comprise antibody constant regions or parts thereof. For example, the heavy chain variable region can be attached at its C -terminal to all or part of a heavy chain like IgA, IgD, IgE, IgG, and IgM, and any isotype subclass. Thus, the antibody or antigen binding fragment thereof described herein can include the CHI, hinge, CH2, CH3. and / or CH4 regions of the heavv chain. In some embodiments, the heavy chain variable region of the antibody or antigen binding fragment thereof described herein is attached at its C -terminal to all or part of an IgG heavy chain.

[0082] The antibody may be an IgG antibody. IgG competes with IgE for binding sites on the allergen and thereby prevent recognition of allergens by IgE bound to Fes receptors on the surface of mast cells and basophils. This may include direct competition by binding to the same epitope or competition through steric hindrance. Furthermore, IgG antibodies bound to the allergen can lead to cross-linking of Fes and inhibitory FcyRIIB receptors, resulting in the decrease of effector cell activity.

[0083] In some embodiments, the antibody or antigen binding fragment thereof does not comprise at least one constant region and / or framework region of IgE. For example, the light chain of the antibody or antigen binding fragment thereof does not comprise a light chain constant region of IgE. In another non-limiting example, the heavy chain of the antibody or antigen binding fragment thereof does not comprise a CHI region, CH2 region, CH1_CH2 hinge region and / or CH3 region of IgE. In still another non-limiting example, the light chain 164937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTof the antibody or antigen binding fragment thereof does not comprise a light chain framework region, e.g., FW LI, FW L2, FW L3 and / or FW L4 of IgE light chain. In still yet another non¬ limiting example, the heavy chain of the antibody or antigen binding fragment thereof does not comprise a heacy chain framework region, e.g., FW Hl, FW H2, FW H3 and / or FW H4 of IgE heavy chain.

[0084] The sequences of IgE polypeptides are known in the art for a number of species, e.g. human IgE (polypeptide; UniProt Ref P01854-2; SEQ ID NO: 27).

[0085] SEQ ID NO: 27 IgE polypeptide sequence UniProt Ref: P01854-2 ASTQSPSVFPLTRCCKNIPSNATSVTLGCLATGYFPEPVMVTWDTGSLNGTTMTLPA TTLTLSGHYATISLLTVSGAWAKQMFTCRVAHTPSSTDWVDNKTFSVCSRDFTPPTV KILQSSCDGGGHFPPTIQLLCLVSGYTPGTINITWLEDGQVMDVDLSTASTTQEGELA STQSELTLSQKHWLSDRTYTCQVTYQGHTFEDSTKKCADSNPRGVSAYLSRPSPFDL FIRKSPTITCLVVDLAPSKGTVNLTWSRASGKPVNHSTRKEEKQRNGTLTVTSTLPVG TRDWIEGETYQCRVTHPHLPRALMRSTTKTSGPRAAPEVYAFATPEWPGSRDKRTL ACLIQNFMPEDISVQWLHNEVQLPDARHSTTQPRKTKGSGFFVFSRLEVTRAEWEQK DEFICRAVHEAASPSQTVQRAVSVNPGLAGGSAQSQRAPDRVLCHSGQQQGLPRAA GGSVPHPRCHCGAGRADWPGPPELDVCVEEAEGEAPWTWTGLCIFAALFLLSVSYS AAITLLMVQRFLSATRQGRPQTSLDYTNVLQPHA.

[0086] In some embodiments of any one of the aspects, the antibody or antigen binding fragment thereof comprises a heavy chain constant region comprising a CHI region comprising an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL QSSGLYSLSSVVTVPSSSLGTQTICNVNHKPSNTKVDKKV (SEQ ID NO: 5). For example, the CHI region comprises an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 5. In some embodiments, the CHI region comprises an amino acid sequence having at least 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 5. In some embodiments of any one of the aspects, the antibody or antigen binding fragment thereof comprises a heavy chain constant region comprising a CHI region comprising an amino acid sequence having 100% identity to SEQ ID NO: 5.

[0087] In some embodiments of any one of the aspects, the antibody or antigen binding fragment thereof comprises a heavy chain constant region comprising a CH2 region comprising an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to 174937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN AKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK(SEQ ID NO: 7 For example, the CH2 region comprises an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 7. In some embodiments, the CH2 region comprises an amino acid sequence having at least 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 7. In some embodiments of any one of the aspects, the antibody or antigen binding fragment thereof comprises a heavy chain constant region comprising a CH2 region comprising an amino acid sequence having 100% identity to SEQ ID NO: 7

[0088] In some embodiments of any one of the aspects, the antibody or antigen binding fragment thereof comprises a heavy chain constant region comprising a CH3 region comprising an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 8) or GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 24) For example, the CH3 region comprises an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 8 or 24. In some embodiments, the CH3 region comprises an amino acid sequence having at least 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 8 or 24. In some embodiments of any one of the aspects, the antibody or antigen binding fragment thereof comprises a heavy chain constant region comprising a CH3 region comprising an amino acid sequence having 100% identity to SEQ ID NO: 8 or 24.

[0089] In some embodiments of any one of the aspects, the antibody or antigen binding fragment thereof comprises a heavy chain constant region comprising a hinge region (CHl_CH2_hinge) comprising an amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to EPKSCDKTHTCPPCP (SEQ ID NO: 6). For example, the hinge region comprises an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 6. In some embodiments, the hinge region comprises an amino acid sequence having at least 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 6. In some embodiments of any one of the aspects, the antibody or antigen binding fragment thereof 184937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTcomprises a heavy chain constant region comprising a CHl_CH2_hinge region comprising an amino acid sequence having 100% identity to SEQ ID NO: 6.

[0090] In some embodiments, of any one of the aspects, the antibody or antigen binding fragment thereof comprises a heavy chain amino acid sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to EVQLVESGGGLVQPGGSLRLSCVASGFSFGSSWMHWVRQDPAKGLVWVARVNGD GSSVSYRDSMEGRFTISRDNAKNTLFLQMNSLRPEDTALYYCVKGKSRRSQYDQWG QGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTS GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTICNVNHKPSNTKVDKKVEPKSCDKT HTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD GVEVHNAI< TI< PREEQYNSTYRVVSVLTVLHQDWLNGI< EYI< CI< VSNI< ALPAPIEI< TI SKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO: 1). For example, the antibody or antigen binding fragment thereof comprises a heavy chain amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 1. In some embodiments, the antibody or antigen binding fragment thereof comprises a heavy chain amino acid sequence having at least 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 1.

[0091] In some embodiments of any one of the aspects, the antibody or antigen binding fragment thereof comprises a heavy chain comprising an amino acid sequence having at least 80% (e.g., at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity to SEQ ID NO: 1, and optionally wherein the heavy chain comprises a LCDR1 sequence having 100% identity to SEQ ID NO: 2; and / or the heavy chain comprises a LCDR2 sequence having 100% identity to SEQ ID NO: 3; and / or the heavy chain comprises a LCDR3 sequence having 100% identity to SEQ ID NO: 4.

[0092] In some embodiments of any one of the aspects, the antibody or antigen binding fragment thereof comprises a heavy chain comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity to SEQ ID NO: 1, and optionally wherein the heavy chain comprises a LCDR1 sequence having 100% identity to SEQ ID NO: 2; and / or the heavy chain comprises a LCDR2194937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTsequence having 100% identity to SEQ ID NO: 3; and / or the heavy chain comprises a LCDR3 sequence having 100% identity to SEQ ID NO: 4.

[0093] In some embodiments of any one of the aspects, the antibody or antigen binding fragment thereof comprises a heavy chain comprising an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity to SEQ ID NO: 1, and optionally wherein the heavy chain comprises aLCDRl sequence having 100% identity to SEQ ID NO: 2; and / or the heavy chain comprises a LCDR2 sequence having 100% identity to SEQ ID NO: 3; and / or the heavy chain comprises a LCDR3 sequence having 100% identity to SEQ ID NO: 4.

[0094] In some embodiments of any one of the aspects, the antibody or antigen binding fragment thereof comprises a heavy chain comprising an amino acid sequence having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity to SEQ ID NO: 1, and optionally wherein the heavy chain comprises a LCDR1 sequence having 100% identity to SEQ ID NO: 2; and / or the heavy chain comprises a LCDR2 sequence having 100% identity to SEQ ID NO: 3; and / or the heavy chain comprises a LCDR3 sequence having 100% identity to SEQ ID NO: 4

[0095] In some embodiments of any one of the aspects, the antibody or antigen binding fragment thereof comprises a heavy chain comprising an amino acid sequence having 100% identity to SEQ ID NO: 1.

[0096] Like the heavy chain variable region, the light chain variable region can also comprise one or more framework (FR) sequences. Accordingly, in some embodiments of any¬ one of the aspects, the light chain variable region further comprises a FR1 (also referred to as FW L I herein) sequence that differs by no more than four, preferably no more than three, more preferably no more than two, most preferably no more than one amino acid from DIQMTQSPSSLSASVGDRVTITCQAS (SEQ ID NO: 20).

[0097] In some embodiments of any one of the aspects, the light chain variable region further comprises a FR2 (also referred to as FW L2 herein) sequence that differs by no more than four, preferably no more than three, more preferably no more than two, most preferably no more than one amino acid from LNWYQQKPGKAPKLLIY (SEQ ID NO: 21).

[0098] In some embodiments of any one of the aspects, the light chain variable region further comprises a FR3 (also referred to as FWJL3 herein) sequence that differs by no more than four, preferably no more than three, more preferably no more than two, most preferably no more than one amino acid from NLETGVPLRFSGGGSGTDFTFTISGLQAEDFATYYC (SEQ ID NO: 22)204937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPT

[0099] In some embodiments of any one of the aspects, the light chain variable region further comprises a FR4 (also referred to as FW L4 herein) sequence that differs by no more than four, preferably no more than three, more preferably no more than two, most preferably no more than one amino acid from FGQGTRLEIK (SEQ ID NO: 23).

[0100] In some embodiments of any one of the aspects, the antibody or antigen binding fragment thereof comprises a light chain variable region comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity to the amino acid sequence DIQMTQSPSSLSASVGDRVTITCQASQDVDKYLNWYQQKPGKAPKLLIYDVSNLETG VPLRFSGGGSGTDFTFTISGLQAEDFATYYCQQYDNLPITFGQGTRLEIK (SEQ ID NO: 19), optionally, at least one (e.g., 1, 2 or all 3) of SEQ ID NOs: 20-23 have 100% identity to SEQ ID NO: 19 For example, the light chain variable region comprises an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity to SEQ ID NO: 19, optionally, at least one (e.g., 1, 2 or all 3) of SEQ ID NOs: 20-23 have 100% identity to SEQ ID NO: 19. In some embodiments of any one of the aspects, the light chain variable region comprises an amino acid sequence having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity to SEQ ID NO: 19, optionally, at least one (e.g., 1, 2 or all 3) of SEQ ID NOs: 20-23 have 100% identity to SEQ ID NO: 19. In some embodiments of any one of the aspects, the antibody or antigen binding fragment thereof comprises a light chain variable region comprising an amino acid sequence having 100% identity to SEQ ID NO: 19.

[0101] In some embodiments of any one of the aspects, the antibody or antigen binding fragment thereof comprises a light chain variable region comprising an amino acid sequence having at least 80% (e.g., at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity to SEQ ID NO: 19, and optionally wherein the light chain comprises a LCDR1 sequence having 100% identity to SEQ ID NO: 15; and / or the light chain comprises a LCDR2 sequence having 100% identity to SEQ ID NO: 16; and / or the light chain comprises a LCDR3 sequence having 100% identity to SEQ ID NO: 17.

[0102] In some embodiments of any one of the aspects, the antibody or antigen binding fragment thereof comprises a light chain variable region comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 214937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPT91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity to SEQ ID NO: 19, and optionally wherein the light chain comprises a LCDR1 sequence having 100% identity to SEQ ID NO: 15; and / or the light chain comprises a LCDR2 sequence having 100% identity to SEQ ID NO: 16; and / or the light chain comprises a LCDR3 sequence having 100% identity to SEQ ID NO: 17.

[0103] In some embodiments of any one of the aspects, the antibody or antigen binding fragment thereof comprises a light chain variable region comprising an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity to SEQ ID NO: 19, and optionally wherein the light chain comprises a LCDR1 sequence having 100% identity to SEQ ID NO: 15; and / or the light chain comprises a LCDR2 sequence having 100% identity to SEQ ID NO: 16; and / or the light chain comprises a LCDR3 sequence having 100% identity to SEQ ID NO: 17.

[0104] In some embodiments of any one of the aspects, the antibody or antigen binding fragment thereof comprises a light chain variable region comprising an amino acid sequence having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity to SEQ ID NO: 19, and optionally wherein the light chain comprises a LCDR1 sequence having 100% identity to SEQ ID NO: 15; and / or the light chain comprises a LCDR2 sequence having 100% identity to SEQ ID NO: 16; and / or the light chain comprises a LCDR3 sequence having 100% identity to SEQ ID NO: 17.

[0105] In some embodiments of any one of the aspects, the antibody or antigen binding fragment thereof comprises a light chain variable region comprising an amino acid sequence having 100% identity to SEQ ID NO: 19.

[0106] The antibody or antigen binding fragment thereof described herein can comprise antibody constant regions or parts thereof. For example, the light chain variable region (VL) can be attached at its C -terminal end to constant antibody light chain domains (CL). Accordingly, in some embodiments of any one of the aspects, the antibody or antigen binding fragment thereof comprises a light chain constant region (CL) comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity to RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVT EQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 18) For example, the CL region comprises an amino acid sequence having at least 90%,224937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTat least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity to SEQ ID NO: 18. In some embodiments, the CL region comprises an amino acid sequence having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity to SEQ ID NO: 18. For example, the CL region comprises an amino acid sequence having 100% identity to SEQ ID NO: 18.

[0107] In some embodiments, of any one of the aspects, the antibody or antigen binding fragment thereof comprises a light chain amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity to an amino acid sequence of DIQMTQSPSSLSASVGDRVTITCQASQDVDKYLNWYQQKPGKAPKLLIYDVSNLETG VPLRFSGGGSGTDFTFTISGLQAEDFATYYCQQYDNLPITFGQGTRLEIKRTVAAPSV FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDST YSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 14). For example, the antibody or antigen binding fragment thereof comprises a light chain amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity to SEQ ID NO: 14. In some embodiments, the antibody or antigen binding fragment thereof comprises a light chain amino acid sequence having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity to SEQ ID NO: 14. For example, the antibody or antigen binding fragment thereof comprises a light chain amino acid sequence having 100% identity to SEQ ID NO: 14.

[0108] In some embodiments of any one of the aspects, the antibody or antigen binding fragment thereof comprises a light chain comprising an amino acid sequence having at least 80% (e.g., at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity to SEQ ID NO: 14, and optionally wherein the light chain comprises a LCDR1 sequence having 100% identity to SEQ ID NO: 15; and / or the light chain comprises a LCDR2 sequence having 100% identity to SEQ ID NO: 16; and / or the light chain comprises a LCDR3 sequence having 100% identity to SEQ ID NO: 17.

[0109] In some embodiments of any one of the aspects, the antibody or antigen binding fragment thereof comprises a light chain comprising an amino acid sequence having at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 234937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPT99% identity to SEQ ID NO: 14, and optionally wherein the light chain comprises a LCDR1 sequence having 100% identity to SEQ ID NO: 15; and / or the light chain comprises a LCDR2 sequence having 100% identity to SEQ ID NO: 16; and / or the light chain comprises a LCDR3 sequence having 100% identity to SEQ ID NO: 17.

[0110] In some embodiments of any one of the aspects, the antibody or antigen binding fragment thereof comprises a light chain comprising an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity to SEQ ID NO: 14, and optionally wherein the light chain comprises a LCDR1 sequence having 100% identity to SEQ ID NO: 15; and / or the light chain comprises a LCDR2 sequence having 100% identity to SEQ ID NO: 16; and / or the light chain comprises a LCDR3 sequence having 100% identity to SEQ ID NO: 17.

[0111] In some embodiments of any one of the aspects, the antibody or antigen binding fragment thereof comprises a light chain comprising an amino acid sequence having at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identity to SEQ ID NO: 14, and optionally wherein the light chain comprises a LCDR1 sequence having 100% identity to SEQ ID NO: 15; and / or the light chain comprises a LCDR2 sequence having 100% identity to SEQ ID NO: 16; and / or the light chain comprises a LCDR3 sequence having 100% identity to SEQ ID NO: 17

[0112] In some embodiments of any one of the aspects, the antibody or antigen binding fragment thereof comprises a light chain comprising an amino acid sequence having 100% identity to SEQ ID NO: 14.

[0113] In another embodiment of this aspect and all other aspects provided herein, the antibody or antigen binding fragment reduces FcsRI receptor activity and / or one or more symptoms of a peanut allergy by at least 20% (e.g., at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, at least 99% or even 100% (i.e., complete inhibition of FcsRI receptor activity or complete reduction of symptoms) as compared to FcsRI receptor activity and / or one or more symptom of a peanut allergy in the absence of the antibody or antigen binding fragment.

[0114] In another embodiment of this aspect and all other aspects provided herein, the antibody or antigen binding fragment reduces reduces allergen mediated immune response by at least 20% (e.g., at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, at least 99% or even 100% (i.e., complete reduction of the allergen mediated immune response) as compared to the allergen mediated immune response in the absence of the antibody or antigen binding fragment. Some allegen mediated 244937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTimmune responses include, but are not limited to a Th2 cell response, B cell activation, basophil activation, eosinophil activation, mast cell activation, and / or IgE induction.

[0115] In another embodiment of this aspect and all other aspects provided herein, the antibody or antigen binding fragment reduces reduces anaphylactic response by at least 20% (e.g., at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, at least 99% or even 100% (i.e., complete reduction of the anaphylactic response) as compared to the anaphylactic response in the absence of the antibody or antigen binding fragment. Some anaphylactic responses include but are not limited to swelling of the face, lips tongue, or throat, difficulty breathing or wheezing, hives, itching, or rash, low blod pressure, rapid heartbeat, dizziness or fainting, nausea, vomiting, or diarrhea, confusion, and / or loss of consciousness.

[0116] A variety of suitable antibody formats are known in the art, such as complete antibodies, e.g., an IgG, or modified forms or fragments of such antibodies, including, as non-limiting examples, single chain antibodies, heterodimers of antibody heavy chains and / or light chains, an Fv fragment (e.g., single chain Fv (scFv), a disulfide bonded Fv), a Fab fragment, a Fab' fragment, a F(ab')2 fragment), a single variable domain (e.g., VH, VL, VHH), a dAb, and modified versions of any of the foregoing (e.g., modified by the covalent attachment of polyalkylene glycol (e.g., polyethylene glycol, polypropylene glycol, polybutylene glycol) or other suitable polymer). Antibody reagents or constructs can, if desired, be linked to an antibody Fc region, comprising one or both of CH2 and CH3 domains, and optionally, a hinge region. Such linkage can provide benefits such as increased serum half-life or promotion of effector function(s). Alternatively, antibody reagents or constructs can be fused to a carrier such as serum albumin to promote increased serum half-life.

[0117] In some embodiments, the antibody or antigen binding fragment described herein comprises a detectable label.

[0118] Antibodies suitable for practicing the methods described herein are preferably monoclonal, and can include, but are not limited to, human, humanized or chimeric antibodies, including single chain antibodies, Fab fragments, F(ab') fragments, fragments produced by a Fab expression library, and / or binding fragments of any of the above. Antibody and antigen fragments thereof can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., IgGl, IgG2, IgG3, IgG4, IgAl and IgA2) or subclass of immunoglobulin molecule, as understood by one of skill in the art.

[0119] In one embodiment, the antibody that binds a peanut allergen is a monoclonal antibody.254937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPT

[0120] Additional types of antibodies include, but are not limited to, chimeric, humanized, and human antibodies. For application in man, it is often desirable to reduce immunogenicity of antibodies originally derived from other species, like mouse. This can be done by construction of chimeric antibodies, or by a process called “humanization”. In this context, a “chimeric antibody” is understood to be an antibody comprising a domain (e.g. a variable domain) derived from one species (e.g. mouse) fused to a domain (e.g. the constant domains) derived from a different species (e.g. human).

[0121] The term “monoclonal antibody” as used herein refers to a population of antibodies that comprise an identical antigen binding domain. In some embodiments, a monoclonal antibody can be produced by a single B cell clone, B cell hybrodima or its equivalent. Such a cell produces only one antibody, such that all antibodies produced by such a clone have the same antigen binding domain. In contrast to polyclonal antibody preparations that typically include different antibodies directed against different determinants (epitopes) on a given target antigen, each monoclonal antibody is directed against a single determinant on the antigen. The term “monoclonal antibody” as used herein is not limited to antibodies produced through hybridoma technology. It is to be understood that the term “monoclonal antibody” refers to an antibody that is derived from a single clone, including any eukaryotic, prokaryotic or phage clone, and not the method by which the antibody is produced. For example, the monoclonal antibodies to be used in accordance with the methods and compositions described herein can be made by the hybridoma method first described by Kohler et al., Nature 256:495 (1975), or can be made by recombinant DNA methods (see, e.g., U. S. Pat. No. 4,816,567). The “monoclonal antibodies” can also be isolated from phage antibody libraries using the techniques described in Clackson et al., Nature 352:624-628 (1991) or Marks et al., J. Mol. Biol. 222:581-597 (1991), for example. A wide variety of methods for producing constructs with the antigen binding domain of monoclonal antibodies are known to those of ordinary skill in the art.

[0122] Antibodies useful in the present methods can be described or specified in terms of the particular CDRs they comprise (see e.g., Tables 1 and 2). The compositions and methods described herein encompass the use of an antibody or derivative thereof comprising a heavy or light chain variable domain, where the variable domain comprises (a) a set of three CDRs, and (b) a set of four framework regions, and in which the antibody or antibody derivative thereof specifically binds a peanut allergen.

[0123] Also provided herein are chimeric antibody derivatives of an anti-peanut allergen polypeptide agent, i.e., antibody molecules in which a portion of the heavy and / or light chain is identical with or homologous to corresponding sequences in antibodies derived from a 264937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTparticular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is / are identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (U. S. Pat. No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA 81:6851-6855 (1984)). Chimeric antibody molecules can include, for example, one or more antigen binding domains from an antibody of a mouse, rat, or other species, with human constant regions. A variety of approaches for making chimeric antibodies have been described and can be used to make chimeric antibodies containing the immunoglobulin variable region which recognizes the selected antigens, on the surface of differentiated cells or tumor-specific cells. See, for example, Takeda et al., 1985, Nature 314:452; Cabilly et al., U. S. Pat. No. 4,816,567; Boss et al.; Tanaguchi et al., European Patent Publication EP171496; European Patent Publication 0173494, United Kingdom patent GB 2177096B).

[0124] The antibodies described herein can also include humanized antibody derivatives. Humanized forms of non-human (e.g., murine) antibodies are chimeric antibodies which contain minimal sequence derived from non-human immunoglobulin. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a hypervariable region of the recipient are replaced by residues from a hypervariable region of a non-human species (donor antibody) such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity, and capacity. In some instances, Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies can comprise residues which are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin sequence. The humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol. 2:593-596 (1992).

[0125] In some embodiments, antibodies described herein include derivatives that are modified, i.e., by the covalent attachment of another type of molecule to the antibody that does not prevent the antibody from binding to its target. For example, but not by way of limitation,274937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTthe antibody derivatives include antibodies that have been modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting / blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of numerous chemical modifications can be carried out by known techniques, including, but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of turicamycin, etc. Additionally, the derivative can contain one or more non-classical amino acids.

[0126] Antibodies or antigen binding fragments thereof that bind peanut allergens as described herein can be generated by any suitable method known in the art. Antibodies can be produced in bacteria, yeast, fungi, protozoa, insect cells, plants, or mammalian cells (see e.g., Frenzel et al. (2013) Front Immunol. 4: 217). A mammalian expression system is generally preferred for manufacturing most of therapeutic proteins, such as antibodies, as they require post-translational modifications. A variety of mammalian cell expression systems are now available for expression of antibodies, including but not limited to immortalized Chinese hamster ovary (CHO) cells, mouse myeloma (NSO), mouse L-cells, myeloma cell lines like J558L and Sp2 / 0, baby hamster kidney (BHK), or human embryo kidney (HEK-293).

[0127] In certain embodiments, the antibodies described herein are produced in antibody producing cells isolated and / or derived from a human or mammalian subject, which permits manipulation and serves as the basis for production of mammalian, including human, hybridoma cell lines. Typically, the host animal is inoculated intraperitoneally with an amount of immunogen, e.g., Raji cells or SCR1 / SCR2 fusion protein, sufficient to generate an immunogenic response and then boosted with similar amounts of the immunogen. Lymphoid cells, preferably spleen lymphoid cells from the host, are collected a few days after the final boost and a cell suspension is prepared therefrom for use in the fusion.

[0128] In some embodiments, the antibody or antigen binding fragment thereof described herein is a humanized antibody. Methods for generating humanized antibodies are known to those of skill in the art and are not described in detail herein. The following four general steps for generating a humanized antibody include: (1) determining the nucleotide and predicted amino acid sequence of the starting antibody light and heavy variable domains (2) designing the humanized antibody, i.e., deciding which antibody framework region to use during the humanizing process (3) the actual humanizing methodologies / techniques and (4) the transfection and expression of the humanized antibody. See, for example, U. S. Pat. Nos.4,816,567; 5,807,715; 5,866,692; and 6,331,415.284937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPT

[0129] In yet another alternative, fully human antibodies can be obtained by using commercially available mice that have been engineered to express specific human immunoglobulin proteins. Transgenic animals that are designed to produce a more desirable (e.g., fully human antibodies) or more robust immune response can also be used for generation of humanized or human antibodies. Examples of such technology are Xenomouse™ from Abgenix, Inc. (Fremont, Calif.) and HuMAb-Mouse® and TC Mouse™ from Medarex, Inc. (Princeton, N. J.).

[0130] In an alternative, antibodies can be made recombinantly and expressed using any method known in the art. Antibodies can be made recombinantly by expressing the gene sequence of a given anti-peanut allergen antibody recombinantly in host cells (e.g., CHO cells). Another method which can be employed is to express the antibody sequence in plants (e.g., tobacco) or transgenic milk. Methods for expressing antibodies recombinantly in plants or milk have been disclosed. See, for example, Peeters, et al. (2001) Vaccine 19:2756; Lonberg, N. and D. Huszar (1995) Int. Rev. Immunol 13:65; and Pollock, et al. (1999) J Immunol Methods 231:147. Methods for making derivatives of antibodies, e.g., humanized, single chain, etc. are known in the art. In another alternative, antibodies can be made recombinantly by phage display technology. See, for example, U. S. Pat. Nos. 5,565,332; 5,580,717; 5,733,743; 6,265,150; and Winter et al., Annu. Rev. Immunol. (1994) 12:433-455. In addition, binding of a peanut allergen to cells can be characterized in a number of assays known in the art, including FACS (Fluorescence Activated Cell Sorting), immunofluorescence, and immunocytochemi stry.

[0131] Immunoassays and flow cytometry sorting techniques such as fluorescence activated cell sorting (FACS) can also be employed to isolate antibodies that are specific for a peanut allergen and that bind to peanut protein epitopes, e.g., Epitope 2, PDB 8G4P of helix 3 of Ara h 2. For example, ELISA can be employed to determine which antibodies are specific for Ara h 2. Flow cytometry can be used to assess how well the antibody(-ies) bind to peanut allergenexpressing cells.

[0132] As used herein, the term “Complementarity Determining Regions” (CDRs, i.e., CDR1, CDR2, and CDR3) refers to the amino acid residues of an antibody variable domain the presence of which are necessary for specific antigen binding. Each variable domain typically has three CDR regions identified as CDR1, CDR2 and CDR3. Each complementarity determining region can comprise amino acid residues from a “complementarity determining region” as defined by Kabat (i.e., residues 26-33 (HCDR1), 51-58 (HCDR2) and 97-108 (HCDR3) in the light chain variable domain and 31-35 (Hl), 50-65 (H2) and 95-102 (H3) in 294937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTthe heavy chain variable domain). Likewise, “frameworks” (FWs) comprise amino acids 1-25 (FW H1), 34-50 (FW H2), 59-96 (FW H3), and 109-119 (FW H4) in the heavy chain variable domain and 1-26 (FW Ll), 33-49 (FW L2), 53-98 (FW L3), and 98-107 (FW L4) in the heavy chain variable domain taking into account the Kabat numbering system (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1987, 1991)).

[0133] The Kabat residue designations do not always correspond directly with the linear numbering of the amino acid residues. The actual linear amino acid sequence can contain fewer or additional amino acids than in the strict Kabat numbering corresponding to a shortening of, or insertion into, a structural component, whether framework or complementarity determining region (CDR), of the basic variable domain structure. The correct Kabat numbering of residues can be determined for a given antibody by alignment of residues of homology in the sequence of the antibody with a “standard” Kabat numbered sequence. Methods and computer programs for determining sequence similarity are publicly available, including, but not limited to, the GCG program package (Devereux et al., Nucleic Acids Research 12: 387, 1984), BLASTP, BLASTN, FASTA (Altschul et al., J. Mol. Biol. 215:403 (1990), and the ALIGN program (version 2.0). The well-known Smith Waterman algorithm can also be used to determine similarity. The BLAST program is publicly available from NCBI and other sources (BLAST Manual, Altschul, et al., NCBI NLM NIH, Bethesda, Md. 20894; BLAST 2.0 at http: / / www.ncbi.nlm.nih.gov / blast / ). In comparing sequences, these methods account for various substitutions, deletions, and other modifications.Table 1: Exemplary heavy chain (HC), light chain (LC) and CDR sequences of exemplary antibodies as described herein.304937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPT

[0134] Immunoglobin peanut antigen binding proteins (e.g., IgG binding proteins) can be modified to reduce immunogenicity. Reduced immunogenicity is desirable in proteins intended for use as therapeutics, as it reduces the chance that the subject will develop an immune response against the therapeutic molecule. Techniques useful for reducing immunogenicity include deletion / modification of potential human T cell epitopes and ‘germlining’ of sequences outside of the CDRs (e.g., framework and Fc). Such methods are known to those of skill in the art and are not described in detail herein.314937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPT

[0135] Standard recombinant nucleic acid methods can be used to express a protein that binds to a peanut allergen. Generally, a nucleic acid sequence encoding the protein is cloned into a nucleic acid expression vector. Of course, if the protein includes multiple polypeptide chains, each chain can be cloned into an expression vector, e.g., the same or different vectors, that are expressed in the same or different cells.

[0136] In certain embodiments, the antibodies described herein are bound to one or more carriers. Carriers can be active and / or inert. Examples of well-known carriers include polypropylene, polystyrene, polyethylene, dextran, nylon, amylases, glass, natural and modified celluloses, polyacrylamides, agaroses and magnetite. The nature of the carrier can be either soluble or insoluble for purposes of the invention. Those skilled in the art will know of other suitable carriers for binding antibodies, or will be able to ascertain such, using routine experimentation.

[0137] The antibodies can also be conjugated to a detectable agent. The complex is useful to detect the antigens to which the antibody specifically binds in a sample, using standard immunochemical techniques such as flow cytometry or immunohistochemistry as described by Harlow and Lane (1988) supra. Detectable markers can also be used to ascertain binding specificity for a type of cell by using the detectable marker with another marker which is definitive for that cell type and analyzing the staining patterns by FACS. There are many different labels and methods of labeling known to those of ordinary skill in the art. Examples of the types of labels which can be used with the antibodies described herein include radioisotopes, enzymes, colloidal metals, fluorescent compounds (e.g., FITC, PE, PECy5, APC, etc.), bioluminescent compounds, and chemiluminescent compounds. Those of ordinary skill in the art will know of other suitable labels for binding to the antibody, or will be able to ascertain such, using routine experimentation. Furthermore, the binding of these labels to an antibody as described herein can be done using standard techniques common to those of ordinary skill in the art.Peanut Allergies

[0138] As used herein, “peanut allergy” refers to a type of food allergy to peanuts. Peanut allergy occurs when an individual's immune system mistakenly identifies peanut proteins as something harmful. Direct or indirect contact with peanuts causes the individual's immune system to release symptom-causing chemicals such as histamines into their bloodstream. Exposure to peanuts can trigger an allergic reaction and can occur in various ways including, without limitation, direct contact (e.g., eating peanuts or peanut-containing foods or through 324937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTdirect skin contact with peanuts); cross-contact (e.g., an unintended introduction of peanuts into a product) or inhalation (e.g., an allergic reaction may occur if an individual inhales dust or aerosols containing peanuts, from a source such as peanut flour or peanut oil cooking spray

[0139] In some embodiments, the antibodies described herein may reduce, minimize, or prevent at least one symptom in a patient sensitive to peanut allergens, such as skin reactions such as hives, redness or swelling, itching or tingling in or around the mouth or throat, digestive problems such as diarrhea, stomach cramps, nausea, or vomiting, tightening of the throat, sneezing, congestion, nasal blockage, coughing, wheezing, bronchoconstriction, rhinitis, or shortness of breath. In other emobodiments, the antibodies may be capable of preventing even more serious in vivo complications associated with exposure to the peanut allergen in sensitized individuals, such as asthmatic responses, swelling of the throat that makes it difficult to breath, a severe drop in blood pressure (shock), rapid pulse, dizziness, lightheadedness or loss of consciousness, anaphylaxis, or even death. Children and adults who have a severe peanut allergy are especially at risk of having this life-threatening reaction.

[0140] The term "allergen," refers to a substance, chemical, particle or composition that is capable of stimulating an allergic response in a susceptible individual. Allergens may be contained within or derived from a food item such as, e.g., peanuts. Alternatively, an allergen may be contained within or derived from a non-food item such as, e.g., dust (e.g., containing dust mite), pollen, insect venom (e.g., venom of bees, wasps, mosquitos, fire ants, etc.), mold, animal fur, animal dander, wool, latex, metals (e.g., nickel), household cleaners, detergents, medication, cosmetics (e.g., perfumes, etc.), drugs (e.g., penicillin, sulfonamides, salicylate, etc.), therapeutic monoclonal antibodies (e.g., cetuximab), ragweed, grass and birch. In some embodiments, an allergen is contained within or derived from peanut. The term "peanut allergen", as used herein, refers to any protein of the Arachis hypogaea species, and isoforms thereof, suggested to cause an allergy for a human. In preferred embodiments, the term "peanut allergen", as used herein, refers to any of the suggested peanut allergens, and isoforms thereof, or a protein with an amino acid sequence of at least 90%, at least 92 %, at least 95%, or at least 98% amino acid sequence identity with such a peanut allergen and isoform thereof. Known peanut allergens can be found on the world wide web at allergen.org. In preferred embodiments, the term "peanut allergen", as used herein, refers to any one of the peanut allergens, and isoforms thereof, selected from Ara h 1, Ara h 2, Ara h 3, Ara h 4, Ara h 5, Ara h 6, Ara h 7, Ara h 8, Ara h 9, Ara h 10, Ara h 11, Ara h 12, Ara h 13, Ara h 14, Ara h 15, Ara h 16, Ara h 17, or Ara h 18, or a protein with an amino acid sequence of at least 90%, at least 92 %, at least 95%, or at least 98% amino acid sequence identity with such 334937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTa peanut allergen and isoform thereof. More preferably, the term "peanut allergen", as used herein, refers to the peanut allergen and isoforms thereof, Ara h 2, or a protein with an amino acid sequence of at least 90%, at least 92 %, at least 95%, or at least 98% amino acid sequence identity with such a peanut allergen and isoform thereof. The terms "allergen" and "antigen" are used interchangeably through the disclosure.

[0141] Allergenic fragments of Ara h 2 are also considered peanut allergens and may be identified according to standard methods.

[0142] As described herein, “Ara h 2” also known as conglutin-7, refers to a peanut allegen and a 2S albumin seed storage protein. The sequences of Ara h 2 polypeptides and nucleic acids encoding such polypeptides are known in the art for a number of species, e.g. human Ara h 2 (polypeptide; NCBI Ref Seq: NP_001392340.1; SEQ ID NO: 25); and mRNA; NCBI Ref Seq: NM_001405411.1; SEQ ID NO: 26). Crystal structure and IgE binding of Ara h 2 are known to those skilled in the art, and are described in Mueller et al., 2011 and / or Min et al., 2025.

[0143] SEQ ID NO: 25 Ara h 2 polypeptide sequence NCBI Ref Seq:NP_001392340.1:makltilvalalfllaahasarqqwelqgdrrcqsqleranlrpceqhlmqkiqrdedsygrdpyspsqdpyspsqdpdrrdpysp spydrrgagssqhqerccnelnefennqrcmcealqqimenqsdrlqgrqqeqqfkrelrnlpqqcglrapqrcdlevesggrdr y

[0144] SEQ ID NO: 26 Ara h 2 mRNA sequence NCBI Ref Seq: NM_001405411.1: aaaaaacaccacacactcttcaatacacattccataaccaccacaacaacaatggccaagctcaccatactagtagccctcgcccttttc ctcctcgctgcccacgcatctgcgaggcagcagtgggaactacaaggagacagaagatgccagagccagctcgagagggcgaac cttaggccctgcgagcaacatctcatgcagaaaatccaacgtgacgaggattcatatggacgggacccgtacagccctagtcaggat ccgtacagccctagtcaggacccggacagacgtgatccgtacagccctagtccatatgatcggagaggcgctggatcctctcagcac caagagaggtgttgcaatgagctgaacgagtttgagaacaaccaaaggtgcatgtgcgaggcattgcaacagataatggagaacca gagcgataggttgcaggggaggcaacaggagcaacagttcaagagggagctcaggaacttgcctcaacagtgcggcctcagggc accacagcgttgcgacttggaagtcgaaagtggcggcagagacagatactaaacacctatctcaaaaaaagaaaagaaaagaaaag aaaatagcttatatataagctattatctatggtaatgttagttttggtaataataaagatcatcactatatgaatgtgttgatcgtgttaactaag gcaagcttaggttatatgagcacctttagagtgcttttatggcgttgtctatgttttgttgctgcagagttgtaaccatcttgaaataatataaa aagatcatgttttgttttggcgagtaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa

[0145] The antibody or antigen binding fragment described herein is capable of binding a peanut allergen. In some embodiments, the antibody or antigen binding fragment described herein a S2 albumin family member. In some embodiments, the antibody or antigen binding fragment described herein is capable of binding Ara h 2. In some embodiments, the antibody or antigen binding fragment described herein is capable of binding helix 3 of Ara h 2.

[0146] In some embodiments, an allergic immune response contemplated herein includes a Th2 T cell response, B-cell activation, basophil activation, eosinophil activation, mast cell344937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTactivation, and / or IgE induction. Additional immune responses include a T cell dependent mechanism involving the upregulation of T helper type-2 (Th2) cytokine production (e.g., IL-4, IL-5, IL-9, and IL-13), B cell class switching leading to the production of IgE antibody, and / or IgE gG ratio. In some embodiments, the antibody or antigen binding fragment described herein inhibits or reduces allergic immune response, i.e., a Th2 cell response, B cell activation, basophil activation, eosinophil activation, mast cell activation, and / or IgE induction.

[0147] In some embodiments, an allergic immune response contemplated herein includes FcsRI receptor activity. The FcsRI complex is the high affinity cell surface receptor for the Fc region of antigen specific immunoglobulin E (IgE) molecules. FcsRI is multimeric and is a member of a family of related antigen / Fc receptors which have conserved structural features and which exhibit similar functional activities in initiating intracellular signaling cascades. In humans, FcsRI controls the activation of mast cells and basophils, and participates in IgE mediated antigen presentation. Multivalent antigens bind and crosslink IgE molecules held at the cell surface by FcsRI. Receptor aggregation induces multiple signaling pathways that control diverse effector responses, including secretion of allergic mediators and the induction of cytokine gene transcription (such as IL-4, IL-6, TNFa and GM-CSF). FcsRI therefore is central to the induction and maintenance of an allergic response and physiologically may confer protection in parasitic infections. In some embodiments, the antibody or antigen binding fragment described herein inhibits or reduces binding of IgE to FcsRI and / or inhibits or reduces FcsRI receptor activity.Polynucleotides

[0148] The disclosure also provides a polynucleotide encoding an antibody or antigen binding fragment thereof described herein. The skilled person will understand that, due to the degeneracy of the genetic code, a given antibody or antigen binding fragment thereof can be encoded by different polynucleotides. These “variants” are encompassed herein.

[0149] In some embodiments of any one of the aspects, the polynucleotide encoding a heavy chain antibody or antigen binding fragment thereof described herein comprises a nucleotide sequence having the nucleotide sequence of: GAGGTGCAACTGGTGGAGTCCGGGGGAGGCTTAGTCCAGCCTGGGGGGTCCCTG AGACTCTCCTGTGTAGCCTCTGGCTTCAGTTTCGGTAGTTCCTGGATGCACTGGGT CCGCCAAGACCCAGCGAAGGGGCTGGTTTGGGTCGCACGTGTCAATGGTGATGG AAGCAGTGTAAGTTATAGAGACTCCATGGAGGGCCGATTCACCATCTCCAGAGA CAACGCCAAGAATACTCTGTTTCTACAAATGAACAGTCTGAGGCCCGAAGACAC354937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTGGCTCTGTATTATTGTGTGAAAGGGAAGTCTCGGAGGAGTCAGTATGACCAGTG GGGCCAGGGAACCCTGGTCACCGTCTCCTCA (SEQ ID NO: 28).

[0150] In some embodiments of any one of the aspects, the polynucleotide encoding a light chain antibody or antigen binding fragment thereof described herein comprises a nucleotide sequence having the nucleotide sequence of: GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTTGGAGACAGAG TCACCATCACTTGCCAGGCGAGTCAGGATGTTGACAAATATTTAAATTGGTATCA GCAGAAACCAGGGAAAGCCCCTAAACTCCTGATCTACGACGTGTCCAATTTGGA AACAGGGGTCCCATTAAGGTTCAGTGGAGGTGGATCTGGGACAGATTTTACTTTC ACCATCAGCGGCCTGCAGGCTGAAGATTTTGCAACATATTACTGTCAACAATATG ATAATTTGCCCATCACCTTCGGCCAAGGGACACGGCTGGAAATTAAA (SEQ ID NO: 29)

[0151] In some embodiments, a nucleic acid encoding an antibody or antigen binding fragment thereof described herein is comprised in a vector. In some embodiments, a nucleic acid sequence encoding an antibody or antigen binding fragment thereof described herein is operably linked to a vector. The term “vector”, as used herein, refers to a nucleic acid construct designed for delivery to a host cell or for transfer between different host cells. As used herein, a vector can be viral or non-viral. The term “vector” encompasses any genetic element that is capable of replication when associated with the proper control elements and that can transfer gene sequences to cells. A vector can include, but is not limited to, a cloning vector, an expression vector, a plasmid, phage, transposon, cosmid, chromosome, virus, virion, etc.

[0152] In some embodiments, the vector is recombinant, e.g., it comprises sequences originating from at least two different sources. In some embodiments of any of the aspects, the vector comprises sequences originating from at least two different species. In some embodiments of any of the aspects, the vector comprises sequences originating from at least two different genes, e.g., it comprises a fusion protein or a nucleic acid encoding an expression product which is operably linked to at least one non-native (e.g., heterologous) genetic control element (e.g., a promoter, suppressor, activator, enhancer, response element, or the like).

[0153] In some embodiments, the vector or nucleic acid described herein is codon-optimized, e.g., the native or wild-type sequence of the nucleic acid sequence has been altered or engineered to include alternative codons such that altered or engineered nucleic acid encodes the same polypeptide expression product as the native / wild-type sequence, but will be transcribed and / or translated at an improved efficiency in a desired expression system. In some embodiments, the expression system is an organism other than the source of the native / wild- 364937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTtype sequence (or a cell obtained from such organism). In some embodiments, the vector and / or nucleic acid sequence described herein is codon-optimized for expression in a mammal or mammalian cell, e.g., a mouse, a murine cell, or a human cell. In some embodiments, the vector and / or nucleic acid sequence described herein is codon-optimized for expression in a human cell. In some embodiments, the vector and / or nucleic acid sequence described herein is codon-optimized for expression in a yeast or yeast cell. In some embodiments, the vector and / or nucleic acid sequence described herein is codon-optimized for expression in a bacterial cell. In some embodiments, the vector and / or nucleic acid sequence described herein is codon-optimized for expression in an E. coli cell.

[0154] As used herein, the term “expression vector” refers to a vector that directs expression of an RNA or polypeptide from sequences linked to transcriptional regulatory sequences on the vector. The sequences expressed will often, but not necessarily, be heterologous to the cell. An expression vector may comprise additional elements, for example, the expression vector may have two replication systems, thus allowing it to be maintained in two organisms, for example in human cells for expression and in a prokaryotic host for cloning and amplification.

[0155] As used herein, the term “viral vector” refers to a nucleic acid vector construct that includes at least one element of viral origin and has the capacity to be packaged into a viral vector particle. The viral vector can contain the nucleic acid encoding an antibody or antigen binding fragment thereof as described herein in place of non-essential viral genes. The vector and / or particle may be utilized for the purpose of transferring any nucleic acids into cells either in vitro or in vivo. Numerous forms of viral vectors are known in the art.Cells

[0156] The disclosure also provides a cell comprising an antibody or an antigen binding fragment described herein. The disclosure further provides a host cell comprising a polynucleotide described herein or a plasmid or vector described herein. As used herein, the term “cell” refers to a single cell as well as to a population of (i.e., more than one) cells.

[0157] A host cell can be a prokaryotic or eukaryotic host cell. Exemplary host cells include, but are not limited to, bacterial cells, yeast cells, plant cell, animal (including insect) or human cells. The host cells can be employed in a method of producing an antibody or antigen binding fragment thereof described herein. Generally, the method comprises: culturing a host cell comprising a polynucleotide described herein or a plasmid or vector described herein under conditions such that the antibody or antigen binding fragment thereof is expressed; and 374937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPToptionally recovering the antibody or antigen binding fragment thereof from the culture medium. The antibody or antigen binding fragment thereof can be concentrated and purified by a variety of biochemical and chromatographic methods, including methods utilizing differences in size, charge, hydrophobicity, solubility, specific affinity, etc. between the antibody or antigen binding fragment thereof and other substances in the cell culture medium. In some embodiments, the antibody or antigen binding fragment thereof is secreted from the host cells.

[0158] The antibody or antigen binding fragment thereof described herein can be produced as recombinant molecules in prokaryotic or eukaryotic host cells, such as bacteria, yeast, plant, animal (including insect) or human cell lines or in transgenic animals. Recombinant methods of producing a polypeptide through the introduction of a vector including nucleic acid encoding the polypeptide into a suitable host cell is well known in the art, such as is described in Sambrook et al., Molecular Cloning: A Laboratory Manual, 2d Ed, Vols 1 to 8, Cold Spring Harbor, NY (1989); M. W. Pennington and B. M. Dunn, Methods in Molecular Biology: Peptide Synthesis Protocols, Vol 35, Humana Press, Totawa, NJ (1994), contents of both of which are herein incorporated by reference.Administering to a cell

[0159] The antibody of antigen binding fragment described herein can inhibit or reduce FcsRI receptor activity and / or one or more symptoms of a peanut allergy. Accordingly, an antibody or antigen binding fragment described herein, or a polynucleotide encoding the same, can be administered to a cell.

[0160] It is noted that administering to the cell can be in vitro or in-vivo. Methods for administering antibodies, antigen binding fragments and polynucleotides to a cell are well known and available to one of skill in the art. As used herein, administering to the cell means contacting the cell with the antibody or antigen binding fragment described herein, or a polynucleotide encoding the same, so that the antibody, the antigen binding fragment or the polynucleotide is taken up by the cell. Generally, the cell can be contacted with the antibody, the antigen binding fragment or the polynucleotide in a cell culture e.g., in vitro or ex vivo, or the antibody, the antigen binding fragment or the polynucleotide can be administrated to a subject, e.g., in vivo. The term “contacting” or “contact” as used herein in connection with contacting a cell includes subjecting the cells to an appropriate culture media, which comprises the antibody, the antigen binding fragment or the polynucleotide. Where the cell is in vivo, “contacting” or “contact” includes administering the compound, e.g., in a pharmaceutical 384937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTcomposition to a subject via an appropriate administration route such that the compound contacts the cell in vivo.For example, when the cell is in vitro, said administering to the cell can include subjecting the cell to an appropriate culture media which comprises the antibody, the antigen binding fragment or the polynucleotide. Where the cell is in vivo, said administering to the cell includes administering the antibody, the antigen binding fragment or the polynucleotide to a subject via an appropriate administration route such that the antibody, the antigen binding fragment or the polynucleotide is administered to the cell in vivo.In one embodiment, the antibody or antigen binding fragment that binds a peanut allergen is provided as a gene therapy to deliver to a patient in need thereof (e.g., a peanut-allergic patient) the antibody or antigen binding fragment. The gene therapy can use a viral vector, such as recombinant adeno-associated virus (AAV, e.g., AAV2), as a vehicle to deliver transgenes that direct expression of the anti-peanut allergen antibody or antigen binding fragment after administration to the patient. In some embodiments, the antigen binding fragment is a single-chain Fab (scFab) or single-chain Fv (scFv). The antibody or antigen binding fragment can be expressed as a single polypeptide, or as two or more separate polypeptides. Where the antibody or antigen binding fragment is introduced into a cell (e.g., a cell in a patient) through an expression vector, it may also be referred to as a “vectorized” protein (e.g., “vectorized” antibody or antibody fragment).Viral vectors may be produced using methods known in the art. Any suitable permissive or packaging cells may be employed to produce the viral particles. For example, mammalian (e.g., 293 or HeLa) or insect (e.g., Sf9) cells may be used as the packaging cell line. Recombinant AAV vectors can be replicated and packaged into infectious viral particles when introduced into host cells that have been infected with a suitable helper virus (or that is expressing suitable helper functions) and that is expressing AAV rep and cap gene products (i.e., AAV Rep and capsid proteins). See, e.g., U. S. Pat. 11,261,463.Compositions, Formulations and Packaging

[0161] Also provided herein are compositions, including pharmaceutical compositions, comprising an antibody or antigen binding fragment that binds a peanut allergen as described herein or a polynucleotide encoding the antibody or antigen binding fragment, or recombinant viral vectors, such as AAV vectors, encoding the antibody or antigen binding fragment. In one embodiment, the compositions are pharmaceutical compositions. Pharmaceutical compositions for use with the methods described herein can be formulated in a conventional 394937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTmanner using one or more physiologically acceptable carriers or excipients. Thus, the compounds and their physiologically acceptable salts and solvates can be formulated for administration by, for example, by aerosol, intravenous, oral or topical route. The compositions can be formulated for intralesional, intratumoral, intraperitoneal, subcutaneous, intramuscular or intravenous injection; infusion; liposome-mediated delivery; topical, intrathecal, gingival pocket, per rectum, intrabronchial, nasal, transmucosal, intestinal, oral, ocular or otic delivery.

[0162] Techniques and formulations generally can be found in Remmington’s Pharmaceutical Sciences, Meade Publishing Co., Easton, PA. For systemic administration, injection is preferred, including intramuscular, intravenous, intraperitoneal, and subcutaneous. For injection, the antibodies described herein can be formulated in liquid solutions, preferably in physiologically compatible buffers such as Hank’s solution or Ringer’s solution. In addition, the antibodies can be formulated in solid form and redissolved or suspended immediately prior to use. Lyophilized forms are also included.

[0163] For oral administration, the pharmaceutical composition can take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulphate). The tablets can be coated by methods well known in the art. Liquid preparations for oral administration can take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations can be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., pharmaceutically acceptable oils, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid). The preparations can also contain buffer salts, flavoring, coloring and sweetening agents as appropriate.

[0164] Preparations for oral administration can be suitably formulated to give controlled release of the active compound. For buccal administration the compositions can take the form of tablets or lozenges formulated in conventional manner. For administration by inhalation, the compounds for use as described herein are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant,404937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTe.g., dichlorodifluoromethane, trichlorofluoromethane, di chlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit can be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g., gelatin for use in an inhaler or insufflator can be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

[0165] The anti-peanut allergen antibodies can be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection can be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions can take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and can contain formulatory agents such as suspending, stabilizing and / or dispersing agents. Alternatively, the active ingredient can be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

[0166] In addition to the formulations described previously, the peanut allergen antibodies or antigen binding fragments thereof (or the polynucleotide encoding the antibody or antigen binding fragment) can also be formulated as a depot preparation. Such long acting formulations can be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the antibodies can be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

[0167] Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration bile salts and fusidic acid derivatives. In addition, detergents can be used to facilitate permeation. Transmucosal administration can be through nasal sprays or using suppositories. For topical administration, the peanut allergen antibodies can be formulated into ointments, salves, gels, or creams as generally known in the art. A wash solution can be used locally to treat an injury or inflammation to accelerate healing.

[0168] The compositions can, if desired, be presented in a pack or dispenser device which can contain one or more-unit dosage forms containing the active ingredient. The pack can for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device can be accompanied by instructions for administration.Dosage and Administration414937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPT

[0169] The method and compositions provided herein can be used to treat a peanut allergy in a subject by administering a therapeutically effective amount of an antibody or antigen binding fragment thereof that binds a peanut allergen. In one embodiment, the subject can be a mammal. In another embodiment, the mammal can be a human, although the approach is effective with respect to all mammals.

[0170] The appropriate dosage range for an antibody described herein (or antigen binding fragment thereof) depends upon the potency of the agent and includes amounts large enough to produce the desired effect, e.g., reduction in at leaset one sign or symptom of a peanut allergy. The dosage should not be so large as to cause unacceptable or life-threatening adverse side effects. Generally, the dosage will vary with the type of antibody or antigen binding fragment, and with the age, condition, and sex of the patient. The dosage can be determined by one of skill in the art and can also be adjusted by the individual physician in the event of any complication.

[0171] The effective amount can be based upon, among other things, the specificity of the antibody, the size of the antibody, the biodegradability of the antibody, the bioactivity and / or the bioavailability of the antibody or antigen binding fragment. For example, if the antibody does not degrade quickly, is bioavailable and highly active, a smaller amount will be required to be effective. One of skill in the art can routinely perform empirical activity tests to determine the bioactivity in bioassays and thus determine the effective amount.

[0172] Typically, the dosage ranges for a peanut allergen antibody or fragment thereof are in the range of 0.001mg / kg body weight to 5 g / kg body weight. In some embodiments, the dosage range is from 0.001 mg / kg body weight to 1g / kg body weight, from 0.001 mg / kg body weight to 0.5 g / kg body weight, from 0.001 mg / kg body weight to 0.1 g / kg body weight, from 0.001 mg / kg body weight to 50 mg / kg body weight, from 0.001 mg / kg body weight to 25 mg / kg body weight, from 0.001 mg / kg body weight to 10 mg / kg body weight, from 0.001 mg / kg body weight to 5 mg / kg body weight, from 0.001 mg / kg body weight to 1 mg / kg body weight, from 0.001 mg / kg body weight to 0.1 mg / kg body weight, from 0.001 mg / kg body weight to 0.005 mg / kg body weight. Alternatively, in some embodiments the dosage range is from 0.1 g / kg body weight to 5 g / kg body weight, from 0.5 g / kg body weight to 5 g / kg body weight, from 1 g / kg body weight to 5 g / kg body weight, from 1.5 g / kg body weight to 5 g / kg body weight, from 2 g / kg body weight to 5 g / kg body weight, from 2.5 g / kg body weight to 5 g / kg body weight, from 3 g / kg body weight to 5 g / kg body weight, from 3.5 g / kg body weight to 5 g / kg body weight, from 4 g / kg body weight to 5 g / kg body weight, from 4.5 g / kg body weight to 5 g / kg body weight, from 4.8 g / kg body weight to 5 g / kg body weight. In one 424937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTembodiment, the dose range is from 5pg / kg body weight to 30pg / kg body weight. Alternatively, the dose range will be titrated to maintain serum levels between 0.5 pg / mL and 30pg / mL. Dosages for monoclonal antibodies can also be based on rational dosage predictions such as those described in Bai et al. “A Guide to Rational Dosing of Monoclonal Antibodies” Clinical Pharmacokinetics 51:119-135 (2012).

[0173] As one of skill in the art will appreciate, the dosage of an antibody or antigen binding fragment described can vary depending upon the dosage form employed and the route of administration utilized. Compositions, methods, and uses that exhibit large therapeutic indices (i.e., the dose ration between toxic and therapeutic effects) are preferred. A therapeutically effective dose can be estimated initially from cell culture assays. Also, a dose can be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50, which achieves a half-maximal inhibition of measured function or activity as determined in cell culture, or in an appropriate animal model. The effects of any particular dosage can be monitored by a suitable bioassay. A therapeutically effective amount is an amount of an anti-peanut allergen agent that is sufficient to produce a statistically significant, measurable change of a given symptom of a peanut allergy (see “Efficacy Measurement” below). Such effective amounts can also be gauged in clinical trials as well as animal studies for a given agent.

[0174] An appropriate therapeutic amount or dose for treating a human subj ect can be informed by data collected in cell cultures or animal models. In some embodiments, the therapeutic efficacy can be estimated by the ED50 in an animal model (the dose therapeutically effective in 50% of the population). Murine models of peanut allergies can be used, in part, to inform one of skill in the art with respect to potency of a given antibody, the dosage range needed for efficacy, and toxic doses.

[0175] Therapeutic compositions can be conventionally administered in a unit dose. The term “unit dose” when used in reference to a therapeutic composition refers to physically discrete units suitable as unitary dosage for the subject, each unit containing a predetermined quantity of an anti -cancer agent calculated to produce the desired therapeutic effect in association with the required physiologically acceptable diluent, i.e., carrier, or vehicle.

[0176] Administration of the doses recited above or as employed by a skilled clinician can be repeated for a limited and defined period of time. In some embodiments, the doses are given once a day, or multiple times a day (e.g., at least two times a day, at least three times a day etc). In a preferred embodiment, the doses recited above are administered daily for several weeks or434937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTmonths. The duration of treatment depends upon the subject’s clinical progress and continued responsiveness to therapy. Continuous, relatively low maintenance doses are contemplated after an initial higher therapeutic dose. In one embodiment of the methods described herein, the anti-peanut allergen agent is administered at least once per day. In one embodiment, the anti-peanut allergen agent is administered daily. In one embodiment, the peanut allergen antibody or antigen binding fragment thereof is administered every other day. In one embodiment, the anti-peanut allergen agent is administered every 6 to 8 days. In one embodiment, the agent is administered weekly.

[0177] Administration of an antibody or fragment thereof described herein can be constant for a certain period of time or periodic and at specific intervals. The agent can be delivered hourly, daily, weekly, monthly, yearly (e.g. in a time release form) or as a one-time delivery. The delivery can be continuous delivery for a period of time, e.g. intravenous delivery.

[0178] The agents described herein can be administered to a subject in need thereof by any appropriate route which results in an effective treatment in the subject. For example, agents useful in the methods and compositions described herein can be administered topically, intravenously (by bolus or continuous infusion), orally, by inhalation, intraperitoneally, intramuscularly, subcutaneously, intracavity, and can be delivered by peristaltic means, if desired, or by other means known by those skilled in the art. The agent can be administered systemically, if so desired.

[0179] In some embodiments, the antibody or antigen binding fragment thereof described herein can be administered to a subject by any mode of administration that delivers the agent systemically or locally to a desired surface or target, and can include, but is not limited to, injection, infusion, instillation, and inhalation administration. To the extent that polypeptide agents can be protected from inactivation in the gut, oral administration forms are also contemplated. “Injection” includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intraventricular, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, sub capsular, subarachnoid, intraspinal, intracerebro spinal, and intrasternal injection and infusion.

[0180] The phrases “parenteral administration” and “administered parenterally” as used herein, refer to modes of administration other than enteral and topical administration, usually by injection. The phrases “systemic administration,” “administered systemically”, “peripheral administration” and “administered peripherally” as used herein refer to the administration of the agents described herein, other than directly into a target site, tissue, or organ, such that it444937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTenters the subject’s circulatory system and, thus, is subject to metabolism and other like processes.

[0181] It is noted that the terms “administered” and “subjected” are used interchangeably in the context of treatment of a condition, e.g., allergy, disease or disorder. In jurisdictions that forbid the patenting of methods that are practiced on the human body, the meaning of “administering” of a composition to a human subject shall be restricted to prescribing a controlled substance that a human subject will be administer to the subject by any technique (e.g., orally, inhalation, topical application, injection, insertion, etc.). The broadest reasonable interpretation that is consistent with laws or regulations defining patentable subject matter is intended. In jurisdictions that do not forbid the patenting of methods that are practiced on the human body, the “administering” of compositions includes both methods practiced on the human body and also the foregoing activities.

[0182] The compositions are administered in a manner compatible with the dosage formulation, and in a therapeutically effective amount. The quantity to be administered and timing depends on the subject to be treated, capacity of the subject's system to utilize the active ingredient, and degree of therapeutic effect desired. An agent can be targeted by means of a targeting moiety, such as e.g., an antibody or targeted liposome technology, if so desired.

[0183] Precise amounts of active ingredient required to be administered depend on the judgment of the practitioner and are particular to each individual. However, suitable dosage ranges for systemic application are disclosed herein and depend on the route of administration. Suitable regimes for administration are also variable, but are typified by an initial administration followed by repeated doses at one or more intervals by a subsequent injection or other administration. Alternatively, continuous intravenous infusion sufficient to maintain concentrations in the blood in the ranges specified for in vivo therapies are contemplated.Efficacy

[0184] The efficacy of a given treatment for a peanut allergy can be determined by the skilled clinician. However, a treatment is considered “effective treatment,” as the term is used herein, if any one or all of the signs or symptoms of the peanut allergy is / are altered in a beneficial manner, or other clinically accepted symptoms or markers of disease are improved, or ameliorated, e.g., by at least 10% following treatment with a peanut allergen antibody or antigen binding fragment thereof. Efficacy can also be measured by failure of an individual to worsen as assessed by stabilization of the condition, or the need for medical interventions (i.e., progression of the symptoms is halted or at least slowed). Methods of measuring these 454937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTindicators are known to those of skill in the art and / or described herein. Treatment includes any treatment of an allergy in an individual or an animal (some non-limiting examples include a human, or a mammal) and includes: (1) inhibiting the response, e.g., arresting, or slowing progression of the response; or (2) relieving the response, e.g., causing regression of symptoms; and (3) preventing or reducing the likelihood of the development of an allergic response, or preventing secondary response associate with allergic responses.

[0185] An effective amount for the treatment of a disease means that amount which, when administered to a mammal in need thereof, is sufficient to result in effective treatment as that term is defined herein, for that disease. Efficacy of an agent can be determined by assessing physical indicators of the disease, such as e.g., pain, inflammation, fever, fatigue etc.

[0186] Efficacy of an agent can be determined by assessing physical indicators of a condition or desired response. It is well within the ability of one skilled in the art to monitor efficacy of administration and / or treatment by measuring any one of such parameters, or any combination of parameters. Efficacy can be assessed in animal models of a condition described herein, for example animal models of a peanut allergy, e.g. a murine model. When using an experimental animal model, efficacy of treatment is evidenced when a statistically significant change in a marker is observed.

[0187] Treatment of a peanut allergy or a symptom thereof includes treatments of skin reactions, hives, skin redness, skin swelling, itching, tightening of the throat, difficulty breathing, shortness of breath, digestive problems such as diarrhea, stomach cramps, nausea, or vomiting, drop in blood pressure and anaphylaxis in response to peanut exposure. In one embodiment, treatment of a peanut allergy includes prevention of the allergic response or a symptom thereof by administration to a subject when no symptoms are present. In some embodiments, treatment of a peanut allergy can comprise reduction of FcsRI receptor activity, reducing anaphylaxis, inhibiting or reduceing effector cell activation, or inhibiting or reducing Th2 cell response, B cell activation, basophil activation, eosinophil activation, mast cell activation, and / or IgE induction.Kits

[0188] An antibody or antigen binding fragment thereof described herein can be provided in a kit, e.g., as a component of a kit. For example, the kit includes (a) an antibody, an antigen fragment or a polynucleotide described herein, and optionally (b) informational material. The informational material can be descriptive, instructional, marketing or other material that relates464937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTto the methods described herein and / or the use of an antibody, an antigen fragment or a polynucleotide described herein for the methods described herein.

[0189] The informational material of the kits is not limited in its form. In one embodiment, the informational material can include information about production of the antibody, antigen binding fragment or the polynucleotide encoding the antibody or the antigen binding fragment, their molecular weight, concentration, date of expiration, batch or production site information, and so forth. In one embodiment, the informational material relates to using the antibody, antigen binding fragment or the polynucleotide to treat, prevent, or diagnosis conditions, e.g., a peanut allergy.

[0190] In one embodiment, the informational material can include instructions to administer the antibody, the antigen binding fragment or the polynucleotide in a suitable manner to perform the methods described herein, e.g., in a suitable dose, dosage form, or mode of administration (e.g., a dose, dosage form, or mode of administration described herein). In another embodiment, the informational material can include instructions to administer the antibody, the antigen binding fragment or the polynucleotide to a suitable subject, e.g., a human, e.g., a human having, or at risk for, a condition described herein, e.g., a peanut allergy.

[0191] The informational material of the kits is not limited in its form. In many cases, the informational material, e.g., instructions, is provided in print but can also be in other formats, such as computer readable material.

[0192] The antibody, antigen binding fragment or the polynucleotide can be provided in any form, e.g., liquid, dried or lyophilized form. It is preferred that the antibody, antigen binding fragment or the polynucleotide be substantially pure and / or sterile. When the antibody, antigen binding fragment or the polynucleotide is provided in a liquid solution, the liquid solution preferably is an aqueous solution, with a sterile aqueous solution being preferred. When the antibody, antigen binding fragment or the polynucleotide is provided as a dried form, reconstitution generally is by the addition of a suitable solvent. The solvent, e.g., sterile water or buffer, can optionally be provided in the kit.

[0193] The kit can include one or more containers for the composition containing the antibody, antigen binding fragment or the polynucleotide. In some embodiments, the kit contains separate containers, dividers or compartments for the composition and informational material. For example, the composition can be contained in a bottle, vial, or syringe, and the informational material can be contained association with the container. In other embodiments, the separate elements of the kit are contained within a single, undivided container. For example, the composition is contained in a bottle, vial or syringe that has attached thereto the informational 474937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTmaterial in the form of a label. In some embodiments, the kit includes a plurality (e.g., a pack) of individual containers, each containing one or more unit dosage forms (e.g., a dosage form described herein) of an antibody or antigen binding fragment or a polynyucleotide. For example, the kit includes a plurality of syringes, ampules, foil packets, or blister packs, each containing a single unit dose of an antibody or antigen binding fragment or a polynyucleotide. The containers of the kits can be air tight, waterproof (e.g., impermeable to changes in moisture or evaporation), and / or light-tight.

[0194] The kit optionally includes a device suitable for administration of the composition, e.g., a syringe, inhalant, dropper (e.g., eye dropper), swab (e.g., a cotton swab or wooden swab), or any such delivery device. In one embodiment, the device is an implantable device that dispenses metered doses of the binding protein. The disclosure also features a method of providing a kit, e.g., by combining components described herein.

[0195] Various aspects described herein can be defined by the following numbered embodiments:

[0196] Embodiment 1: An antibody or antigen binding fragment thereof comprising:a) a heavy chain variable region (VH) comprising: (i) a complementarity determining region 1 (HCDR1) having an amino acid sequence of GFSFGSSW (SEQ ID NO: 2); (ii) a complementarity determining region 2 (HCDR2) having an amino acid sequence of VNGDGSSV (SEQ ID NO: 3); and (iii) a complementarity determining region 3 (HCDR3) having an amino acid sequence of VKGKSRRSQYDQ (SEQ ID NO: 4); andb) a light chain variable region (VL) comprising: (i) a complementarity determining region I (LCDR1) having an amino acid sequence of QDVDKY (SEQ ID NO: 15); (ii) a complementarity determining region 2 (LCDR2) having an amino acid sequence of DVS (SEQ ID NO: 16); and (iii) a complementarity determining region 3 (LCDR3) having an amino acid sequence of QQYDNLPIT (SEQ ID NO: 17).

[0197] Embodiment 2: The antibody or antigen binding fragment of embodiment 1, wherein the antibody or antigen binding fragment comprises a single domain antibody, an scFv, a monoclonal antibody, a humanized antibody, a human antibody, a recombinant antibody, a chimeric antibody, or a Fab fragment.

[0198] Embodiment 3: The antibody or antigen binding fragment of any one of embodiments 1-2, wherein the heavy chain variable region further comprises a Framework region 1 (FW_H1) sequence that differs by no more than four, preferably no more than three, more preferably no 484937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTmore than two, most preferably no more than one amino acid from EVQLVESGGGLVQPGGSLRLSCVAS (SEQ ID NO: 10).

[0199] Embodiment 4: The antibody or antigen binding fragment of any one of embodiments 1-3, wherein the heavy chain variable region further comprises a Framework region 2 (FW H2) sequence that differs by no more than four, preferably no more than three, more preferably no more than two, most preferably no more than one amino acid from MHWVRQDPAKGLVWVAR (SEQ ID NO: 11).

[0200] Embodiment 5: The antibody or antigen binding fragment of any one of embodiments 1-4, wherein the heavy chain variable region further comprises a Framework region 3 (FW H3) sequence that differs by no more than four, preferably no more than three, more preferably no more than two, most preferably no more than one amino acid from SYRDSMEGRFTISRDNAKNTLFLQMNSLRPEDTALYYC (SEQ ID NO: 12).

[0201] Embodiment 6: The antibody or antigen binding fragment of any one of embodiments 1 -5, wherein the heavy chain variable region further comprises a Framework region 4 (FW H4) sequence that differs by no more than four, preferably no more than three, more preferably no more than two, most preferably no more than one amino acid from WGQGTLVTVSS (SEQ ID NO: 13)

[0202] Embodiment 7: The antibody or antigen binding fragment of any one of embodiments 1-6, wherein the antibody or antigen binding fragment comprises a heavy chain amino acid sequence having at least 80% identity to the amino acid sequence EVQLVESGGGLVQPGGSLRLSCVASGFSFGSSWMHWVRQDPAKGLVWVARVNGD GSSVSYRDSMEGRFTISRDNAKNTLFLQMNSLRPEDTALYYCVKGKSRRSQYDQWG QGTLVTVSS (SEQ ID NO: 9), and wherien the heavy chain comprises a HCDR1 sequence having 100% identity to SEQ ID NO: 2, a HCDR2 sequence having 100% identity to SEQ ID NO: 3, and a HCDR3 sequence having 100% identity to SEQ ID NO: 4.

[0203] Embodiment 8: The antibody or antigen binding fragment of any one of embodiments 1-7, wherein the light chain variable region further comprises a Framework region 1 (FW Ll) sequence that differs by no more than four amino acids from DIQMTQSPSSLSASVGDRVTITCQAS (SEQ ID NO: 20).

[0204] Embodiment 9: The antibody or antigen binding fragment of any one of embodiments 1-8, wherein the light chain variable region further comprises a Framework region 2 (FW_L2) sequence that differs by no more than four amino acids from LNWYQQKPGKAPKLLIY (SEQ ID NO: 21)494937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPT

[0205] Embodiment 10: The antibody or antigen binding fragment of any one of embodiments 1-9, wherein the light chain variable region further comprises a Framework region 3 (FW_L3) sequence that differs by no more than four amino acids from NLETGVPLRFSGGGSGTDFTFTISGLQAEDFATYYC (SEQ ID NO: 22).

[0206] Embodiment 11: The antibody or antigen binding fragment of any one of embodiments 1-10, wherein the light chain variable region further comprises a Framework region 4 (FW_L4) sequence that differs by no more than four amino acids from FGQGTRLEIK (SEQ ID NO: 23).

[0207] Embodiment 12: The antibody or antigen binding fragment of any one of embodiments 1-11, wherein the antibody or antigen binding fragment comprises a light chain amino acid sequence having at least 80% identity to the amino acid sequence DIQMTQSPSSLSASVGDRVTITCQASQDVDKYLNWYQQKPGKAPKLLIYDVSNLETG VPLRFSGGGSGTDFTFTISGLQAEDFATYYCQQYDNLPITFGQGTRLEIK (SEQ ID NO: 19), and wherein the light chain comprises a LCDR1 sequence having 100% identity to SEQ ID NO: 15, a LCDR2 sequence having 100% identity to SEQ ID NO: 16, and a LCDR3 sequence having 100% identity to SEQ ID NO: 17.

[0208] Embodiment 13: The antibody or antigen binding fragment of any one of embodiments 1-12, wherein the antibody or antigen binding fragment comprises a heavy chain constant region 1 (CHI) comprising an amino acid sequence having at least 85% identity to ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVL QSSGLYSLSSVVTVPSSSLGTQTICNVNHKPSNTKVDKKV (SEQ ID NO: 5).

[0209] Embodiment 14: The antibody or antigen binding fragment of any one of embodiments 1-13, wherein the antibody or antigen binding fragment comprises a heavy chain constant region 2 (CH2) comprising an amino acid sequence having at least 85% identity to APEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN AKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK(SEQ ID NO: 7)

[0210] Embodiment 15: The antibody or antigen binding fragment of any one of embodiments 1-14, wherein the antibody or antigen binding fragment comprises a heavy chain constant region 3 (CH3) comprising an amino acid sequence having at least 85% identity to GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV LDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 8) or GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPV504937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO: 24)

[0211] Embodiment 16: The antibody or antigen binding fragment of any one of embodiments 1-15, wherein the antibody or antigen binding fragment comprises a heavy chain hinge region (CHl_CH2_hinge) comprising an amino acid sequence having at least 85% identity to EPKSCDKTHTCPPCP (SEQ ID NO: 6).

[0212] Embodiment 17: The antibody or antigen binding fragment of any one of embodiments 1-16, wherein the antibody or antigen binding fragment comprises a heavy chain amino acid sequence having at least 85% identity to EVQLVESGGGLVQPGGSLRLSCVASGFSFGSSWMHWVRQDPAKGLVWVARVNGD GSSVSYRDSMEGRFTISRDNAKNTLFLQMNSLRPEDTALYYCVKGKSRRSQYDQWG QGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTS GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTICNVNHKPSNTKVDKKVEPKSCDKT HTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD GVEVHNAI< TI< PREEQYNSTYRVVSVLTVLHQDWLNGI< EYI< CI< VSNI< ALPAPIEI< TI SKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO: 1), and wherein the heavy chain comprises a HCDR1 sequence having 100% identity to SEQ ID NO: 2, a HCDR2 sequence having 100% identity to SEQ ID NO: 3, and a HCDR3 sequence having 100% identity to SEQ ID NO: 4.

[0213] Embodiment 18: The antibody or antigen binding fragment of any one of embodiments 1-17, wherein the antibody or antigen binding fragment comprises a light chain constant region (CL) comprising an amino acid sequence having at least 85% identity to RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVT EQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO:14), and wherein the light chain comprises a LCDR1 sequence having 100% identity to SEQ ID NO: 15, a LCDR2 sequence having 100% identity to SEQ ID NO: 16, and a LCDR3 sequence having 100% identity to SEQ ID NO: 17.

[0214] Embodiment 19: The antibody or antigen binding fragment of any one of embodiments 1-18, wherein the antibody or antigen binding fragment comprises an IgGl backbone.

[0215] Embodiment 20: The antibody or antigen binding fragment of embodiment 19, wherein the IgGl backbone is a human IgGl backbone.514937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPT

[0216] Embodiment 21: The antibody or antigen binding fragment of any one of embodiments 1-20, wherein the antibody or antigen binding fragment does not comprise at least one constant region of IgE.

[0217] Embodiment 22: The antibody or antigen binding fragment of any one of embodiments 1-21, wherein antibody or antigen binding fragment further comprises a detectable label.

[0218] Embodiment 23: The antibody or antigen binding fragment of any one of embodiments 1-22, wherein the antibody or antigen binding fragment binds to a peanut antigen.

[0219] Embodiment 24: The antibody or antigen binding fragment of any one of embodiments 1-23, wherein the antibody or antigen binding fragment binds to a S2 albumin family member.

[0220] Embodiment 25: The antibody or antigen binding fragment of any one of embodiments 1-24, wherein the antibody or antigen binding fragment binds to Ara h 2.

[0221] Embodiment 26: The antibody or antigen binding fragment of any one of embodiments 1-25, wherein the antibody or antigen binding fragment binds to helix 3 of Ara h 2.

[0222] Embodiment 27: The antibody or antigen binding fragment of any one of embodiments 1-26, wherein the antibody or antigen binding fragment inhibits or reduces FcsRI receptor activity and / or one or more symptoms of a peanut allergy by at least 20% as compared to FcsRI receptor activity and / or one or more symptom of a peanut allergy in the absence of the antibody or antigen binding fragment.

[0223] Embodiment 28: The antibody or antigen binding fragment of any one of embodiments 1-27, wherein the antibody or antigen binding fragment inhibits or reduces an allergen mediated immune response by at least 20% as compared an allergen mediated immune response in the absence of the antibody or antigen binding fragment.

[0224] Embodiment 29: The antibody or antigen binding fragment of any one of embodiments 1-28, wherein the antibody or antigen binding fragment inhibits or reduces an anaphylactic response by at least 20% as compared an anaphylactic response in the absence of the antibody or antigen binding fragment.

[0225] Embodiment 30: The antibody or antigen binding fragment of any one of embodiments 1-29, wherein the antibody or antigen binding fragment inhibits or reduces effector cell activation, e.g., effector cell activation by a S2 albumin family member such as Arah 2.

[0226] Embodiment 31: A composition comprising an antibody or antigen binding fragment of any one of embodiments 1-30.

[0227] Embodiment 32: The composition of embodiment 31, wherein the composition comprises a pharmaceutically acceptable excipient or carrier.524937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPT

[0228] Embodiment 33: A cell comprising an antibody or antigen binding fragment of any one of embodiments 1-30.

[0229] Embodiment 34: A polynucleotide comprising a nucleotide sequence encoding an antibody or antigen binding fragment of any one of embodiments 1-30.

[0230] Embodiment 35: The polynucleotide of embodiment 33, wherein the polynucleotide is comprised in a vector.

[0231] Embodiment 36: A composition comprising a polynucleotide of embodiment 34 or 35.

[0232] Embodiment 37: A cell comprising a polynucleotide of embodiment 34 or 35.

[0233] Embodiment 38: A kit comprising: (a) an antibody or antigen binding fragment of any one of embodiments 1-30; (b) a polynucleotide of embodiment 34 or 35; (c) a composition of embodiment 31, 32, or 36; or (d) a cell of embodiment 33 or 37.

[0234] Embodiment 39: The kit of embodiment 38, further comprising instructions for use thereof.

[0235] Embodiment 40: A method of treating a peanut allergy comprising administering an antibody or antigen binding fragment of any one of embodiments 1-30, or a polynucleotide of embodiment 34 or 35, or a composition of embodiment 31, 32, or 36, or a cell of embodiment 33 or 37 to a subject in need thereof.

[0236] Embodiment 41: The method of embodiment 40, wherein the method inhibits or reduces one or more symptoms of a peanut allergy.

[0237] Embodiment 42: The method of embodiment 40 or 41, wherein the one or more symptoms of a peanut allergy are selected from the group consisting of skin reactions, hives, skin redness, skin swelling, itching, tightening of the throat, difficulty breathing, shortness of breath, digestive problems such as diarrhea, stomach cramps, nausea, or vomiting, drop in blood pressure and anaphylaxis.

[0238] Embodiment 43: The method of any one of embodiments 40-42, wherein the method reduces FcsRI receptor activation.

[0239] Embodiment 44: The method of any one of embodiments 40-43, wherein the method reduces the duration or severity of the allergic immune response to peanut proteins.

[0240] Embodiment 45: The method of embodiment 44, wherein the allergic immune response is a Th2 cell response, B cell activation, basophil activation, eosinophil activation, mast cell activation, and / or IgE induction.

[0241] Embodiment 46: The method of embodiment 45, wherein the Th2 cell response, B cell activation, basophil activation, eosinophil activation, mast cell activation, and / or IgE induction is assayed from one or more biological samples obtained from the subject.534937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPT

[0242] Embodiment 47: The method of embodiment 40, wherein the subject is diagnosed with or in need of treatment for a peanut allergy.

[0243] Embodiment 48: A method for reducing or blocking anaphylaxis or at least one response associated with a peanut allergy, the method comprising administering a therapeutically effective amount of an antibody or antigen binding fragment of any one of embodiments 1-30, or a polynucleotide of embodiment 33 or 34, or a composition of embodiment 31, 32, or 36, or a cell of embodiment 33 or 37 to a subject in need thereof.

[0244] Embodiment 49: The method of any one of embodiments 40-48 further comprising a step of diagnosing the subject with the peanut allergy.

[0245] Embodiment 50: The method of any one of embodiments 40-49, wherein the subject is a mammal.

[0246] Embodiment 51: The method of any one of embodiments 40-50, wherein the subject is human.

[0247] Embodiment 52: A composition of any one of embodiments 1-30 for use in the treatment of a peanut allergy, or at least one symptom thereof in a subject.Definitions

[0248] For convenience, certain terms employed herein, in the specification, examples and appended claims are collected herein. Unless stated otherwise, or implicit from context, the following terms and phrases include the meanings provided below. Unless explicitly stated otherwise, or apparent from context, the terms and phrases below do not exclude the meaning that the term or phrase has acquired in the art to which it pertains. The definitions are provided to aid in describing particular embodiments, and are not intended to limit the claimed invention, because the scope of the invention is limited only by the claims. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular.

[0249] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as those commonly understood to one of ordinary skill in the art to which this invention pertains. Although any known methods, devices, and materials may be used in the practice or testing of the invention, the methods, devices, and materials in this regard are described herein. Definitions of common terms in immunology and molecular biology can be found in The Merck Manual of Diagnosis and Therapy, 20th Edition, published by Merck Sharp & Dohme Corp., 2018 (ISBN 0911910190, 978-0911910421); Robert S. Porter et al. (eds.), The Encyclopedia of Molecular Cell Biology and Molecular Medicine, published by544937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTBlackwell Science Ltd., 1999-2012 (ISBN 9783527600908); and Robert A. Meyers (ed.), Molecular Biology and Biotechnology: a Comprehensive Desk Reference, published by VCH Publishers, Inc., 1995 (ISBN 1-56081-569-8); Immunology by Werner Luttmann, published by Elsevier, 2006; Janeway's Immunobiology, Kenneth Murphy, Allan Mowat, Casey Weaver (eds.), W. W. Norton & Company, 2016 (ISBN 0815345054, 978-0815345053); Lewin's Genes XI, published by Jones & Bartlett Publishers, 2014 (ISBN-1449659055); Michael Richard Green and Joseph Sambrook, Molecular Cloning: A Laboratory Manual, 4th ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N. Y., USA (2012) (ISBN 1936113414); Davis et al., Basic Methods in Molecular Biology, Elsevier Science Publishing, Inc., New York, USA (2012) (ISBN 044460149X); Laboratory Methods in Enzymology: DNA, Jon Lorsch (ed.) Elsevier, 2013 (ISBN 0124199542); Current Protocols in Molecular Biology (CPMB), Frederick M. Ausubel (ed.), John Wiley and Sons, 2014 (ISBN 047150338X, 9780471503385), Current Protocols in Protein Science (CPPS), John E. Coligan (ed.), John Wiley and Sons, Inc., 2005; and Current Protocols in Immunology (CPI) (John E. Coligan, ADA M Kruisbeek, David H Margulies, Ethan M Shevach, Warren Strobe, (eds.) John Wiley and Sons, Inc., 2003 (ISBN 0471142735, 9780471142737), the contents of which are all incorporated by reference herein in their entireties.

[0250] Further, the practice of the present invention can employ, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature, such as, “Molecular Cloning: A Laboratory Manual”, second edition (Sambrook et al., 1989); “Oligonucleotide Synthesis” (M. J. Gait, ed., 1984); “Animal Cell Culture” (R. I. Freshney, ed., 1987); “Methods in Enzymology” (Academic Press, Inc.); “Current Protocols in Molecular Biology” (F. M. Ausubel et al., eds., 1987, and periodic updates); “PCR: The Polymerase Chain Reaction”, (Mullis et al., ed., 1994); “A Practical Guide to Molecular Cloning” (Perbal Bernard V., 1988); “Phage Display: A Laboratory Manual” (Barbas et al., 2001)..

[0251] The term “antibody” refers to a protein that includes at least one immunoglobulin variable domain or immunoglobulin variable domain sequence. For example, an antibody can include a heavy (H) chain variable region (abbreviated herein as VH), and a light (L) chain variable region (abbreviated herein as VL). In another example, an antibody includes two heavy (H) chain variable regions and two light (L) chain variable regions. The term “antibody” encompasses antigen binding fragments of antibodies (e.g., single chain antibodies, Fab and sFab fragments, F(ab')2, Fd fragments, Fv fragments, scFv, and domain antibodies (dAb)554937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTfragments (de Wildt et al., Eur J Immunol. 1996; 26(3):629-39.)) as well as complete antibodies. An antibody can have the structural features of IgA, IgG, IgE, IgD, IgM (as well as subtypes thereof). Antibodies can be from any source, but primate (human and non-human primate) and primatized are preferred.

[0252] The VH and VL regions can be further subdivided into regions of hypervariability, termed “complementarity determining regions” (“CDR”), interspersed with regions that are more conserved, termed “framework regions” (“FW” or “FR”). The extent of the framework region and CDRs has been precisely defined (see, Kabat, E. A., et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U. S. Department of Health and Human Services, NTH Publication No. 91-3242, and Chothia, C. et al. (1987) J. Mol. Biol. 196:901-917, see also www.hgmp.mrc.ac.uk). Kabat definitions are used herein. Each VH and VL is typically composed of three CDRs and four FRs, arranged from amino-terminus to carboxyterminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.

[0253] As used herein, an “immunoglobulin variable domain sequence” refers to an amino acid sequence which can form the structure of an immunoglobulin variable domain such that one or more CDR regions are positioned in a conformation suitable for an antigen binding site. For example, the sequence can include all or part of the amino acid sequence of a naturally-occurring variable domain. For example, the sequence may omit one, two or more N- or C-terminal amino acids, internal amino acids, may include one or more insertions or additional terminal amino acids, or may include other alterations. In one embodiment, a polypeptide that includes immunoglobulin variable domain sequence can associate with another immunoglobulin variable domain sequence to form an antigen binding site, e.g., a structure that preferentially interacts with a peanut allergen.

[0254] The VH or VL chain of the antibody can further include all or part of a heavy or light chain constant region, to thereby form a heavy or light immunoglobulin chain, respectively. In one embodiment, the antibody is a tetramer of two heavy immunoglobulin chains and two light immunoglobulin chains, wherein the heavy and light immunoglobulin chains are interconnected by, e.g., disulfide bonds or a linker. In IgGs, the heavy chain constant region includes three immunoglobulin domains, CHI, CH2 and CH3. The light chain constant region includes a CL domain. The variable region of the heavy and light chains contains a binding domain that interacts with an antigen. The constant regions of the antibodies typically mediate the binding of the antibody to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (Clq) of the classical complement system. The light chains of the immunoglobulin can be of types kappa or lambda.564937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPT

[0255] One or more regions of an antibody can be human or effectively human. For example, one or more of the variable regions can be human or effectively human. For example, one or more of the CDRs can be human, e.g., HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and LC CDR3. Each of the light chain CDRs can be human. HC CDR3 can be human. One or more of the framework regions can be human, e.g., FR1, FR2, FR3, and FR4 of the HC or LC. For example, the Fc region can be human. In one embodiment, all the framework regions are human, e.g., derived from a human somatic cell, e.g., a hematopoietic cell that produces immunoglobulins or a non-hematopoietic cell. In one embodiment, the human sequences are germline sequences, e.g., encoded by a germline nucleic acid. In one embodiment, the framework (FR) residues of a selected Fab can be convertered to the amino-acid type of the corresponding residue in the most similar primate germline gene, especially the human germline gene. One or more of the constant regions can be human or effectively human. For example, at least 70, 75, 80, 85, 90, 92, 95, 98, or 100% of an immunoglobulin variable domain, the constant region, the constant domains (CHI, CH2, CH3, CL1), or the entire antibody can be human or effectively human.

[0256] All or part of an antibody can be encoded by an immunoglobulin gene or a segment thereof. Exemplary human immunoglobulin genes include the kappa, lambda, alpha (IgAl and IgA2), gamma (IgGl, IgG2, IgG3, IgG4), delta, epsilon and mu constant region genes, as well as the many immunoglobulin variable region genes. Full-length immunoglobulin “light chains” (about 25 KDa or about 214 amino acids) are encoded by a variable region gene at the NH2-terminus (about 110 amino acids) and a kappa or lambda constant region gene at the COOH-terminus. Full-length immunoglobulin “heavy chains” (about 50 KDa or about 446 amino acids), are similarly encoded by a variable region gene (about 116 amino acids) and one of the other aforementioned constant region genes, e.g., gamma (encoding about 330 amino acids). The length of human HC varies considerably because HC CDR3 varies from about 3 aminoacid residues to over 35 amino-acid residues.

[0257] An “effectively human” immunoglobulin variable region is an immunoglobulin variable region that includes a sufficient number of human framework amino acid positions such that the immunoglobulin variable region does not elicit an immunogenic response in a normal human. An “effectively human” antibody is an antibody that includes a sufficient number of human amino acid positions such that the antibody does not elicit an immunogenic response in a normal human.

[0258] A “humanized” immunoglobulin variable region is an immunoglobulin variable region that is modified to include a sufficient number of human framework amino acid positions such 574937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTthat the immunoglobulin variable region does not elicit an immunogenic response in a normal human (i.e., a subject that does not have a peanut allergy). Descriptions of “humanized” immunoglobulins include, for example, U. S. Pat. No. 6,407,213 and U. S. Pat. No. 5,693,762.

[0259] As used herein, “binding affinity” refers to the apparent association constant or Ka. The Ka is the reciprocal of the dissociation constant (Kd). A binding protein can, for example, have a binding affinity of at least 105, 106, 107, 108, 109, IO10and 1011M1for a particular target molecule, e.g., a peanut allergen. Higher affinity binding of a binding protein to a first target (e.g., a peanut allergen) relative to a second target (e.g., a non-specific protein) can be indicated by a higher Ka (or a smaller numerical value Kd) for binding the first target than the Ka (or numerical value Kd) for binding the second target. In such cases, the binding protein has specificity for the first target (e.g., a protein in a first conformation or mimic thereof) relative to the second target (e.g., the same protein in a second conformation or mimic thereof; or a second protein). Differences in binding affinity (e.g., for specificity or other comparisons) can be at least 1.5, 2, 3, 4, 5, 10, 15, 20, 37.5, 50, 70, 80, 91, 100, 500, 1000, 104or 105fold.

[0260] In some embodiments, the antibody or antigen binding fragment thereof specifically binds to a peanut allergen present on the cell-surface with a KD of 10'5M (10000 nM) or less, e.g., 10'6M or less, 10'7M or less, 10'8M or less, 10'9M or less, 10'10M or less, 10'11M or less, or IO’12M or less and binds to that target at least lOOx, or lOOOx, or 10,000x and preferably more strongly than it binds to an off-target or distinct cell-surface marker or protein. The person of ordinary skill in the art can determine appropriate conditions under which the polypeptide agents described herein selectively bind a peanut allergen using any suitable methods, such as titration of the antibody or an antigen binding fragment thereof in a suitable cell binding assay. Binding affinity can be determined by a variety of methods including equilibrium dialysis, equilibrium binding, gel filtration, ELISA, surface plasmon resonance, or spectroscopy (e.g., using a fluorescence assay). Exemplary conditions for evaluating binding affinity are in TRIS-buffer (50 mM TRIS, 150 mM NaCl, 5 mM CaCh at pH7.5). These techniques can be used to measure the concentration of bound and free binding protein as a function of binding protein (or target) concentration. The concentration of bound binding protein ([Bound]) is related to the concentration of free binding protein ([Free]) and the concentration of binding sites for the binding protein on the target where (N) is the number of binding sites per target molecule by the following equation:[B ound]=N • [Free] / (( 1 / Ka)+ [Free] ).

[0261] It is not always necessary to make an exact determination of Ka, though, since sometimes it is sufficient to obtain a quantitative measurement of affinity, e.g., determined 584937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTusing a method such as ELISA or FACS analysis, is proportional to Ka, and thus can be used for comparisons, such as determining whether a higher affinity is, e.g., 2-fold higher, to obtain a qualitative measurement of affinity, or to obtain an inference of affinity, e.g., by activity in a functional assay, e.g., an in vitro or in vivo assay.

[0262] As used herein, an “antigen binding fragment” refers that portion of an antibody that is necessary and sufficient for binding to a given antigen. At a minimum, an antigen binding fragment of a conventional antibody will comprise six complementarity determining regions (CDRs) derived from the heavy and light chain polypeptides of an antibody arranged on a scaffold that permits them to selectively bind the antigen. A commonly used antigen binding fragment includes the VH and V2 domains of an antibody, which can be joined either via part of the constant domains of the heavy and light chains of an antibody, or, alternatively, by a linker, such as a peptide linker. Non-conventional antibodies, such as camelid and short antibodies have only 2 heavy chain sequences, denoted, for example VHH. These can be used in a manner analogous to Vu / VL-containing antigen binding fragments. Non-limiting examples of antibody fragments encompassed by the term antigen binding fragment include: (i) a Fab fragment, having VL, CL, VH and CHI domains; (ii) a Fab' fragment, which is a Fab fragment having one or more cysteine residues at the C-terminus of the CHI domain; (iii) an Fd fragment having VH and CHI domains; (iv) a Fd' fragment having VH and CHI domains and one or more cysteine residues at the C-terminus of the CHI domain; (v) an Fv fragment having the VL and VH domains of a single arm of an antibody; (vi) a dAb fragment (Ward et al., Nature 341, 544-546 (1989)) which consists of a VH domain; (vii) F(ab')2 fragments, a bivalent fragment including two Fab' fragments linked by a disulphide bridge at the hinge region; (viii) single chain antibody molecules (e.g., single chain Fv; scFv) (Bird etal., Science 242:423-426 (1988); and Huston et al., PNAS (USA) 85:5879-5883 (1988)); (ix) “diabodies” with two antigen binding sites, comprising a heavy chain variable domain (VH) connected to a light chain variable domain (VL) in the same polypeptide chain (see, e.g., EP 404,097; WO 93 / 11161; and Hollinger etal., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993)); and (x) “linear antibodies” comprising a pair of tandem Fd segments (VH-CH1-VH-CH1) which, together with complementary light chain polypeptides, form a pair of antigen binding regions (Zapata et al. Protein Eng. 8(10): 1057-1062 (1995); and U. S. Pat. No. 5,641,870). The molecules of Fv, scFv or diabody can be stabilized by incorporating disulfide bridges linking the VH and VL domains. Minibodies comprising a scFv fragment linked to a CH3 domain can also be obtained. Other examples of binding fragments are Fab’, which differs from Fab fragments by the addition of some residues at the carboxyl terminus of the CHI domain of the heavy chain,594937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTincluding one or more cysteines of the hinge region of the antibody, and Fab’-SH, which is a Fab’ fragment in which the cysteine residue(s) of the constant domains carries a free thiol group.

[0263] In some embodiments of any one of the aspects, the antibody or the antigen binding fragment is an isolated antibody or antigen binding fragment. An “isolated antibody” is intended to refer to an antibody that is substantially free of other antibodies having different antigenic specificities (e.g., an isolated antibody that specifically binds to a peanut allergen is substantially free of antibodies that specifically bind antigens other than a peanut allergen). An isolated antibody that specifically binds to a peanut allergen can, however, have crossreactivity to other antigens, such as to a peanut allergen molecule from other species. Moreover, an isolated antibody can be substantially free of other cellular material and / or chemicals.

[0264] As used herein, the term “specificity” refers to the number of different types of antigens or antigenic determinants to which an antibody or antibody fragment thereof as described herein can bind. The specificity of an antibody or antibody fragment thereof can be determined based on affinity and / or avidity. The affinity, represented by the equilibrium constant for the dissociation (KD) of an antigen with an antigen binding protein, is a measure of the binding strength between an antigenic determinant and an antigen binding site on the antige binding protein, such as an antibody or antibody fragment thereof: the lesser the value of the KD, the stronger the binding strength between an antigenic determinant and the antigen binding molecule. Alternatively, the affinity can also be expressed as the affinity constant (KA), which is 1 / KD). Accordingly, an antibody or antibody fragment thereof as defined herein is said to be “specific for” a first target or antigen compared to a second target or antigen when it binds to the first antigen with an affinity (as described above, and suitably expressed, for example as a KD value) that is at least 10 times, such as at least 100 times, and preferably at least 1000 times, and up to 10000 times or more better than the affinity with which said amino acid sequence or polypeptide binds to another target or polypeptide. Antibody affinities can be determined, for example, by a surface plasmon resonance based assay (such as the BIACORE assay described in PCT Application Publication No. W02005 / 012359); enzyme-linked immunosorbent assay (ELISA); and competition assays (e.g., RIA’s), for example.

[0265] As used herein, “avidity” is a measure of the strength of binding between an antigen binding molecule (such as an antibody or antibody fragment thereof described herein) and the pertinent antigen. Avidity is related to both the affinity between an antigenic determinant and its antigen binding site on the antigen binding molecule, and the number of pertinent binding sites present on the antigen binding molecule. Typically, antigen binding proteins (such as an 604937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTantibody or portion of an antibody as described herein) will bind to their cognate or specific antigen with a dissociation constant (KD) of 10'5to 10'12moles / liter or less, such as 10'7to 10’12moles / liter or less, or 10'8to 10'12moles / liter (i.e., with an association constant (KA) of 105to 1012liter / moles or more, such as 107to 1012liter / moles or 108to 1012liter / moles). Any KD value greater than 10'4mol / liter (or any KA value lower than 104M'1) is generally considered to indicate non-specific binding. The KD for biological interactions which are considered meaningful (e.g., specific) are typically in the range of IO'10M(0.1 nM)to 10'5M (10000 nM). The stronger an interaction, the lower is its KD. For example, a binding site on an antibody or portion thereof described herein will bind to the desired antigen with an affinity of less than 500 nM, such as less than 200 nM, or less than 10 nM, such as less than 500 pM. Specific binding of an antigen binding protein to an antigen or antigenic determinant can be determined in any suitable manner, including, for example, Scatchard analysis and / or competitive binding assays, such as radioimmunoassays (RIA), enzyme immunoassays (EIA) and sandwich competition assays, and the different variants thereof known in the art; as well as other techniques as mentioned herein.

[0266] Accordingly, as used herein, “selectively binds” or “specifically binds” refers to the ability of an antibody or antigen binding fragment thereof as described herein to bind to a target, such as a peanut allergen, with a KD 10'5M (10000 nM) or less, e.g., 10'6M, 10'7M, 10'8M, 10'9M, 10'10M, 10'11M, IO’12M, or less. Specific binding can be influenced by, for example, the affinity and avidity of the polypeptide agent and the concentration of polypeptide agent. The person of ordinary skill in the art can determine appropriate conditions under which the polypeptide agents described herein selectively bind the targets using any suitable methods, such as titration of a polypeptide agent in a suitable cell binding assay.

[0267] As used herein, the term “selectively inhibits” means that an agent, such as a bispecific antibody agent, inhibits, as that term is used herein, the association of a first ligand-receptor pair (e.g., a peanut allergen and its cognate ligand) but does not substantially inhibit the association of a relevant second ligand-receptor pair.

[0268] The term “universal framework” refers to a single antibody framework sequence corresponding to the regions of an antibody conserved in sequence as defined by Kabat (“Sequences of Proteins of Immunological Interest”, US Department of Health and Human Services) or corresponding to the human germline immunoglobulin repertoire or structure as defined by Chothia and Lesk, J. Mol. Biol. 196:910-917 (1987). The Kabat database is now also maintained on the world wide web. The compositions and methods described herein provide for the use of a single framework, or a set of such frameworks, which have been found to permit the 614937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTderivation of virtually any binding specificity though variation in the hypervariable regions alone. The universal framework can be a VL framework (V or VK), such as a framework that comprises the framework amino acid sequences encoded by the human germline DPK1, DPK2, DPK3, DPK4, DPK5, DPK6, DPK7, DPK8, DPK9, DPKIO, DPK12, DPK13, DPK15, DPK16, DPK18, DPK19, DPK20, DPK21, DPK22, DPK23, DPK24, DPK25, DPK26 or DPK 28 immunoglobulin gene segment. If desired, the VL framework can further comprise the framework amino acid sequence encoded by the human germline JK1, JK2, JK3, JK4, or JK5 immunoglobulin gene segments. In other embodiments the universal framework can be a VH framework, such as a framework that comprises the framework amino acid sequences encoded by the human germline DP4, DP7, DP8, DP9, DP10, DP31, DP33, DP38, DP45, DP46, DP47, DP49, DP50, DP51, DP53, DP54, DP65, DP66, DP67, DP68 or DP69 immunoglobulin gene segments. In some embodiments, the VH framework can further comprise the framework amino acid sequence encoded by the human germline JHI, JH2, JH3, JH4, Ju4b, JH5 or JH6 immunoglobulin gene segments.

[0269] An “Fv” fragment is an antibody fragment which contains a complete antigen recognition and binding site. This region consists of a dimer of one heavy and one light chain variable domain in tight association, which can be covalent in nature, for example in a singlechain Fv or scFv (see below). It is in this configuration that the three CDRs of each variable domain interact to define an antigen binding site on the surface of the VH-VL dimer. Collectively, the six CDRs or a subset thereof confer antigen binding specificity to the antibody. However, even a single variable domain (or half of an Fv comprising only three CDRs specific for an antigen) can have the ability to recognize and bind antigen, although usually at a lower affinity than the entire binding site.

[0270] As used herein, “antibody variable domain” refers to the portions of the light and heavy chains of antibody molecules that include amino acid sequences of Complementarity Determining Regions (CDRs; i.e., CDR1, CDR2, and CDR3), and Framework Regions (FRs). VH refers to the variable domain of the heavy chain. VL refers to the variable domain of the light chain. For the methods and compositions described herein, the amino acid positions assigned to CDRs and FRs can be defined according to Kabat (Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md., 1987 and 1991)). Amino acid numbering of antibodies or antigen binding fragments is also according to that of Kabat.

[0271] A “Fab” of “Fab fragment” fragment contains a variable and constant domain of the light chain and a variable domain and the first constant domain (CHI) of the heavy chain.624937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTF(ab')2 antibody fragments comprise a pair of Fab fragments which are generally covalently linked near their carboxy termini by hinge cysteines between them. Other chemical couplings of antibody fragments are also known in the art.

[0272] “Single-chain Fv” or “scFv” antibody fragments comprise the VH and VL domains of an antibody, wherein these domains are present in a single polypeptide chain. Generally, the Fv polypeptide further comprises a polypeptide linker between the VH and VL domains, which permits the scFv to form the desired structure for antigen binding. For a review of scFv, see Pluckthun in The Pharmacology of Monoclonal Antibodies, Vol 113, Rosenburg and Moore eds. Springer-Verlag, New York, pp. 269-315 (1994).

[0273] The term “diabodies” refers to small antibody fragments with two antigen binding sites, which fragments comprise a heavy chain variable domain (VH) connected to a light chain variable domain (VL) in the same polypeptide chain (VH and VL). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen binding sites. Diabodies are described more fully in, for example, EP 404,097; WO 93 / 11161; and Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993).

[0274] The expression “linear antibodies” refers to the antibodies described in Zapata et al., Protein Eng., 8(10): 1057-1062 (1995). Briefly, these antibodies comprise a pair of tandem Fd segments (VH-CHI-VH-CH1) which, together with complementary light chain polypeptides, form a pair of antigen binding regions. Linear antibodies can be bispecific or monospecific.

[0275] An “affinity matured” antibody is one with one or more alterations in one or more CDRs thereof which result in an improvement in the affinity of the antibody for antigen, compared to a parent antibody which does not possess those alteration(s). Preferred affinity matured antibodies will have nanomolar or even picomolar affinities for the target antigen. Affinity matured antibodies are produced by procedures known in the art. Marks et al. Bio / Technology 10:779-783 (1992) describes affinity maturation by VH and VL domain shuffling. Random mutagenesis of CDR and / or framework residues is described by: Barbas et al. Proc Nat. Acad. Sci, USA 91:3809-3813 (1994); Schier etal. Gene 169:147155 (1995); Yeltonetal. J. Immunol.155:1994-2004 (1995); Jackson et al., J. Immunol. 154(7):3310-9 (1995); and Hawkins et al., J. Mol. Biol. 226:889-896 (1992).

[0276] As used herein in relation to antibody domains, “complementary” refers to when two immunoglobulin domains belong to families of structures which form cognate pairs or groups or are derived from such families and retain this feature. For example, a VH domain and a VL domain of a natural antibody are complementary; two VH domains are not complementary, and 634937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTtwo VL domains are not complementary. Complementary domains can be found in other members of the immunoglobulin superfamily, such as the Va and Vp (or y and 5) domains of the T cell receptor. Domains which are artificial, such as domains based on protein scaffolds which do not bind epitopes unless engineered to do so, are non-complementary. Likewise, two domains based on, for example, an immunoglobulin domain and a fibronectin domain are not complementary.

[0277] As used herein, the term “humanized antibody” refers to forms of antibodies that contain sequences from non-human (e.g., murine) antibodies as well as human antibodies. Such antibodies are chimeric antibodies which contain minimal sequence derived from non-human immunoglobulin. In general, the humanized antibody will ideally comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the framework (FR) regions are those of a human immunoglobulin sequence. The humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol 2:593-596 (1992)). The constant region, can if desired, include one or more modifications that modify or disrupt interaction of the human or humanized antibody with an Fc receptor, as described herein. Humanization can be essentially performed following the method of Winter and co-workers (Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature 332:323-3'27 (1988); Verhoeyen et al., Science 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody.

[0278] As used herein, a “subject” means a human or animal. Usually the animal is a vertebrate such as a primate, rodent, domestic animal or game animal. Primates include chimpanzees, cynomologous monkeys, spider monkeys, and macaques, e.g., Rhesus. Rodents include mice, rats, woodchucks, ferrets, rabbits and hamsters. Domestic and game animals include cows, horses, pigs, deer, bison, buffalo, feline species, e.g., domestic cat, canine species, e.g., dog, fox, wolf, avian species, e.g., chicken, emu, ostrich, and fish, e.g., trout, catfish and salmon. In some embodiments, the subject is a mammal, e.g., a primate, e.g., a human. The terms, “individual,” “patient” and “subject” are used interchangeably herein.

[0279] Preferably, the subject is a mammal. The mammal can be a human, non-human primate, mouse, rat, dog, cat, horse, or cow, but is not limited to these examples. Mammals other than humans can be advantageously used as subjects that represent animal models of644937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTallergies. A subject can be male or female. In addition, a subject can be of any age, including a neonate, a toddler, a child, a pre-adolescent, an adolescent, or an adult or geriatric subject.

[0280] A subject can be one who has been previously diagnosed with or identified as suffering from or having a condition in need of treatment (e.g., a peanut allergy) or one or more complications related to such a peanut allergy. Alternatively, a subject can also be one who has not been previously diagnosed as having a peanut allergy or one or more complications related thereto. For example, a subject can be one who exhibits one or more risks to such a condition.

[0281] A “subject in need” of treatment for a particular condition can be a subject having that condition, diagnosed as having that condition, or at risk of developing that condition.

[0282] In jurisdictions that forbid the patenting of methods that are practiced on the human body, the meaning of “administering” of a composition to a human subject shall be restricted to prescribing a controlled substance that a human subj ect will self-administer by any technique (e.g., orally, inhalation, topical application, injection, insertion, etc.). The broadest reasonable interpretation that is consistent with laws or regulations defining patentable subject matter is intended. In jurisdictions that do not forbid the patenting of methods that are practiced on the human body, the “administering” of compositions includes both methods practiced on the human body and also the foregoing activities.

[0283] The term “therapeutically effective amount” refers to an amount of an inhibitor as described herein, that is effective to block or reduce peanut allergy symptoms, e.g., anaphylaxis thereby treating a peanut allergy. Amounts will vary depending on the specific condition, e.g., an allergy, disease or disorder, its state of progression, age, weight and gender of a subject, among other variables. Thus, it is not possible to specify an exact “effective amount”. However, for any given case, an appropriate “effective amount” can be determined by one of ordinary skill in the art using only routine experimentation.

[0284] As used herein, the terms “treat,” “treatment,” “treating,” or “amelioration” refer to therapeutic treatments, wherein the object is to reverse, alleviate, ameliorate, inhibit, slow down or stop the progression or severity of at least one symptom of a peanut allergy (e.g., skin reactions, hives, skin redness, skin swelling, itching, tightening of the throat, difficulty breathing, shortness of breath, anaphylaxis etc.). The term “treating” includes reducing or alleviating at least one adverse effect or symptom of a condition, e.g., an allergy, a disease or disorder. Treatment is generally “effective” if one or more symptoms or clinical markers of the peanut allergy being treated is reduced. Alternatively, treatment is “effective” if the progression of the peanut allergy is reduced or halted. That is, “treatment” includes not just the improvement of symptoms or markers, but also a cessation of at least slowing of progress or 654937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTworsening of symptoms that would be expected in absence of treatment. Beneficial or desired clinical results include, but are not limited to, alleviation of one or more symptom(s), diminishment of extent of disease, stabilized (z.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total). The term “treatment” of a disease also includes providing relief from the symptoms or side-effects of the disease (including palliative treatment).

[0285] The term “prophylactically effective amount” refers to an amount of an antibody or antigen binding fragment thereof which is effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result, e.g., the amount of an anti-peanut allergen antibody or fragment thereof to delay the onset of or reduce the intensity of at least one symptom of a peanut allergy. Typically, since a prophylactic dose of an anti-peanut antigen antibody is administered to a subject prior to onset of a peanut allergy or at an early stage of peanut allergy, the dose necessary for a prophylactically effective amount can be less than the therapeutically effective amount. A prophylactically effective amount of an anti-peanut allergen antibody or fragment thereof is also one in which any toxic or detrimental effects of the compound are outweighed by the beneficial effects.

[0286] As used herein, the terms “prevent,” “preventing” and “prevention” refer to the avoidance or delay in manifestation of one or more symptoms or measurable markers of a condition, disease or disorder, e.g., of a peanut allergy or allergic reaction. A delay in the manifestation of a symptom or marker is a delay relative to the time at which such symptom or marker manifests in a control or untreated subject with a similar likelihood or susceptibility of developing the condition, e.g., an allergy, disease or disorder. The terms “prevent,” “preventing” and “prevention” include not only the avoidance or prevention of a symptom or marker of the condition, e.g., an allergy, disease or disorder, but also a reduced severity or degree of any one of the symptoms or markers of the condition, e.g., an allergy, disease or disorder, relative to those symptoms or markers in a control or non-treated individual with a similar likelihood or susceptibility of developing the condition, e.g., an allergy, disease or disorder, or relative to symptoms or markers likely to arise based on historical or statistical measures of populations affected by the condition, e.g., an allergy, a disease or disorder. By “reduced severity” is meant at least a 10% reduction in the severity or degree of a symptom or measurable disease marker, relative to a control or reference, e.g., at least 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99% or even 100% (i.e., no symptoms or measurable markers).664937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPT

[0287] The terms “decrease”, “reduce”, “reduction”, or “inhibit” are all used herein to mean a decrease by a statistically significant amount. In some embodiments, “reduce,” “reduction”, “decrease” or “inhibit” means a decrease by at least 10% as compared to a reference level (e.g. the absence of a given treatment) and can include, for example, a decrease by at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or more. As used herein, “reduction” or “inhibition” does not encompass complete inhibition or reduction as compared to a reference level. “Complete inhibition” is a 100% inhibition as compared to a reference level.

[0288] The terms “increased”, “increase”, “enhance”, or “activate” are all used herein to mean an increase by a statically significant amount. In some embodiments, the terms “increased”, “increase”, “enhance”, or “activate” can mean an increase of at least 10% as compared to a reference level, for example an increase of at least about 20%, or at least about 30%, or at least about 40%, or at least about 50%, or at least about 60%, or at least about 70%, or at least about 80%, or at least about 90% or up to and including a 100% increase or any increase between 10-100% as compared to a reference level, or at least about a 2-fold, or at least about a 3 -fold, or at least about a 4-fold, or at least about a 5-fold or at least about a 10-fold increase, or any increase between 2-fold and 10-fold or greater as compared to a reference level.

[0289] As used herein, the terms "identity", "identical" and the like refer to the sequence similarity between two polymeric molecules, e.g., between two polypeptide molecules or between two polynucleotide molecules. Sequence alignments and determination of sequence identity can be done, e.g., using the Basic Local Alignment Search Tool (BLAST) originally described by Altschul et al. 1990 (J Mol Biol 215: 403-10), such as the " Blast 2 sequences" algorithm described by Tatusova and Madden 1999 (FEMS Microbiol Lett 174: 247-250). Methods for aligning sequences for comparison are well-known in the art. Various programs and alignment algorithms are described in, for example: Smith and Waterman (1981) Adv. Appl. Math. 2:482; Needleman and Wunsch (1970) J. Mol. Biol. 48:443; Pearson and Lipman (1988) Proc. Natl. Acad. Sci. U. S. A. 85:2444; Higgins and Sharp (1988) Gene 73:237-44; Higgins and Sharp (1989) CAB IOS 5:151-3; Corpet et al. (1988) Nucleic Acids Res. 16:10881-90; Huang et al. (1992) Comp. Appl. Biosci. 8:155-65; Pearson et al. (1994) Methods Mol. Biol. 24:307-31; Tatiana et al. (1999) FEMS Microbiol. Lett. 174:247-50. A detailed consideration of sequence alignment methods and homology calculations can be found in, e.g.,674937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTAltschul et al. (1990) J. Mol. Biol. 215:403-10. The National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST™; Altschul et al. (1990)) is available from several sources, including the National Center for Biotechnology Information (Bethesda, MD), and on the internet, for use in connection with several sequence analysis programs. A description of how to determine sequence identity using this program is available on the internet under the "help" section for BLAST™. For comparisons of nucleic acid sequences, the " Blast 2 sequences" function of the BLAST™ (Blastn) program may be employed using the default parameters. Nucleic acid sequences with even greater similarity to the reference sequences will show increasing percentage identity when assessed by this method. Typically, the percentage sequence identity is calculated over the entire length of the sequence. For example, a global optimal alignment is suitably found by the Needleman-Wunsch algorithm with the following scoring parameters: Match score: +2, Mismatch score: -3; Gap penalties: gap open 5, gap extension 2. The percentage identity of the resulting optimal global alignment is suitably calculated by the ratio of the number of aligned bases to the total length of the alignment, where the alignment length includes both matches and mismatches, multiplied by 100. Preferably sequence identity is assessed over the length of the shorter of the two sequences being compared.

[0290] The "percent identity" or "percent homology" of two polynucleotide or two polypeptide sequences can be determined by comparing the sequences using the GAP computer program (a part of the GCG Wisconsin Package, version 10.3 (Accelrys, San Diego, Calif.)) using its default parameters.

[0291] The term “nucleic acid” refers to a deoxyribonucleotide or ribonucleotide and polymers thereof in either single strand or double strand form. The term “nucleic acid” is used interchangeably with gene, nucleotide, polynucleotide, cDNA, DNA, and mRNA. The polynucleotides can be in the form of RNA or DNA. Polynucleotides in the form of DNA, cDNA, genomic DNA, nucleic acid analogs, and synthetic DNA are within the scope of the present invention. Unless specifically limited the term encompasses nucleic acids containing known analogues of natural nucleotides that have similar binding properties as the natural nucleic acid. Unless specifically limited, a particular nucleotide sequence also encompasses conservatively modified variants thereof (for example, those containing degenerate codon substitutions) and complementary sequences as well as the sequences specifically described.

[0292] The polynucleotides can be composed of any polyribonucleotide or polydeoxyribonucleotide, which can be unmodified RNA or DNA or modified RNA or DNA. For example, polynucleotides can be composed of single or double stranded regions, mixed 684937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTsingle or double stranded regions. In addition, the polynucleotides can be triple stranded regions containing RNA or DNA or both RNA and DNA. Modified polynucleotides include modified bases, such as tritylated bases or unusual bases such as inosine. A variety of modifications can be made to RNA and DNA; thus polynucleotide includes chemically, enzymatically, or metabolically modified forms.

[0293] The DNA may be double-stranded or single-stranded, and if single stranded, may be the coding (sense) strand or non-coding (anti-sense) strand. The coding sequence that encodes the polypeptide may be identical to the coding sequence provided herein or may be a different coding sequence, which sequence, as a result of the redundancy or degeneracy of the genetic code, encodes the same polypeptides as the DNA provided herein.

[0294] A variant DNA or amino acid sequence can be at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more, identical to a native or reference sequence. The degree of homology (percent identity) between a native and a mutant sequence can be determined, for example, by comparing the two sequences using freely available computer programs commonly employed for this purpose on the world wide web (e.g. BLASTp or BLASTn with default settings).

[0295] In some embodiments of the various aspects described herein, the degree of complementarity, when optimally aligned using a suitable alignment algorithm, is about or more than about 50%, 60%, 75%, 80%, 85%, 90%, 95%, 97.5%, 99%), or more. Optimal alignment can be determined with the use of any suitable algorithm for aligning sequences. Exemplary algorithms for determining optimal alignment include, but are not limited to, the Smith-Waterman algorithm, the Needleman-Wunsch algorithm, algorithms based on the Burrows-Wheeler Transform (e.g., the Burrows Wheeler Aligner), ClustalW, Clustal X, BLAT, Novoalign (Novocraft Technologies; available at www.novocraft.com), ELAND (Illumina, San Diego, CA), SOAP (available at soap.genomics.org.cn), and Maq (available at maq. sourceforge.net).

[0296] The articles “a” and “an” are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.

[0297] The term “including” is used herein to mean, and is used interchangeably with, the phrase “including but not limited” to.

[0298] The term “or” is used herein to mean, and is used interchangeably with, the term “and / or,” unless context clearly indicates otherwise.694937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPT

[0299] The term “such as” is used herein to mean, and is used interchangeably, with the phrase “such as but not limited to”.

[0300] As used herein, the term “comprising” means that other elements can also be present in addition to the defined elements presented. The use of “comprising” indicates inclusion rather than limitation.

[0301] As used herein the term “consisting essentially of’ refers to those elements required for a given embodiment. The term permits the presence of additional elements that do not materially affect the basic and novel or functional characteristic(s) of that embodiment of the invention.

[0302] The term “consisting of’ refers to compositions, methods, and respective components thereof as described herein, which are exclusive of any element not recited in that description of the embodiment.

[0303] Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular.

[0304] Other than in the operating examples, or where otherwise indicated, all numbers expressing quantities of ingredients or reaction conditions used herein should be understood as modified in all instances by the term “about.” The term “about” when used in connection with percentages can mean ±1%. In some embodiments of the various aspects described herein, the term “about” when used in connection with percentages can mean ±5%. The term “about” is used herein to provide literal support for the exact number that it precedes, as well as a number that is near to or approximately the number that the term precedes. In determining whether a number is near to or approximately a specifically recited number, the near or approximating unrecited number may be a number which, in the context in which it is presented, provides the substantial equivalent of the specifically recited number.

[0305] As used herein, the use of “or” means “and / or” unless stated otherwise. Furthermore, the use of the term “including” as well as other forms, such as “includes” and “included”, is not limiting. Also, terms such as “element” or “component” encompass both elements and components comprising one unit and elements and components that comprise more than one subunit, unless specifically stated otherwise.

[0306] The abbreviation, “e.g.” is derived from the Latin exempli gratia, and is used herein to indicate a non-limiting example. Thus, the abbreviation “e.g.” is synonymous with the term “for example.”

[0307] The term “operably linked”, “operably connected” or equivalent expressions as used herein refer to the arrangement of various nucleic acid elements relative to each such that the 704937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTelements are functionally connected and are able to interact with each other in the manner intended. Such elements may include, without limitation, a promoter, an enhancer and / or a regulatory element, a polyadenylation sequence, one or more introns and / or exons, and a coding sequence of a gene of interest to be expressed. The nucleic acid sequence elements, when properly oriented or operably linked, act together to modulate the activity of one another, and ultimately may affect the level of expression of an expression product. By modulate, it is meant increasing, decreasing, or maintaining the level of activity of a particular element. The position of each element relative to other elements may be expressed in terms of the 5' terminus and the 3' terminus of each element, and the distance between any particular elements may be referenced by the number of intervening nucleotides, or base pairs, between the elements. As understood by the skilled person, operably linked implies functional activity, and is not necessarily related to a natural positional link. Indeed, when used in a vector, cis-regulatory elements will typically be located immediately upstream of the promoter (although this is generally the case, it should definitely not be interpreted as a limitation or exclusion of positions within the vector, but this needs not be the case in vivo, e.g., a regulatory element sequence naturally occurring downstream of a gene whose transcription it affects is able to function in the same way when located upstream of the promoter. Hence, in some embodiments, the regulatory or enhancing effect of the regulatory element is positionindependent.

[0308] The terms “wild-type” or “wt” or “WT” or “native” as used herein is meant an amino acid sequence or a nucleotide sequence that is found in nature, including allelic variations. A wild-type protein, polypeptide, polynucleotide, DNA, RNA, and the like has an amino acid sequence or a nucleotide sequence that has not been intentionally modified.

[0309] The term “statistically significant” or “significantly” refers to statistical significance and generally means a two standard deviation (2SD) or greater difference.

[0001] Groupings of alternative elements or embodiments of the invention disclosed herein are not to be construed as limitations. Each group member can be referred to and claimed individually or in any combination with other members of the group or other elements found herein. One or more members of a group can be included in, or deleted from, a group for reasons of convenience and / or patentability. When any such inclusion or deletion occurs, the specification is herein deemed to contain the group as modified thus fulfilling the written description of all Markush groups used in the appended claims.

[0002] Other terms are defined herein within the description of the various aspects of the disclosure.714937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPT

[0001] It should be understood that this invention is not limited to the particular methodology, protocols, and reagents, etc., described herein and as such can vary. The terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of the present invention, which is defined solely by the claims.

[0002] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. All documents, or portions of documents, cited in this application, including, but not limited to, patents, patent applications, articles, books, and treatises, are hereby expressly incorporated by reference in their entirety for any purpose.

[0003] The description of embodiments of the disclosure is not intended to be exhaustive or to limit the disclosure to the precise form disclosed. While specific embodiments of, and examples for, the disclosure are described herein for illustrative purposes, various equivalent modifications are possible within the scope of the disclosure, as those skilled in the relevant art will recognize. For example, while method steps or functions are presented in a given order, alternative embodiments may perform functions in a different order, or functions may be performed substantially concurrently. The teachings of the disclosure provided herein can be applied to other procedures or methods as appropriate. The various embodiments described herein can be combined to provide further embodiments. Aspects of the disclosure can be modified, if necessary, to employ the compositions, functions and concepts of the above references and application to provide yet further embodiments of the disclosure. These and other changes can be made to the disclosure in light of the detailed description. All such modifications are intended to be included within the scope of the appended claims.

[0004] Specific elements of any of the foregoing embodiments can be combined or substituted for elements in other embodiments. Furthermore, while advantages associated with certain embodiments of the disclosure have been described in the context of these embodiments, other embodiments may also exhibit such advantages, and not all embodiments need necessarily exhibit such advantages to fall within the scope of the disclosure.

[0310] The technology described herein is further illustrated by the following examples which in no way should be construed as being further limitingEXAMPLES EXAMPLE 1: ORIGINS AND DIVERSITY OF PAN-ISOTYPE HUMAN BONE MARROW PLASMA CELLS

[0311] Abstract724937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPT

[0312] Bone marrow plasma cells (BMPCs) produce durable, protective IgM, IgG, and IgA antibodies, and in some cases, pro-allergic IgE antibodies, but their properties and sources are unclear. Single BMPC transcriptional and clonal heterogeneity in food-allergic and non-allergic individuals were charted across CD 19 protein expression, given its inverse correlation to BMPC longevity. Transcriptional and clonal diversity revealed distinct functional profiles. Additionally, distribution of somatic hypermutation and intraclonal antibody sequence variance suggest that CD19lowand CD19hlghBMPCs arise from recalled memory and germinal center B cells, respectively. Most IgE BMPCs were from peanut-allergic individuals; two out of 32 from independent donors bound peanut antigens in vitro and in vivo. These findings shed light on BMPC origins and highlight the bone marrow as a source of pathogenic IgE in peanut allergy.

[0313] Introduction

[0314] Antibodies circulating in the bloodstream are indicative of learned immunity from prior infection, vaccination, and in some cases, exposure to allergens. Steady state levels of antibodies over time can play a major role in influencing susceptibility to infection (1, 2) and allergies (3). Bone marrow plasma cells (BMPCs) are a long-lived source of stable circulating antibodies, with longer-lasting subsets having undergone germinal center (GC) affinity maturation. Longer-lasting subsets exhibit low CD 19 expression (4), which is thought to arise from CD19-expressing BMPCs progressively losing CD 19 from the plasma cell surface (5). While it is known that recalled immunity can lead to more durable long-lived antibody levels (6, 7), a mechanistic link between recalled immunity and greater levels of CD19lowplasma cells is unclear.

[0315] In addition, while BMPC production of IgM, IgG, and IgA plays an important role in steady-state protection from infectious invasion, long-lived production of IgE in allergic individuals may sensitize them to dangerous allergic attacks. Of particular intrigue is the unique regulation of IgE production in comparison to production of other antibody isotypes. Upon class switch recombination to IgE, B cells rapidly differentiate to short-lived plasma cells before quickly vanishing (8-10). By contrast, IgG B cells can maintain a stable memory pool in circulation and give rise to long-lived plasma cells. Maintenance of allergic memory can be possible through secondary heavy chain class switch recombination from allergen-specific IgG memory cells (10-14). IgE BMPCs have been detected in allergic individuals (15, 16). However, cells producing food allergen-specific IgE have only been detected in peripheral blood and intestinal mucosa to date (17-20), where B cell activation and IgH class-switching 734937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTcan occur. Given that many individuals have severe and persistent allergies across decades, a bone marrow source for pathogenic, IgE-producing cells has long been speculated (15, 16, 21-23). While T cell help is associated with long-lived BMPC generation and is likely necessary for IgE production (24-26) in humans, the contribution of BMPCs to pathogenic IgE in food allergy remains unknown (27). The analysis of allergic and non-allergic bone marrow samples described herein sheds new light on the likely sources of long-lived plasma cells and identifies the bone marrow as a source of pathogenic IgE antibodies in peanut allergy.

[0316] Human BMPCs exhibit a heterogeneous transcriptional landscape

[0317] To study the source dynamics of bone marrow plasma cells and to gain insights into potential long-lived IgE production, bone marrow samples were collected from nine individuals, six with food allergies and three without any history of food allergies (Table 1). VDJ and 5’ gene expression single-cell RNA sequencing paired with CITE-seq were performed on CD138-enriched, FACS-purified BMPCs (Fig. 1A & Fig. 6). 60,548 individual BMPCs were sequenced and 11 Ig gene-independent BMPC clusters were identified with comparable numbers of genes and transcripts (unique molecular identifiers, UMIs) expressed in each cluster, as well as a low proportion of mitochondrial gene expression and detectable Ig expression (Fig. 1B-C & Fig. 7). Cells showed robust expression of plasma cell-defining transcription factors and markers (28-31) and lacked expression of B cell lineage-defining genes, confirming their plasma cell identity (Fig. 1D-F). All clusters contained BMPCs expressing different heavy chain (IgH) and light chain (IgL) isotypes but differed in IgH somatic hypermutation (SHM) (Figs. 1G-I, Fig. 7, & Fig. 8) and surface CD 19 protein levels (Fig. 1 J). 54 IgE BMPCs were identified which were primarily found in cluster 6 and to a lesser extent in cluster 8 (Fig. IG). Analysis of B cell receptor (BCR) sequences identified around half of all BMPC sequences as singlets. Within expanded clonal families, a high level of connectivity of shared clonotypes between clusters was identified, as has been previously found for mouse BM LLPCs (32) (Fig. IK) and moderate connectivity was identified between different IgH isotypes, of which IgAl, IgGl, and IgG2 were the most common among clonal families that spanned multiple isotypes (Fig. 8). The 20 largest clonal families (clone size 24-132 cells) spanned multiple clusters and were dominated by IgAl or IgGl BMPCs, with relatively minor contributions of other isotypes (Fig. 8).

[0318] Differentially expressed genes (DEGs) were identified for each cluster (Fig. 2A-B). Some clusters distinctly expressed cellular features associated with metabolism (cluster 6), MHC-II expression (cluster 8), interferon response (cluster 9), and proliferation (cluster 10).744937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTProliferating cells in cluster 10 likely represent plasmablasts. Cluster 6 was further investigated given its association with IgE and what appeared to be a tendency toward high metabolic demand. Gene set enrichment analysis (GSEA) identified amino acid biosynthesis, ER stress responses, and translation as key upregulated processes, while genes associated with cell migration were underrepresented in cluster 6 compared to all other BMPCs (Fig. 2C-D). Indeed, genes associated with amino acid transport, transamination, folate synthesis, and mitochondrial unfolded protein response (UPR) were more highly expressed in cluster 6 (Fig.2E), and amino acid availability has been identified as a limiting step in ASC generation (33). Similarly, genes encoding translation factors were highly expressed in cluster 6 (Fig. 2F), while molecules associated with cell migration and adhesion in plasma cells were downregulated (Fig. 2G) (34). Interestingly, cluster 4 highly expressed CCR10 and had the highest proportion of IgM and IgA2 plasma cells, which is consistent with a gut origin (35).

[0319] As previously reported (5, 35), differences in the expression of TNF receptor superfamily genes and NF-KB signaling were observed (Fig. 2H-J). However, their expression did not seem to be correlated. Unexpectedly, MHC-I genes were identified to be differentially expressed among mature BMPCs (Fig. 2K). Cluster 8 showed marked enrichment of MHC-II genes (Fig. 2K) and GSEA identified gene sets associated with the regulation of T cell activation as enriched within cluster 8 (Fig. 2L), which supports that these BMPCs have an immature phenotype (36).

[0320] GSEA was consistent with an interferon signature in cluster 9 and an active cell cycle signature for cluster 10. It also identified differential regulation of mitochondrial energy production (up in clusters 0, 1, 5, and 8; down in clusters 2, 3, and 7), ribosome synthesis (up in clusters 1 and 4; down in clusters 3 and 7), translation (up in cluster 5; down in cluster 3), ROS detoxification (up in cluster 0), T cell activation (up in cluster 8; down in clusters 0, 4, and 6), production of TNFSF cytokines (up in cluster 4), and retrograde transport of proteins from Golgi and ER (down in cluster 4) (Fig. 9).

[0321] These results shed light on the heterogeneity of BMPCs beyond IgH expression. In addition, this dataset confirms that there is heterogeneous NF-KB signaling and TNFRSF expression among BMPCs, as has been found in other datasets (5). ER stress, MHC expression levels, and metabolism-associated genes were also identified as additional sources of BMPC heterogeneity.

[0322] Origins of human BMPCs754937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPT

[0323] BMPCs have been proposed to progressively lose CD 19 expression as they mature into long-lived cells (4, 5). Heterogeneous surface CD 19 expression was observed among mature BMPCs (clusters 2 & 3). Mouse BMPC longevity has been shown to be correlated with different surface markers, such as TIGIT, CXCR3, EpCAM, and Ly6A (32). However, differences in expression of these markers were not observed among human BMPCs. Therefore, SHM levels and clonal dynamics were analyzed with respect to CD 19 protein levels.

[0324] SHM levels were observed as higher in CD19hlghBMPCs and lower in CD19lowBMPCs (Fig. 3 A-B). This held true for IgA and IgG BMPCs, while IgE, IgD, and IgM BMPCs with different surface CD 19 expression levels did not exhibit differences in IgH SHM (Fig. 10). In addition, BMPCs with higher SHM are more likely to be CD19hlghthan BMPCs with low SHM and vice versa (Fig. 3C), and a significant correlation between surface CD 19 expression and IgH SHM was found (Fig. 10). IgG and IgM BMPCs were more prevalent in the CD19lowpopulation, while IgA BMPCs were more prevalent in the CD19hlghBMPC population (Fig.3D), which was consistent across individuals (Figs. 11-12).

[0325] If CD19lowBPMCs mature from CD19hlghBMPCs, it is unclear why they would have lower SHM. One possibility is that BMPCs with higher SHM levels may have higher attrition rates due to potentially higher genotoxic stress induced by off-target mutations, as has been suggested for memory B cells (37). A non-mutually exclusive possibility is that CD19lowand CD19hlghcells descend from different cellular ancestors. Essentially all BMPCs have undergone substantial SHM (Fig. 7), suggesting passage through the GC B cell stage during their developmental path. GC B cells can develop directly into plasma cells after primary antigen exposure or differentiate into circulating memory B cells (MBCs), which can subsequently differentiate into plasma cells after a recall stimulus. Aspects of intra-clonal SHM helped distinguish from which of these scenarios BMPCs arose (Fig. 3E). A key assumption in this model is that MBCs and GC B cells (or their descendants) have different rates of CD 19 loss upon differentiation.

[0326] Long-lived GC-derived MBCs possess lower levels of SHM than GC-derived plasma cells do because MBCs exit from GCs earlier than plasma cells do (38). Circulating MBCs rapidly proliferate and differentiate into antibody secreting cells upon secondary antigen exposure with minimal re-entry to GCs (39). Therefore, MBC progeny are either singlets or identical clones of each other (isogenic clones), reflecting MBC-to-plasma cell differentiation in the absence of GC re-entry. On the other hand, direct GC B cell-to-plasma cell exports likely have a relatively higher degree of intra-clonal variations of the same sequence (heterogenic clones), given GC dynamics (Fig. 3E). Indeed, heterogenic clones show higher SHM levels 764937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTthan isogenic clones do (Fig. 3F), supporting the idea that MBC recall may contribute to the CD19lowBMPC pool, and direct GC B cell to plasma cell differentiation may contribute to the CD19hlghBMPC pool. Consistent with this, heterogenic clones tended to accumulate in the CD19hlghBMPC compartment (Fig. 3G). Furthermore, the frequency of CD19lowBMPC-associated IgG and IgM clones was also higher among singlets and isogenic clones, consistent with abundances of long-lived peripheral IgM and IgG MBCs (40). The frequency of CD19hlghBMPC-associated IgA was higher among heterogenic clones (Fig. 3H), consistent with high levels of IgA class switching and direct plasma cell outputs from mucosal tissue GCs (40, 41).

[0327] To further dissect the relationship between surface CD19 expression and BMPC origin, the composition of the most mutated and least mutated heterogenic clones was looked at (Fig.31 & 13). As expected, CD19hlghBMPCs tended to be overrepresented among the most mutated heterogenic clones, while CD19lowBMPCs tended to be overrepresented among the least mutated heterogenic clones (Fig. 31- J). All types of clonal structures were homogenously distributed among clusters (Fig. 13).

[0328] Taken together, the data are consistent with a model where direct GC-derived plasma cells contribute to the CD19hlghBMPC pool, while plasma cells derived from MBCs that directly differentiate into plasma cells contribute to the CD19lowBMPC pool. The differences observed for surface CD 19 expression among BMPCs could be explained by different rates of CD 19 expression loss and / or rates of removal of CD 19 protein from the cell surface from MBC or GCB cells. This model provides a mechanistic framework that is consistent with observations that recalled immunity induces longer-lived, stable antibody levels (6, 7), and is non-mutually exclusive with a model in which CD19hlghBMPCs lose CD19 expression as they mature into CD19lowBMPCs (5).

[0329] IgE BMPCs in food-allergic individuals

[0330] It has long been thought that long-lived plasma cells in the bone marrow may contribute to allergic sensitization, particularly in peanut allergy, where sensitization can last for decades without new allergen exposure (21, 22). Instances of transfer of food allergies through bone marrow donations have also been documented, which would be consistent with a long-lived source of allergen-specific antibodies (42, 43). However, allergen-specific BMPCs are not readily detected due to their extreme rarity.

[0331] By combining VDJ and 5’ transcriptome reads, 54 IgE BMPCs were identified in this dataset (Fig. 4A & Fig. 14). Even though 49% of BMPCs were derived from food-allergic individuals, 47 / 54 (87%) of IgE BMPCs were derived from these individuals, who also had 774937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTsignificantly higher IgE titers in blood (Fig. 15). A larger than expected fraction of IgM and IgD BMPCs were also found, and a lower fraction of IgG4 BMPCs was also found in food-allergic individuals (Fig. 4B). These proportions also held true when donors were analyzed separately (Fig. 15). The inverse correlation of IgG4 BMPCs in peanut allergy is consistent with the notion that IgG4 may offer a protective shield to reduce clinical sensitization (44-46). Neither sex nor age were correlated with fraction of BMPCs of any given isotype, except maybe for IgM, for which age tended to be correlated with a lower proportion of IgM BMPCs (P = 0.0526) (Fig. 15).

[0332] The enrichment of IgE BMPCs in cluster 6, and to a lesser extent in cluster 8 (Fig. 4C & Fig. 15), pointed towards an active metabolism / ER stress and immature phenotype, respectively. Most IgE BMPC sequences consisted of singlets, but IgE clone was found that was composed of 2 non-identical sequences, as well as a clone composed of one IgGl and one IgE non-identical sequences (Fig. 16). These data are consistent with both the rarity of IgE BMPCs and an MBC source of IgE BMPCs based on low surface CD19 expression (Fig. 13) and a bias towards intermediate-low SHM levels (90.1% of IgE BMPCs with VDJ data).

[0333] Analysis of IgH isotype-specific DEGs (Fig. 4D) showed that IgM cells expressed the highest amount of JCHAIN, which is consistent with IgM’s pentameric structure. They also upregulated chemokine receptors associated with skin and gut homing (e.g. CCR10) (35), downregulated genes associated with ER stress (e.g. TXNIP), and upregulated genes associated with a more immature phenotype (FOXP1, KLHL14). IgA BMPCs expressed high levels of genes associated with amino acid metabolism (SLC3A2, ATF5, SHMT2), as well as higher levels of MYC. This finding is consistent with a model in which IgA BMPCs are exported from the gut as GC emigrants rather than from a memory B cell pool. IgE BMPCs expressed high levels of LAPTM5, a known negative regulator of BCR signaling. GSEA revealed that genes associated with the maintenance of proteins in the ER lumen are downregulated in IgE BMPCs (Fig. 4E & Fig. 16). Both IgD and IgE BMPCs expressed high levels of ER stress- and translation-associated genes (PDIA4, PDIA5, CALR, DERL3, ribosomal proteins, tRNA synthetases, translation initiation factors) (Fig. 4F-G). IgE BMPCs also upregulated genes associated with plasma cell identity transcription factor IRF4, the amino acid transporter SLC3A2, and actin sequester protein TMSB4X. While allergen-specific MBCs that differentiate towards IgE-producing cells have been recently described to express CD23, IL4R, and IL13R (12, 13), only slight differences in FCER2 expression (coding for CD23) on IgE BMPCs was found. Finally, IgE BMPCs expressed very high levels of JCHAIN, which were higher than those of IgA BMPCs and second only to those of IgM BMPCs (Fig. 4F-G & Fig. 16).784937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPT

[0334] Given that JCHAIN expression has been linked to high Ig production independent of IgH isotype (47-50), patterns of JCHAIN expression were explored in this dataset. CD19lowBMPCs and SHMlowBMPCs expressed higher amounts of JCHAIN, independently of IgH isotype (Fig. 17). Additionally, heterogenic clonal families expressed slightly lower amounts of JCHAIN compared to singlets and isogenic clonal families (Fig. 17). These results point towards a high Ig secretion phenotype for MBC-derived BMPCs. On the other hand, it might also be reflective of a mucosal origin, since JCHAIN expression in IgG and IgD mucosal plasma cells has been noted (48, 51-53). There is also the possibility of an entirely unknown function, given that JCHAIN expression has been observed in other immune and non-immune cell types in both vertebrates and invertebrates (54-57).

[0335] The results are consistent with a high Ig production phenotype and / or a mucosal origin for IgE BMPCs. However, immunoglobulin variable region transcripts did not seem to vary appreciably among BMPCs of different isotypes (Fig. 4H), so additional post-transcriptional mechanisms could potentially contribute to the phenotype.

[0336] BMPCs can be a source of peanut-binding IgE antibodies

[0337] To test for IgE BMPCs’ antigen specificity and antibody function, IgE BMPC sequences from the initial cohort, one additional peanut-allergic individual, and an individual with a dairy food allergy were cloned. These two subjects did not pass the criteria to be included in gene expression analyses due to strong batch effects, but BCR sequence data were available, nonetheless. All VDJ sequences were cloned into a human IgGl backbone to screen for peanut reactivity. Out of 32 cloned IgE BMPC sequences derived from food-allergic individuals, two peanut-reactive, IgE BMPC-derived monoclonal antibodies were found from two donors with history of anaphylaxis against peanuts (P0069 and P0544) (Fig. 5A). While antibody P69P4 strongly bound to Ara h 2 but not to Ara h 6 peanut antigens, antibody P544P1 did not bind to Ara h 2 and weakly bound to Ara h 6, as determined by ELISA (Fig. 5A). Neither antibody sequence was polyreactive, as determined by ELISA binding to Spike protein or mouse serum albumin (MSA), nor were they previously reported public peanut-binding sequences (10, 17).

[0338] The peanut-binding monoclonal antibodies were further characterized through biolayer interferometry (BLI). While P544P1 did not bind specifically to biotinylated Ara h 2 or Ara h 6 in this assay, P69P4 showed a sub-nanomolar affinity (KD) for biotinylated natural Ara h 2 (Fig. 5B). Competition-based epitope mapping of this monoclonal antibody identified binding localized primarily to helix 3 of Ara h 2 (Epitope 2, PDB 8G4P) (58, 59) (Fig. 5C-D). Notably, subject P0069, from whom the antibody was derived, underwent oral immunotherapy for 794937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTpeanut allergy in the past. Antibodies that bind epitope 2 in Ara h 2 have been associated with positive responses to oral immunotherapy. However, she failed to induce tolerance against peanut antigens during therapy.

[0339] To test whether this IgE BMPC-derived antibody could have physiologically relevant binding to peanut in vivo, BALB / c mice were sensitized with peanut extract. P69P4 monoclonal antibody (P69P4 IgG) or an isotype-matched mAb (isotype) was then administered the day before challenging with intravenous peanut extract to induce anaphylaxis (Fig. 5E). Given that P69P4’s VDJ sequence (IgE BMPC-derived) is expressed on an IgGl backbone, it binds to peanut antigens but does not activate FceRI receptors, therefore effectively blocking any anaphylactic responses upon peanut challenge. As expected, mice administered with the IgG isotype control developed anaphylactic responses, as measured by a drop in body temperature after peanut challenge. However, mice that were administered P69P4 prior to challenge did not exhibit a drop in body temperature, responding indistinguishably from unsensitized mice (Fig.5E-F). While the presence of only two instances of peanut-binding IgE plasma cells, each identified in independent peanut allergic study subjects within this cohort, may be limited, it does indicate the potential for IgE BMPCs in peanut-allergic individuals to generate peanutbinding antibodies. Notably, one of these instances demonstrates significant physiological relevance in vivo.

[0340] In summary, human BMPCs are shown to exhibit intrinsic transcriptional heterogeneity with different cellular origins. Recalled MBCs may contribute directly to longer-lived CD19lowBMPCs while GC-derived plasma cells may contribute relatively more to the CD19hlghBMPC pool. Together with the idea that CD19lowBMPCs contain the longest-lived cells, this model is compatible with observations showing that immune recall induces greater stable antibody levels and with the notion that loss of CD 19 expression during BMPC maturation occurs independently of cellular ancestry. This work also highlights J chain expression as a potential indicator of greater per cell antibody production, enriched in longer lived CD19lowBMPCs, along with relatively lower SHM on average. In addition, this work also shows a high metabolism / ER-stress cellular state in IgE BMPCs and identifies them as a source of allergenspecific IgE in peanut allergy, with functional consequence in vivo. The data here shed light on sources of pathogenic antibodies in food allergy and cellular ancestry of human bone marrow plasma cells.

[0341] Materials and Methods804937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTTable 1: Cohort demographics! - Populations FACS-sorted by CD 19 surface expression before sequencing. Data on CD 19 expression not used for analyses.# - VDJ rearrangements cloned into IgGl for peanut binding testing$ - Data not included in clustering because of strong batch effects.n.r - not reported814937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPT824937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPT

[0342] Bone marrow aspirates, peripheral blood collection., and sample preparations

[0343] All clinical procedures were approved by the Institutional Review Board of Brigham and Women’s Hospital (IRB Protocol Number: 2018P002007). Participants provided written consent for the study, laboratory tests were conducted to gather clinical data, and the data was stored in a secure data repository. Study participants who either had a history of food allergy and anaphylaxis or not (Supplementary Table 1) were recruited. Bone marrow (BM) aspirates and peripheral blood were collected from each group. 20-40 mL of BM aspirate was obtained from the posterior superior iliac spine using heparin or EDTA collection tubes (BD). Red blood cells (RBCs) were lysed in BM samples using 0.8% ammonium chloride solution (Stem Cell Technologies). Samples were then directly used for downstream applications, including magnetic enrichment, flow cytometry, cell sorting, and single B cell sequencing. Peripheral blood was collected on EDTA tubes (BD Biosciences). Peripheral blood mononuclear cells (PBMCs) were isolated from peripheral blood by density gradient centrifugation using Ficoll PLUS medium (Cytiva) and stored in serum -free cry opreservation medium Cellbanker 2 (Amsbio). Plasma was saved after Ficoll gradient separation and stored at -80°C until further use. PBMCs were aliquoted and stored until use at -80°C. RBCs were lysed using RBC lysis buffer (eBioscience) before downstream applications after thawing.

[0344] Bone marrow plasma cell sorting.834937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPT

[0345] RBC-lysed bone marrow cells were positively selected using CD138 microbeads kit (Miltenyi Biotec) and stained with anti-CD138-PE (clone Mil 5, BioLegend, 1:50), anti-CD38-APC-Cy7 (clone HB-7, BioLegend, 1:50), anti-CD19-BV605 (clone HIB19, BioLegend, 1:50), anti-IgD-PerCP-Cy5.5 (clone IA6-2, BioLegend, 1:50), anti-CD3-FITC (clone HIT3a, BioLegend, 1:50), anti-CD14-FITC (clone 63D3, BioLegend, 1:50), and DAPI (ThermoFisherScientific, 1:2,000) (see Methods). Additionally, sorted samples were labeled with TotalSeq-C Hashtag 1-5 antibodies (Total Seq-C0251, TotalSeq-C0252, TotalSeq-C0253, TotalSeq-C0254, TotalSeq-C0255) (0.5 pg per 1,000,000 cells) and TotalSeq-C0050 antiCD 19 antibody (BioLegend) for demultiplexing individual samples in downstream analysis. CD38hlCD138+cells were sorted with a FACS Aria II cell sorter (BD Biosciences) into cooled 1.5-mL tubes (BioRad). When TotalSeq-C0050 anti-CD19 antibody was not available, cells were further sorted into CD19hlghor CD19lowpopulations.

[0346] FACS data were collected with the BD FACSDiva (v.8.0) software. FlowJo v.10.7.1 (BD Biosciences) was used for flow cytometry data analysis.

[0347] 10X Genomics scRNA-seq

[0348] Using a Single-Cell 5 'Library and Gel Bead kit v.1.1 (10X Genomics, 1000165) and Next GEM Chip G Single-Cell kit (10X Genomics, 1000120), the magnetically enriched, FACS-sorted BMPC single cell suspension was loaded onto a Chromium single-cell controller (10X Genomics) to generate single-cell gel beads in the emulsion (GEMs) according to the manufacturer’s protocol. 4,000 - 15,000 cells were added to each channel and approximately 50 -70 % were recovered. Captured cells were lysed and released RNA was barcoded through reverse transcription in individual GEMs. The 5 'gene expression (GEX) libraries, single-cell V(D)J libraries (1000016) and cell surface protein libraries were constructed according to manufacturer protocols. Library quality was assessed using a 2200 TapeStation (Agilent). mRNA libraries were sequenced to an average of 30,000 reads per cell using Illumina Novaseq sequencer with a paired-end 150-bp (PE150) reading strategy (Dana Farber Cancer Institute).

[0349] 10X data pre-processing and quality control

[0350] scRNA-seq reads were processed with Cell Ranger (v3.1), which quantified transcript counts per putative cell. Quantification was performed using the STAR aligner against the GRCh38 transcriptome.

[0351] Data was analyzed with the Seurat package (v5.0.1) (60) in RStudio. Cells expressing less than 5% of mitochondrial genes and between 200 and 4,000 RNAs were retained for further analysis. Barcodes were demultiplexed based on hashtag oligonucleotide count distribution and proportion among all hashing antibodies in a run-dependent manner. Cells expressing CD3E 844937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPT(T cells), NKG7, PRF1 (NK cells), S100A9 (neutrophils), FCGR3A, CD14 (monocytes), COL1A1, APOE, CSF1R (macrophages and fibroblasts), HBB (erythroid) were discarded.

[0352] Isotype assignation of cells

[0353] Isotype assignation was performed via a combination of gene expression (GEX) and BCR (VDJ) libraries. If a barcode in GEX had a corresponding barcode in VDJ with heavy chain isotype information, that barcode was assigned the identified VDJ isotype. If a barcode in GEX had a corresponding barcode in VDJ without heavy chain isotype information, or if it did not have a corresponding barcode in VDJ, heavy chain isotype was assigned based on GEX via the following criteria: i) more than half of IgH isotypes corresponded to a given isotype, and ii) the cell expressed more than 20 counts of the given isotype. Cells that were not assigned a heavy chain isotype with confidence were discarded. When benchmarked against VDJ-based isotype assignation, GEX-based isotype inference performed accurately for 95.09-99.99% of the barcodes with corresponding VDJ isotype information (Fig. 14). This method identified isotype class and subclass with remarkable specificity, ranging from 95.56% to 99.99% depending on heavy chain isotype (Fig. 14). Isotype class (IgM / DZE / G / A & IgK / L) was defined based on isotype subclass determined by GEX or VDJ data (IgM / D / E / Gl / G2 / G3 / G4 / Al / A2 & IgK / L 1 / L2 / L3 / L4 / L5 / L6 / L7).

[0354] Batch-correction., clustering and surface CD19 protein expression

[0355] Variable feature selection was performed after excluding immunoglobulin genes (V, D, J, and C genes for all IgH and IgL isotypes, including pseudogenes, and contaminant nonannotated Ig genes AC233755.1 and AC233755.2) and XIST to account for sex differences. PCA was performed on the initial dataset containing Ig genes based on the variable features defined without Ig genes.

[0356] Batch correction between 10X runs was performed with Harmony (vl.2.0) (61). Cells were clustered using the Louvain algorithm with a resolution of 0.67. Integration metrics were calculated using the scIntegrationMetrics package (vl.1) (62). Runs that did not at least double their iLISI score after batch correction were not included in clustering and gene expression-related analyses (see Table 1) but were retained for IgE BCR sequence analysis (see “Antibody production and binding reactivity screening with ELISA” section below).

[0357] Surface CD 19 expression was assessed using oligonucleotide-tagged anti -CD 19 antibodies (see “Bone marrow plasma cell sorting” and “Materials” sections above). Antibody capture data was log-transformed and Z-scored to normalize for batch effects between runs. CD 19 expression bins (low, mid, high) were defined by ranking surface CD 19 expression: the854937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTtop 30 expressors were defined as CD19hlgh, the middle 40 were defined as CD19mid, and the bottom 30 were defined as CD19low.

[0358] Differential gene expression testing and gene set enrichment analysis (GSEA)

[0359] Differentially expressed genes (DEGs) were identified on whole data using FindMarkers in Seurat. DEGs were identified for clusters and for isotype classes by comparing each group versus all the rest. For IgE cells, additional DEGs were identified by comparing IgE cells versus other heavy chain isotypes on a 1 vs 1 basis. Data from these analyses were used for heatmaps, bubble plots, violin plots, and volcano plots.

[0360] Prior to GSEA 63), data were pseudobulked with Seurat (v5.0.1) by donor and by cluster, or by donor and isotype class. DEGs were determined using DESeq2 (vl.42.0) (64) and these data were used as input for GSEA using clusterProfiler (v4.10.0) (65).

[0361] Somatic hypermutation and clonal composition analyses

[0362] Input VDJ data was processed using IgBlast to determine gene segment usage and CDR positions. Somatic hypermutation (SHM) was determined by comparison of the BCR heavy chain nucleotide sequence with the germline sequence. SHM bins (low, mid, high) were defined by ranking heavy chain SHM: the top 30 most mutated cells were defined as SHMhlgh, the middle 40 were defined as SHMmid, and the bottom 30 were defined as SHMlow.

[0363] The Immcantation package was then used to define BCR clonotypes (Change-0 vl.3.0) (66) based on heavy chain CDR3 amino acid sequence similarity and identical usage of IGHV and IGHJ genes. The hamming distance cut-off (0.85) was determined by SHazaM (vl.1.2) (66). Clonal relationships were graphed using circlize (vO.4.15) (67) in R.

[0364] Clonal families were classified into 3 categories based on their lineage structure - i) heterogenic clones, consisting of clones with at least 2 cells with unique sequences representing an expanded clone differing in mutations, ii) isogenic clones, consisting of clonotypes with at least 2 cells, where all cells have identical sequences, representing an expanded clone with identical mutations and iii) singlets, consisting of cells that are not part of an expanded clone and have unique sequences. Heterogenic and isogenic clonal families with at least 5 cells were used for CD 19 distribution, SHM distribution, and isotype frequency analyses.

[0365] Antibody production and binding reactivity screening with ELISA

[0366] Heavy and light chain variable domain gene fragments were synthesized from IgE BMPC scVDJ-seq data based on raw matrices. Antibody sequences were then cloned into human IgGl vectors, expressed, and purified by Twist Bioscience.

[0367] To evaluate the binding reactivity of antibodies from BMPCs, ELISA was carried out. Briefly, 96-well ELISA plates (ThermoFisher) were coated with 100 ng / well of peanut extract 864937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTprotein (Ukko), 100 ng / well Ara h 2 (Millipore Sigma), or 50 ng / well Ara h 6 (Ukko) in 50 pL coating buffer (0. IM NaHCO3 / Na2CO3, pH = 9.5) at 4°C overnight. Plates were blocked with 150 pL of 5% BSA in PBS for at least 2 hours. 50 pL of purified antibodies were added to the plates (4 pg / mL - 0.0024 pg / mL, 2-fold serial dilutions in 2% BSA) and incubated for 1 hour. Plates were washed 4 times with PBS + 0.05% Tween-20 (PBST). 50 pL / well of anti -human IgG-alkaline phosphatase (Southern Biotech) (1 pg / mL in PBST + 1% BSA) was added and incubated for 1 hour at room temperature. Plates were washed three times with PBST. 100 pL / well of developing solution (0.1 M glycine, pH 10.4, 1 mM MgCh, 1 mM ZnCh, 1.6 mg / mL alkaline phosphatase substrate -nitrophenyl phosphate (Sigma-Aldrich)) was then added to the plates and incubated for 2 hours at room temperature. Absorbance was measured at 405 nm using a microplate reader (Biotek Synergy Hl). EC50 and AUC were calculated with GraphPad Prism 10.

[0368] Quantification of mAbs and affinity determination

[0369] Purified IgGl mAbs were quantified using anti-human Fab-CHl (FAB2G) biosensors (Sartorius) as previously described (5S). To measure affinity, biotinylated natural Ara h 2 (InBio) diluted in kinetics buffer (Dulbecco’s PBS, 1% BSA, 0.02% Tween-20) was loaded onto streptavidin sensors (Sartorius) for 100 seconds. Antibody affinities were measured using a minimum of 5 concentrations after 3-fold dilutions from 2 ug / mL. Experiments were performed using Octet R2 Protein Analysis System (Sartorius) and affinity was calculated using Octet Analysis Studio Software, version 12.2, and GraphPad Prism, version 9.3.1, as previously described.

[0370] Epitope determination

[0371] To localize epitopes of mAbs, an in-tandem assay was used on BLI, as previously described (5S). Briefly, antibodies were diluted in kinetics buffer, (10 pg / mL primary mAbs and 5 pg / mL secondary mAbs). For primary antibodies, previously described monoclonal Ara h 2 specific antibodies, 23P34, 13T5, 22S1, and 13T1, with known epitope characterization (PDBs 8DB4 and 8G4P) (5S, 59) were used. Streptavidin sensors (Sartorius) were loaded with biotinylated natural Ara h 2 (InBio). Secondary antibodies were grouped into a separate epitope if binding was 0.16 nm or higher (>4 times the SD of nonbinding antibodies, based on previous work (5S). Analysis was performed using Octet Analysis Studio Software, version 12.2, and GraphPad Prism, version 9.3.1.

[0372] Protection of BALB / c anaphylaxis using allergen-specific IgG antibody

[0373] To evaluate in vivo binding of peanut-specific IgE BMPC BCR sequences (Fig. 5C), an active peanut anaphylaxis model was used using female WT BALB / c mice (Jackson 874937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTLaboratory, 000651). Mice were sensitized to peanut antigens by intraperitoneal (i.p.) injection at day 0 and day 7 with 20 pg peanut extract in 100 pL PBS mixed with 100 pL Alum (ThermoFisher). In parallel, mice immunized with PBS and Alum without peanut extract were prepared as a control group. On day 20, mice were intravenously (i.v.) injected with 200 pg of antibodies. On day 21, anaphylaxis was induced by challenging mice with i.v. injection of 20 pg peanut extract in 100 pL PBS. The mice's temperature was measured with a DAS-8027IUS temperature probe system (BMDS) before challenge and every 5 minutes for 90 minutes after the antigen challenge.

[0374] Statistical analysis and data visualization

[0375] Plots were generated in Prism Graphpad (vlO.1.1) or in R using ggplot2 (v3.4.4) (6S), circlize (vO.4.15) (67), Seurat (v5.0.1) (60), and clusterProfiler (v4.10.0) (65). Flow cytometry data was visualized using FlowJo vlO.7.1.

[0376] Unpaired non-parametric tests were used to assess statistical differences. Mann-Whitney tests were used when comparing two independent groups, Kruskal-Wallis tests were used when comparing three or more independent groups, and Friedman tests were used when comparing three dependent groups. All post-hoc tests were performed by comparing all means or ranks against all other means or ranks. Sample sizes are indicated in figure legends.References1. D. S. Khoury et al., Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 Infection. Nat Med 27, 1205- 1211 (2021).2. G. Regev-Yochay et al., Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV- 2 in households in Israel (ICoFS): a prospective cohort study. Lancet Microbe 4, e309-e318 (2023).3. H. A. Sampson, D. G, Ho, Relationship between food-specific IgE concentrations and the risk of positive food challenges in children and adolescents. J Allergy Clin Immunol 100, 444-451 (1997).4. J, L. Halliley et al., Long-Lived Plasma Cells Are Contained within the CD19(- )CD38(hi)CD138(+) Subset in Human Bone Marrow. Immunity 43, 132- 145 (2015).5. M. Duan et al., Understanding heterogeneity of human bone marrow plasma cell maturation and survival pathways by single-cell analyses. Cell Rep 42, 112682 (2023).6. Y. Chen et al., Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production. Cell, (2020).7. Y. Chen, et al.. Immune recall improves antibody durability and breadth to SARS- CoV-2 variants. Sci Immunol, eabp8328 (2022).884937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPT8. K. Haniuda, S. Fukao, T. Kodama, H. Hasegawa, I). Kitamura, Autonomous membrane IgE signaling prevents IgE -memory formation. Nat Immunol 17, 1109-1117 [2016).9. Z. Yang et al., Regulation of B cell fate by chronic activity of the IgE B cell receptor. Elife 5, (2016).10. S. U. Patil et al., Peanut oral immunotherapy transiently expands circulating Ara h 2 -specific B cells with a homologous repertoire in unrelated subjects. J Allergy Clin Immunol 136, 125-134 ell2 (2015).11. A. Erazo et al,, Unique maturation program of the IgE response in vivo. Immunity 26, 191-203 (2007).12. M. Ota et al., CD23(+)IgGl(+) memory B cells are poised to switch to pathogenic IgE production in food allergy. Sci Transl Med 16, eadi0673 (2024).13. J. F. E. Koenig et al., Type 2-polarized memory B cells hold allergen-specific IgE memory. Sci Transl Med 16, eadi0944 (2024).14. T. J. Looney et al., Human B-cell isotype switching origins of IgE. J Allergy Clin Immunol 137, 579-586 e577 (2016).15. S. Asrat, et al., Chronic allergen exposure drives accumulation of long-lived IgE plasma cells in the bone marrow7, giving rise to serological memory. Sci Immunol 5, (2020).16. S. Asrat et al., TRAPnSeq allows high-throughput profiling of antigen-specific antibody-secreting cells. Cell Rep Methods 3, 100522 (2023).17. D. Croote, S. Darmanis, K. C. Nadeau, S. R. Quake, High-affinity allergen-specific human antibodies cloned from single IgE B cell transcriptomes. Science 362, 1306-1309 (2018).18. R. A. Hoh et al., Origins and clonal convergence of gastrointestinal IgE (+) B cells in human peanut allergy. Sci Immunol 5, (2020),19. R. Jimenez-Saiz et al., Human BCR analysis of single-sorted, putative IgE(+ ) memory B cells in food allergy. J Allergy Clin Immunol 144, 336-339 e336 (2019).20. R. A. Hoh et al., Single B-cell deconvolution of peanut-specific antibody responses in allergic patients. J Allergy Clin Immunol 137, 157-167 (2016).21. D. Van Hemelen et al., Dramatically decreased T cell responses but persistent IgE upon reduced pollen exposure. Immunobiology 224, 645-648 (2019).22. E. A. Erwin, J. A. Woodfolk, H. R. James, S. M. Satinover, T. A. Platts-Mills, Changes in cat specific IgE and IgG antibodies with decreased cat exposure. Ann Allergy Asthma Immunol 112, 545-550 e541 (2014).23. L. C. Wu, H. Scheerens, Targeting IgE production in mice and humans. Curr Opin Immunol 31, 8-15 (2014).24. B. Zhang, et al., Divergent T follicular helper cell requirement for IgA and IgE production to peanut during allergic sensitization. Sci Immunol S, (2020).25. U. Gowthaman, J. S. Chen, S. C. Eisenbarth, Regulation of IgE by T follicular helper cells. J Leukoc Biol 107, 409-418 (2020).26. U. Gowthaman et al., Identification of a T follicular helper cell subset that drives anaphylactic IgE. Science 365, (2019).27. D. R. Wesemann, C. R. Nagler, Origins of peanut allergy-causing antibodies. Science 367, 1072-1073 (2020).28. M. J. McCarron, P. W. Park, D. R. Fooksman, CD138 mediates selection of mature plasma cells by regulating their survival. Blood 129, 2749-2759 (2017), 29. D. R. Fooksman, Z. Jing, R. Park, New insights into the ontogeny, diversity, maturation and survival of long-lived plasma cells. Nat Rev Immunol, (2024).894937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPT30. J. Tellier et al., Blimp-1 controls plasma cell function through the regulation of immunoglobulin secretion and the unfolded protein response. Nat Immunol 17, 323-330 (2016).31. S. L. Nutt, N, Taubenheim, J. Hasbold, L. M, Corcoran, P. D. Hodgkin, The genetic network controlling plasma cell differentiation. Semin Immunol 23, 341- 349 (2011).32. X. Liu, J. Yao, Y. Zhao, J. Wang, H. Qi, Heterogeneous plasma cells and long-lived subsets in response to immunization, autoantigen and microbiota. Nat Immunol 23, 1564-1576 (2022).33. R. Vijay et al., Infection-induced plasmablasts are a nutrient sink that impairs humoral immunity to malaria. Nat Immunol 21, 790-801 (2020).34. Z. Benet, Z. Jing, D. R. Fooksman, Plasma cell dynamics in the bone marrow niche. Cell Rep 34, 108733 (2021).35. J. Tellier et al., Unraveling the diversity and functions of tissue-resident plasma cells. Nat Immunol 25, 330-342 (2024).36. I. Chernova et al., Lasting antibody responses are mediated by a combination of newly formed and established bone marrow plasma cells drawn from clonally distinct precursors. J Immunol 193, 4971-4979 (2014).37. A. D. Gitlin et al., Independent Roles of Switching and Hypermutation in the Development and Persistence of B Lymphocyte Memory. Immunity 44, 769- 781 (2016).38. F. J. Weisel, G. V. Zuccarino-Catania, M. Chikina, M. J. Shlomchik, A Temporal Switch in the Germinal Center Determines Differential Output of Memory B and Plasma Cells. Immunity 44, 116-130 (2016).39. L. Mesin et al., Restricted Clonality and Limited Germinal Center Reentry Characterize Memory B Cell Reactivation by Boosting. Cell l80, 92-106 elll (2020).40. G. E. Phad et al., Clonal structure, stability and dynamics of human memory B cells and circulating plasmablasts. Nat Immunol 23, 1076-1085 (2022).41. J. R. Wilmore et al., IgA Plasma Cells Are Long-Lived Residents of Gut and Bone Marrow That Express Isotype- and Tissue-Specific Gene Expression Patterns, Front Immunol 12, 791095 (2021).42. A. Bellou, G. Kanny, S. Fremont, D. A. Moneret-Vautrin, Transfer of atopy following bone marrow transplantation. Ann Allergy Asthma Immunol 78, 513- 516 (1997).43. J. M. Agosti et al., Transfer of allergen-specific IgE-mediated hypersensitivity with allogeneic bone marrow transplantation. N Engl J Med 319, 1623-1628 (1988).44. S. M. Jones et al., Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol 124, 292-300, 300 e291-297 (2009). 45. B. P. Vickery et al., Peanut oral immunotherapy modifies IgE and IgG4 responses to major peanut allergens. J Allergy Clin Immunol 131, 128-134 el21-123 (2013).46. T. Keswani et al., Neutralizing IgG(4) antibodies are a biomarker of sustained efficacy after peanut oral immunotherapy. J Allergy Clin Immunol, (2024).47. G. Lamson, M. E. Koshland, Changes in J chain and mu chain RNA expression as a function of B cell differentiation. J Exp Med 160, 877-892 (1984).48. C. D. Castro, M. F. Flajnik, Putting J chain back on the map: how might its expression define plasma cell development? J Immunol 193, 3248-3255 (2014).904937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPT49. J. Mestecky, R. J. Winchester, T. Hoffman, H. G. Kunkel, Parallel synthesis of immunoglobulins and J chain in pokeweed mitogen-stimulated normal cells and in lymphoblastoid cell lines. J Exp Med 145, 760-765

[1977] .50. W. H. Kutteh et al,. Biosynthesis of J -chain in human lymphoid cells producing immunoglobulins of various isotypes. Mol Immunol 20, 967-976

[1983] .51. P. Brandtzaeg, F. R. Korsrud, Significance of different J chain profiles in human tissues: generation of IgA and IgM with binding site for secretory component is related to the J chain expressing capacity of the total local immunocyte population, including IgG and IgD producing cells, and depends on the clinical state of the tissue. Clin Exp Immunol 58, 709-718 (1984).52. F. R. Korsrud, P. Brandtzaeg, Immunohistochemical evaluation of J-chain expression by intra- and extra-follicular immunoglobulin-producing human tonsillar cells, Scand J Immunol 13, 271-280 (1981).53. P. Brandtzaeg, Immunohistochemical characterization of intracellular J-chain and binding site for secretory component (SC) in human immunoglobulin (Ig)- producing cells. Mol Immunol 20, 941-966 (1983).54. T. Takahashi et al., The joining (J) chain is present in invertebrates that do not express immunoglobulins. Proc Natl Acad Sci U SA 93, 1886-1891 (1996), 55. F. E. Bertrand, 3rd, L. G. Billips, G. L. Gartland, H. Kubagawa, H. W. Schroeder, Jr., The J chain gene is transcribed during B and T lymphopoiesis in humans.} Immunol 156, 4240-4244 (1996).56. E. Kallberg, T. Leanderson, Joining-chain (J-chain) negative mice are B cell memory deficient. Eur J Immunol 36, 1398-1403 (2006),57. K. Kawasaki, Y. Ohta, C. D. Castro, M. F. Flajnik, The immunoglobulin J chain is an evolutionarily co-opted chemokine. Proc Natl Acad Sci U S A 121, e2318995121 (2024),58. N. A. LaHood et al., Immunotherapy-induced neutralizing antibodies disrupt allergen binding and sustain allergen tolerance in peanut allergy. J Clin Invest 133, (2023).59. J, Min et al., Design of an Ara h 2 hypoallergen from conformational epitopes. Clin Exp Allergy 54, 46-55 (2024).60. R. Satija, J. A. Farrell, D, Gennert, A. F. Schier, A. Regev, Spatial reconstruction of single-cell gene expression data. Nat Biotechnol 33, 495-502 (2015).61. I. Korsunsky et al„ Fast, sensitive and accurate integration of single-cell data with Harmony. Nat Methods 16, 1289-1296 (2019).62. M. Andreatta et al., Semi-supervised integration of single-cell transcriptomics data. Nat Commun 15, 872 (2024).63. A. Subramanian et al., Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102, 15545-15550 (2005).64. M. I. Love, W. Huber, S. Anders, Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15, 550 (2014).65. T. Wu et al., clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation (Camb) 2, 100141 (2021).66. N. T. Gupta et al., Change-O: a toolkit for analyzing large-scale B cell immunoglobulin repertoire sequencing data. Bioinformatics 31, 3356- 3358 (2015).67. Z. Gu, L. Gu, R. Eils, M. Schlesner, B. Brors, circlize Implements and enhances circular visualization in R. Bioinformatics 30, 2811-2812 (2014).914937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPT68, H. Wickham, C. Sievert, SpringerLink, in Use R! (Springer Springer International Publishing: Imprint: Springer, Cham, 2016).

[0377] All patents and other publications; including literature references, issued patents, published patent applications, and co-pending patent applications; cited throughout this application are expressly incorporated herein by reference for the purpose of describing and disclosing, for example, the methodologies described in such publications that might be used in connection with the technology described herein. These publications are provided solely for their disclosure prior to the filing date of the present application. Nothing in this regard should be construed as an admission that the inventors are not entitled to antedate such disclosure by virtue of prior invention or for any other reason. All statements as to the date or representation as to the contents of these documents are based on the information available to the applicants and do not constitute any admission as to the correctness of the dates or contents of these documents.924937-1056-9264 10043214-000108WOPT

Claims

1. Attorney Docket No. 043214-000108WOPTCLAIMSWhat is claimed is1. An antibody or antigen binding fragment thereof comprising:a) a heavy chain variable region (VH) comprising:i. a complementarity determining region 1 (HCDR1) having an amino acid sequence of GFSFGSSW (SEQ ID NO: 2);ii. a complementarity determining region 2 (HCDR2) having an amino acid sequence of VNGDGSSV (SEQ ID NO: 3); and iii. a complementarity determining region 3 ( HCDR3 ) having an amino acid sequence of VKGKSRRSQYDQ (SEQ ID NO: 4); andb) a light chain variable region (VL) comprising:i. a complementarity determining region I (LCDR1) having an amino acid sequence of QDVDKY (SEQ ID NO: 15);ii. a complementarity determining region 2 (LCDR2) having an amino acid sequence of DVS (SEQ ID NO: 16); andiii. a complementarity determining region 3 (LCDR3) having an amino acid sequence of QQYDNLPIT (SEQ ID NO: 17).

2. The antibody or antigen binding fragment of claim 1, wherein the antibody or antigen binding fragment comprises a single domain antibody, an scFv, a monoclonal antibody, a humanized antibody, a human antibody, a recombinant antibody, a chimeric antibody, or a Fab fragment.

3. The antibody or antigen binding fragment of any one of claims 1-2, wherein the heavy chain variable region further comprises a Framework region 1 (FW_H1) sequence that differs by no more than four, preferably no more than three, more preferably no more than two, most preferably no more than one amino acid from EVQLVESGGGLVQPGGSLRLSCVAS (SEQ ID NO: 10).

4. The antibody or antigen binding fragment of any one of claims 1-3, wherein the heavy chain variable region further comprises a Framework region 2 (FW H2) sequence that differs by no more than four, preferably no more than three, more preferably no more than two, most preferably no more than one amino acid from MHWVRQDPAKGLVWVAR (SEQ ID NO: 11).

5. The antibody or antigen binding fragment of any one of claims 1-4, wherein the heavy chain variable region further comprises a Framework region 3 (FW H 3) sequence that934937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTdiffers by no more than four, preferably no more than three, more preferably no more than two, most preferably no more than one amino acid from SYRDSMEGRFTISRDNAKNTLFLQMNSLRPEDTALYYC (SEQ ID NO: 12).

6. The antibody or antigen binding fragment of any one of claims 1-5, wherein the heavy chain variable region further comprises a Framework region 4 (FW H4) sequence that differs by no more than four, preferably no more than three, more preferably no more than two, most preferably no more than one amino acid from WGQGTLVTVSS (SEQ ID NO: 13)7. The antibody or antigen binding fragment of any one of claims 1-6, wherein the antibody or antigen binding fragment comprises a heavy chain amino acid sequence having at least 80% identity to the amino acid sequence EVQLVESGGGLVQPGGSLRLSCVASGFSFGSSWMHWVRQDPAKGLVWVAR VNGDGSSVSYRDSMEGRFTISRDNAKNTLFLQMNSLRPEDTALYYCVKGKSR RSQYDQWGQGTLVTVSS (SEQ ID NO: 9), and wherien the heavy chain comprises a HCDR1 sequence having 100% identity to SEQ ID NO: 2, a HCDR2 sequence having 100% identity to SEQ ID NO: 3, and a HCDR3 sequence having 100% identity to SEQ ID NO:

48. The antibody or antigen binding fragment of any one of claims 1-7, wherein the light chain variable region further comprises a Framework region 1 (FW Ll) sequence that differs by no more than four amino acids from DIQMTQSPSSLSASVGDRVTITCQAS (SEQ ID NO: 20).

9. The antibody or antigen binding fragment of any one of claims 1-8, wherein the light chain variable region further comprises a Framework region 2 (FW_L2) sequence that differs by no more than four amino acids from LNWYQQKPGKAPKLLIY (SEQ ID NO: 21)10. The antibody or antigen binding fragment of any one of claims 1-9, wherein the light chain variable region further comprises a Framework region 3 (FW_L3) sequence that differs by no more than four amino acids from NLETGVPLRFSGGGSGTDFTFTISGLQAEDFATYYC (SEQ ID NO: 22).

11. The antibody or antigen binding fragment of any one of claims 1-10, wherein the light chain variable region further comprises a Framework region 4 (FW_L4) sequence that differs by no more than four amino acids from FGQGTRLEIK (SEQ ID NO: 23).

12. The antibody or antigen binding fragment of any one of claims 1-11, wherein the antibody or antigen binding fragment comprises a light chain amino acid sequence 944937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPThaving at least 80% identity to the amino acid sequence DIQMTQSPSSLSASVGDRVTITCQASQDVDKYLNWYQQKPGKAPKLLIYDVS NLETGVPLRFSGGGSGTDFTFTISGLQAEDFATYYCQQYDNLPITFGQGTRLEIK (SEQ ID NO: 19), and wherein the light chain comprises a LCDR1 sequence having 100% identity to SEQ ID NO: 15, a LCDR2 sequence having 100% identity to SEQ ID NO: 16, and a LCDR3 sequence having 100% identity to SEQ ID NO: 17.

13. The antibody or antigen binding fragment of any one of claims 1-12, wherein the antibody or antigen binding fragment comprises a heavy chain constant region 1 (CHI) comprising an amino acid sequence having at least 85% identity to ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTF PAVLQSSGLYSLSSVVTVPSSSLGTQTICNVNHKPSNTKVDKKV (SEQ ID NO: 5).

14. The antibody or antigen binding fragment of any one of claims 1-13, wherein the antibody or antigen binding fragment comprises a heavy chain constant region 2 (CH2) comprising an amino acid sequence having at least 85% identity to APEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGV EVHNAI< TI< PREEQYNSTYRVVSVLTVLHQDWLNGI< EYI< CI< VSNI< ALPAPIE KTISKAK (SEQ ID NO: 7).

15. The antibody or antigen binding fragment of any one of claims 1-14, wherein the antibody or antigen binding fragment comprises a heavy chain constant region 3 (CH3) comprising an amino acid sequence having at least 85% identity to GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS PGK (SEQ ID NO: 8) or GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS PG (SEQ ID NO: 24)16. The antibody or antigen binding fragment of any one of claims 1-15, wherein the antibody or antigen binding fragment comprises a heavy chain hinge region (CHl_CH2_hinge) comprising an amino acid sequence having at least 85% identity to EPKSCDKTHTCPPCP (SEQ ID NO: 6).

17. The antibody or antigen binding fragment of any one of claims 1-16, wherein the antibody or antigen binding fragment acomprises a heavy chain amino acid sequence having at least 85% identity to 954937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTEVQLVESGGGLVQPGGSLRLSCVASGFSFGSSWMHWVRQDPAKGLVWVAR VNGDGSSVSYRDSMEGRFTISRDNAKNTLFLQMNSLRPEDTALYYCVKGKSR RSQYDQWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPE P VT VSWNSGALTSGVHTFP AVLQS SGL YSLS S VVTVPS S SLGTQTICNVNHKP SNTKVDKKVEPKSCDKTHTCPPCPAPEAAGAPSVFLFPPKPKDTLMISRTPEV TCVVVDVSHEDPEVI< FNWYVDGVEVHNAI< TI< PREEQYNSTYRVVSVLTVL HQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 1), and wherien the heacy chain comprises a HCDR1 sequence having 100% identity to SEQ ID NO: 2, a HCDR2 sequence having 100% identity to SEQ ID NO: 3, and a HCDR3 sequence having 100% identity to SEQ ID NO: 4.

18. The antibody or antigen binding fragment of any one of claims 1-17, wherein the antibody or antigen binding fragment comprises a light chain constant region (CL) comprising an amino acid sequence having at least 85% identity to RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNS QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR GEC (SEQ ID NO: 14), and wherein the light chain comprises a LCDR1 sequence having 100% identity to SEQ ID NO: 15, a LCDR2 sequence having 100% identity to SEQ ID NO: 16, and a LCDR3 sequence having 100% identity to SEQ ID NO: 17.

19. The antibody or antigen binding fragment of any one of claims 1-18, wherein the antibody or antigen binding fragment comprises an IgGl backbone.

20. The antibody or antigen binding fragment of claim 19, wherein the IgGl backbone is a human IgGl backbone.

21. The antibody or antigen binding fragment of any one of claims 1-20, wherein the antibody or antigen binding fragment does not comprise at least one constant region of IgE.

22. The antibody or antigen binding fragment of any one of claims 1-21, wherein antibody or antigen binding fragment further comprises a detectable label.

23. The antibody or antigen binding fragment of any one of claims 1-22, wherein the antibody or antigen binding fragment binds to a peanut antigen.

24. The antibody or antigen binding fragment of any one of claims 1-23, wherein the antibody or antigen binding fragment binds to a S2 albumin family member.964937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPT25. The antibody or antigen binding fragment of any one of claims 1-24, wherein the antibody or antigen binding fragment binds to Ara h 2.

26. The antibody or antigen binding fragment of any one of claims 1-25, wherein the antibody or antigen binding fragment binds to helix 3 of Ara h 2.

27. The antibody or antigen binding fragment of any one of claims 1-26, wherein the antibody or antigen binding fragment inhibits or reduces FcsRI receptor activity and / or one or more symptoms of a peanut allergy by at least 20% as compared to FcsRI receptor activity and / or one or more symptom of a peanut allergy in the absence of the antibody or antigen binding fragment.

28. The antibody or antigen binding fragment of any one of claims 1-27, wherein the antibody or antigen binding fragment inhibits or reduces an allergen mediated immune response by at least 20% as compared to an allergen mediated immune response in the absence of the antibody or antigen binding fragment.

29. The antibody or antigen binding fragment of any one of claims 1-28, wherein the antibody or antigen binding fragment inhibits or reduces an anaphylactic response by at least 20% as compared an anaphylactic response in the absence of the antibody or antigen binding fragment.

30. The antibody or antigen binding fragment of any one of claims 1-29, wherein the antibody or antigen binding fragment inhibits or reduces effector cell activation, e.g., effector cell activation by a S2 albumin family member such as Arah 2.

31. A composition comprising an antibody or antigen binding fragment of any one of claims 1-30.

32. The composition of claim 31, wherein the composition comprises a pharmaceutically acceptable excipient or carrier.

33. A cell comprising an antibody or antigen binding fragment of any one of claims 1-30.

34. A polynucleotide comprising a nucleotide sequence encoding an antibody or antigen binding fragment of any one of claims 1-30.

35. The polynucleotide of claim 33, wherein the polynucleotide is comprised in a vector.

36. A composition comprising a polynucleotide of claim 34 or 35.

37. A cell comprising a polynucleotide of claim 34 or 35.

38. A kit compri sing:a) an antibody or antigen binding fragment of any one of claims 1-30; b) a polynucleotide of claim 34 or 35;c) a composition of claim 31, 32, or 36; or974937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPTd) a cell of claim 33 or 37.

39. The kit of claim 38, further comprising instructions for use thereof.

40. A method of treating a peanut allergy comprising administering an antibody or antigen binding fragment of any one of claims 1-30, or a polynucleotide of claim 34 or 35, or a composition of claim 31, 32, or 36, or a cell of claim 33 or 37 to a subject in need thereof.

41. The method of claim 40, wherein the method inhibits or reduces one or more symptoms of a peanut allergy.

42. The method of claim 40 or 41, wherein the one or more symptoms of a peanut allergy are selected from the group consisting of skin reactions, hives, skin redness, skin swelling, itching, tightening of the throat, difficulty breathing, shortness of breath, digestive problems such as diarrhea, stomach cramps, nausea, or vomiting, drop in blood pressure and anaphylaxis.

43. The method of any one of claims 40-42, wherein the method reduces FcsRI receptor activation.

44. The method of any one of claims 40-43, wherein the method reduces the duration or severity of the allergic immune response to peanut proteins.

45. The method of claim 44, wherein the allergic immune response is a Th2 cell response, B cell activation, basophil activation, eosinophil activation, mast cell activation, and / or IgE induction.

46. The method of claim 45, wherein the Th2 cell response, B cell activation, basophil activation, eosinophil activation, mast cell activation, and / or IgE induction is assayed from one or more biological samples obtained from the subject.

47. The method of claim 40, wherein the subject is diagnosed with or in need of treatment for a peanut allergy.

48. A method for reducing or blocking anaphylaxis or at least one response associated with a peanut allergy, the method comprising administering a therapeutically effective amount of an antibody or antigen binding fragment of any one of claims 1-30, or a polynucleotide of claim 33 or 34, or a composition of claim 31, 32, or 36, or a cell of claim 33 or 37 to a subject in need thereof.

49. The method of any one of claims 40-48 further comprising a step of diagnosing the subject with the peanut allergy.

50. The method of any one of claims 40-49, wherein the subject is a mammal.

51. The method of any one of claims 40-50, wherein the subject is human.984937-1056-9264 10043214-000108WOPTAttorney Docket No. 043214-000108WOPT52. A composition of any one of claims 1-30 for use in the treatment of a peanut allergy, or at least one symptom thereof in a subject.994937-1056-9264 10043214-000108WOPT